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ive 
Supramolecular chemistry is the domain of chemistry beyond molecules 
which focuses on the chemical systems made up of a discrete number of assembled 
molecular subunits or components. It is a highly interdisciplinary field of science 
covering the chemical, physical, and biological features of highly organized chemical 
species held together by means of intermolecular interactions. Molecular recognition 
is regarded as the most fundamental type of supramolecular chemistry because all 
supramolecular chemistry is based on how molecules recognize and influence each 
other and how they perform specific functions due to molecular interactions and since 
water is essential to life, understanding the phenomenon of molecular recognition in 
water is of great importance. But supramolecular chemistry is much more than 
molecular recognition. Concepts such as templatcd synthesis, self-assembly, and self-
sorting have made supramolecular synthesis a powerful tool to construct large and 
complex chemical architecture from simple building blocks with an inherent program 
of well-designed binding sites. Based on these concepts, functional supramolecules 
have been developed, among them molecular switches, logic gates, molecular 
containers, elevators, valves and springs. supramolecular catalysts and many more. 
Cyclodextrins are among the most important molecular hosts studied in 
supramolecular chemistry. These are doughnut shaped molecules capable of 
encapsulating small molecules or part of large molecules. They discriminate between 
different molecules, constitutional isomers and enantiomers and formation of host-
guest complex results in altered chemical, physical and biological properties of guest. 
This has attracted chemists, physicists, biologists and others in attempts to take 
advantage of their unique properties. Their lack of toxicity forms the basis of 
widespread applications in pharmaceutical, agrochemical and food industry. 
The structure establishment of cyclodextrin complexes or supramolecules in 
general, is a challenging task in solution state considering the fact that the inclusion 
phenomenon is a dynamic process and hence deriving instantaneous information with 
regard to structural changes is not easy. A combination of experimental and 
computational methods is generally considered appropriate. NMR spectroscopy, most 
frequently used technique, provides direct evidence of formation, stoichiometry and 
binding constant of the complex and helps in identifying part of the guest in the 
cavity. Information regarding mode and depth of penetration of guest is also deduced 
sometimes. Simulations, the molecular mechanics and dynamics, studies are then 
performed in the light of these results. The simulation results are used to study the 
energetic of complexation phenomenon, whether the complex formation is feasible 
and which of the two modes of entries is more favored. If the results are found 
compatible with NMR data, the minimum energy configuration is then analyzed in 
view of the ROESY data. It is generally considered the most probable configuration if 
all the intermolecular contacts in the ROESY spectrum can be explained. But these 
structures are highly ambiguous because ROESY peak intensities depend mainly of 
inter-proton distances and slight modification of the configuration should affect 
ROESY peak intensities drastically. 
The aim and objective of the study undertaken was to develop efficient 
method to deduce more detailed structure of cyclodextrin complexes, in particular and 
supramolecular systems in general, than is otherwise obtained. Several 
pharmaceutical compounds, which possess at least one aromatic ring, were selected 
for the study as the guests because cyclodextrin cavity is considered best fit for 
aromatic ring. The choice of pharmaceutical compounds was prompted by the 
potential use of these complexes in the pharmaceutical industry. 
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Part A: Cyclodextrins: structure, properties and applications 
1.1 Historical background of cyclodextrins: from simple molecules to 
innovative structures 
Supramolecular chemistry is one of the most flourishing and active fields of 
science. It is described by Lehn as the chemistry beyond molecules" [1]. The 
importance of this field was emphasized further when Cram. Lehn. and Pederson. 
pioneers of this field were awarded 1987 Nobel Prize for chemistry for their work on 
molecular recognition. The formation of "host-guest" complexes was a breakthrough 
development where a host selectively binds to a guest. A supramolecule consists of 
many molecules/ions held together by weak non-bonding interactions [2]. Among 
many different studied hosts. cyclodextrins (CDs) are most promising and important 
macrocycles. They have been described as "unique seductive molecules". 
The entire development of CDs from simple molecules to scientific innovative 
structures has been divided into three stages by Szejtli [3-5]. The period from 1891 to 
1936 is called discovery period. During this period the three main naturally occurring 
CDs were identified and characterized although their chemical structure and 
properties were still unknown. The period from 1936 to 1970 is called exploratory 
period. During this period the exact chemical structure and physiochemical properties 
of CDs became known. The period from 1970 to-date is called utilization period 
during which there was emphasis on large scale industrial production of CDs and their 
applications in various fields. 
CDs were discovered in 1891 by Villiers [6] by digesting starch with Bacillus 
umvlobactor. He obtained about 3g of a crystalline substance from 1000g of starch, 
and determined its composition to be (C6H1005)2.3H20. and since it resembled 
cellulose he named it "cellulosine". In 1903, while studying food poisoning, the 
Austrian microbiologist Schardinger [7] reported the formation of a-dextrin and R-
dextrin-compounds identical to Villier's "cellulosine". In the early literature CDs 
were also referred as cycloamylose, cycloglucoamylose etc. In 1935. 'y-CD 
(cyclomaltooctaose) was discovered by Freudenberg and Jacobi [8]. The correct 
chemical structures of CDs were not published until 1938. It was Freudenberg, who 
characterized them as cyclic structures composed of a-1. 4-linked glucose units [9]. In 
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the 1950s, the chemical process for the production of CDs was thoroughly 
investigated by French and coworkers [10] and the existence of larger CDs was 
confirmed. Also, during this time Cramer et al [11] first began to uncover the 
potential of CDs as complex forming agent. They first investigated the applications of 
CDs in drug formulations. [12] and noted the stabilization, volatility reduction, and 
solubility changes that occurred as a result of complex formation of drugs with CDs. 
In 1953, the first patent on CDs and their inclusion complexes was registered [12]. In 
1976- a-and (3-CDs were officially approved as food additives in Japan and in the 
same year the world's first CD containing pharmaceutical product, prostaglandin 
E21[3-CD (Prostarmon ETM sublingual tablets), was marketed in Japan by Ono 
Pharmaceutical Co. [13]. The first "International Symposium on CDs" was organized 
in 1981 [14] and since then, symposia have been held every second year and 
presentations have increased exponentially both in quality and quantity. During the 
years 1980-2000 encouraging results of adequate toxicological studies became 
available which had huge positive impact on Cl) research. 
In 1970 the price oft Kg of P-CD was US$ 2000, and it was available only as 
a rare line chemical, but today the cost of CDs has reduced dramatically and it is 
relatively inexpensive material and readily available. In 2009, around 9400 tons of 
CDs were industrially produced [15]. About forty-three thousand CDs relevant 
abstracts have been published by 2010 (Fig.l). At present there are hundreds of 
pharmaceuticals, food, cosmetics and other household products containing CDs. New 
CDs-based technologies are constantly being developed. Thus even after hundred 
years of their discovery CDs continue to fascinate investigators both in the area of 
pure research and applied technologies. 
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1.2 Structural features and properties 
Enormous interest in CDs can be attributed to their unusual architecture of the 
molecular structure. Three natural a-, [3- and y- CDs are crystalline, homogeneous and 
non-hygroscopic substances, consisting of six (a-), seven (0-), and eight (y-) D-
glucose units attached by a-(1—►4) glycosidic linkages [ 16]. CDs containing more 
than eight D-glucose units are also known [ 17]. The internal diameter of CDs 
increases with increase in number of glucose units, while the height remains constant 
at 7.9 A (Fig. 2). 
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Fig. 2. Structure and pictorial representation of three natural CDs. 
Each of the chiral glucose units is in the rigid 4C1 chair conformation, giving 
the macrocycle shape of a hollow truncated cone with all the secondary hydroxyl 
groups (0(2)-H and 0(3)-H) located on the wider rim, while all the primary hydroxyl 
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groups (0(6)-H) on the narrower rim. The primary hydroxyls on the narrow side of 
the cavity can rotate, thus partially blocking the cavity, in contrast to the secondary 
hydroxyls which are attached by relatively rigid chains and thus cannot rotate. The 
presence of numerous hydroxyl groups, on the outside surface of the CDs makes them 
highly water soluble. The interior of the cavity is lined with (from the secondary 
hydroxyl rim inwards) a row of CH groups (the C-3 carbons). then a row of glycosidic 
oxygen, and then a row of C-5 CH groups. Intra-molecular hydrogen bonds 0(3)-
H.....0(2)-H or 0(3)....H-0(2) exist between the secondary hydroxyl groups of 
adjacent glucose units, forming a complete secondary belt in a-CD (Fig. 3). This 
hydrogen belt is incomplete in a-CD molecule due to the presence of one glucose 
units in distorted position. Consequently. instead of the six possible H-bonds, only 
four can be established simultaneously. The y-CDs has non-coplanar, more flexible 
structure and is, therefore, more water soluble of the three CDs. 
HYDRO 
GROUP 
Fig. 3. 3D molecular model of (3-CD. 
The non-bonding electron pairs of the glycosidic oxygen bridges are directed 
toward the inside of the cavity, producing a high electron density and lending it some 
Lewis base character. These features suggest that the CD cavity is relatively 
hydrophobic compared to the exterior surfaces which are hydrophilic [3,18,19]. Some 
important properties and molecular dimensions of the three most common CDs are 
listed in Table 1. 
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Table 1. Physical properties and molecular dimensions of CDs. 
Property 	 a-CD 	n-CD 	 y-CD 
Empirical formula(anhydrous) CMHM03o Ca2Hr0035 C4BHe0O40 
No. of glucose units 6 7 8 
Molecular weight (anhydrous) (g 972.85 1134.99 1297.14 moL-) 
Solubility in water 
(g 100ml-' at room temp.) 14.5 1.R5 23.2 
Cavity diameter, A 4.7-5.3 6.0-6.5 7.5-8.3 
Height of torus, A 7,9 7.9 7.9 
Diameter of outer periphery. A 14.6 15.4 17.5 
Cavity volume, A 174 262 427 
Crystal forms Hexagonal Monoclinic Quadratic 
(from water) plates parallelograms prisms 
Crystal water ,wt % 10.2 13.2-14.5 8.13-17.7 
Diffusion constant at 40°C 3.443 3.224 1000 
°C 
[a]0  150+ 0.5 162.5± 0.5 177.4+ 0.5 
v 	value, min'1 5.8 166 2300 
For improving the complexation properties of CDs and to make them suitable 
for various applications, numerous CD derivatives have been prepared. Each 
glucopyranose unit of CD has three free hydroxyl groups which differ in reactivity. 
Reagents, pH, temperature, etc. affect the relative reactivity of these hydroxyl groups. 
Various functional groups can be covalently attached to these hydroxyl groups (20, 
21]. Considering the presence of 18, 21 and 24 substitutable hydroxyl groups in a-, 
and y-CDs, respectively, and involving cleavage of either 0-H, C-0 or C-C bonds, 
the number of possible derivatives of CDs are unlimited. The hydrogen atom or 
hydroxyl group of CDs can be substituted by various groups like alkyl-, 
0 
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hydroxyalkyl-, carboxyalkyl-, amino-, thio-, tosyl-, glucosyl-, maltosyl, etc. and 
thousands of esters, ethers, anhydro-, deoxy-, acidic, basic etc. derivatives can be 
prepared by chemical or enzymatic reaction. Of the large number of derivatives of 
CDs, only a few are suitable for large scale industrial production. Complicated 
multistep reactions, use of expensive, toxic, environment polluting reagents and 
purification of the products by chromatography are major hindrances. To produce tons 
at an acceptable price only about a dozen of the known Cl) derivatives are taken into 
consideration. Since, the three hydroxyl groups differ slightly in their reactivity the 
substitution is usually random [22,23]. This explains the reason why there is slight 
difference in complexing ability of same substituted CDs obtained from different 
suppliers and sometimes from one batch to another from the same supplier. Almost all 
the known derivatives can be classified as carriers (solubilizers and stabilizers) for 
biologically active substances, enzyme models, separating agents (for 
chromatography), catalysts and additives (as detergents. viscosity modifiers etc.) [3-
19]. Some commercially used derivatives of CDs are shown in Table 2. 
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Table 2. Commercially used derivatives of CDs. 
Compound Rt R2 R3 
Hydrophilic derivatives 
Methylated CDs 
3-0-methyl- (ME) H CH3 H 
2, 6-Di-O-methyl- (DM) CH3  H CH3 
2, 3, 6-Tri-O-methyl- (TM) CHI CHI CH, 
Randomly methylated- (RM) Rt, Rz, R3= H or CH, 
Hydroxy-alkylated CDs 
2-Hydroxyethyl- (2-HE) CH,CH20H H H 
2-Hydroxypropyl- (2-HP) CH2CH(OH)CH, 	H H 
3-Hydroxypropyl- (3-HP) H CH,CH,CH,OH H 
2, 3-Dihydroxypropyl- (2, 3-DHP) CH2CH(OH)CH,OH 	CH1CH(OH)CH2OH H 
Branched CD 
6-0-Glucosyl- H H glucose 
6-0-Maltosyl- H H maltose 
2,6-0-Dimaltosyl- maltose H maltose 
Hydrophobic derivatives 
Alkylated CD 
2, 6-Di-O-ethyl- (DE) C2H5 H C2H5  
2, 3, 6-Tri-O-ethyl- (TE) C,H, C,H5 C2H5 
Acylated CD 
2, 3-Di-O-hexanoyl- (DH) COC,H i i COC,H,, H 
2, 3, 6-Tri-O-acetyl- (TA) COCH, COCH3 COCB3 
2, 3, 6-Tri-O-propanoyl- (TP) COC2H5 COCH5 COC2H5 
2, 3, 6-Tri-0-butanoyI- (TB) COC3H, COC,H, COC,H, 
2, 3, 6-Tri-O-valeryl- (TV) COC4H9 COC4}h COCA 
2, 3, 6-Tri-0-hexanoyl- (TI!) C0051111 COCsH,, COCsfln 
2, 3, 6-Tri-Ooctanoyl- (TO) COC,H1s COC,H,, COC,H,, 
Ionizable derivatives 
Anionic CD 
6-0-(Carboxymethyl)- (CM) H H CH2CO2Na 
CDs sulphates (CS) R1 , R 2, Ra = H or SO3Na 
Sulfobutyl ether- (SHE) Ri, R2, R,- H or (CH,),SO3Na 
8 
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1.3 Applications of Cyclodextrins 
Inclusion of a compound in the cavity of CDs exerts a profound effect on the 
physicochemical properties of guest molecules as they are temporarily locked or 
caged within the host cavity giving rise to beneficial modifications of guest 
molecules, which are not achievable otherwise [3]. The physicochemical properties of 
the guest that are affected are solubility enhancement, stabilization of labile guests 
against the degradative effects of oxidation, visible or W light and heat, control of 
volatility and sublimation, taste modification by masking off flavors, unpleasant odors 
and controlled release of drugs and flavors. CDs are, therefore. extensively used in 
food, pharmaceuticals, cosmetics, environment protection, bioconversion, packing 
and textile industries [24]. The market for CDs is continuously growing because they 
are stable, non-toxic and relatively economical. 
Of all the applications of CDs, a large portion of their uses is devoted to the 
field of pharmaceuticals. At present more than 35 CD-drug formulations are approved 
and marketed worldwide (Table 3) [25]. In the pharmaceutical industry, CDs have 
primarily been applied as solubilizers for lipophilic drugs to enhance their 
bioavailability and to reduce adverse effects after oral, parenteral or other routes of 
administration. In food industry, CDs are being investigated as stabilizers for 
flavoring agents and to reduce unpleasant odor and taste. In cosmetic industry, CDs 
are being tested as stabilizers of chemically labile compounds, to obtain prolonged 
action, to decrease local irritation and to reduce unpleasant odors. CDs are also 
applied as general processing aids and are used to direct chemical reactions, 
compatibilize materials and control volatility. The present discussion includes a brief 
account on industrial applications of CDs with particular emphasis on pharmaceutical 
industry. 
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Table 3. Some marketed pharmaceutical products containing CDs. 
Drug 	 Formulation 	Trade name 	Company(Country) 
Alprostadil (PGE1) 
Cefotiam hexetil HCI 
Benexate HCI 
Nimesulide 
Omeprazole 
PGE2 
Piroxicam 
Intravenous 
Oral 
Oral 
Oral 
Oral 
Sublingual 
Oral 
a-CD 
Prostavastin 	Pfizer (Europe. Japan, USA) 
Pansporin T 
	
"Takeda (Japan) 
a-CD 
Ulgut, Lonmiel 
	
Teikoku, Shionogi (Japan) 
Nimedex 	Novartis (Europe) 
Omebeta 	Betafarm (Europe) 
Prostarmon E 	Ono (Japan) 
Brexin.Cicladon Chiesi (Europe), Ache (Brazil) 
2-Hydroxypropyl-3-CD 
Cisapride Rectal 	Propulsid Janssen (Europe) 
Hydrocortisone Buccal 	Dexocort Actavis (Europe) 
Indomethacin Eye drops 	Indocid Chauvin (Europe) 
Itraconazole Oral, Intravenous 	Sporanox Janssen (Europe, USA) 
Mitomycin Intravenous 	Mitozytrex Novartis (Europe) 
2-Hydroxypropyl-y-CD 
Diclofenac sodium Eye drop 	Voltaren Novartis (Europe) 
Sulfobutylether-(-CD sodium 
Voriconazole Intravenous 	Vfend Pfizer (USA, Europe, Japan) 
Ziprasidone mesylate Intramuscular 	Geodon, Zeldox Pfizer (USA, Europe) 
Randomly methylated-p-CD 
17(-Estradiol Nasal Spray 	Aerodiol Server (Europe) 
Chloramphenicol Eye drop 	Clorocil Oftalder (Europe) 
FIC 
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1.3.1 Solubility enhancement 
The most common application of CDs is to enhance implicitly the aqueous 
solubility of the hydrophobic guest molecules. CDs themselves have a hydrophilic 
outer surface and a lipophilic cavity in the centre. The hydroxyl groups present on the 
surface interact with the polar solvent molecules, which contribute to the solubility of 
the complex and not the portion of the guest included in the CD cavity. Modification 
of these hydroxyl groups of CD markedly affects the solubility properties. 
Substitution of hydroxyl groups with hydroxypropyl, carboxymethyl, tertiary amine 
or quaternary amine increases the water solubility upto 60% or more. On the other 
hand, substitution of hydroxyl groups by aliphatic groups like hexyl or acetyl 
increases its solubility in organic solvents. 
A drug can be orally available only if it is dissolved and absorbed through 
gastrointestinal tract in such a way that it generates adequate drug levels at the 
pharmacologically active site to ensure that the desired action is obtained in a 
reproducible manner. The addition of CDs increases the water solubility of several 
poorly water-soluble substances. In some cases this results in improved 
bioavailability, increasing the pharmacological effect allowing a reduction in the dose 
of the drug administered. 
Itraconazole, an antifungal agent, is insoluble in water that can be solubilized 
using co-solvents but the resulting formulation precipitates in the stomach. 
Complexation with 1P4-CD prevents its precipitation in stomach thus allowing its 
use in oral dosage formulation [26]. Similarly, a 16-fold and 3-fold increase in the 
water solubility of felodipine and amlodipine, respectively, were reported on 
complexation with ME-j3-CD [27]. Nifedipine, an antihypertensive drug is practically 
insoluble in water but its complexation with p-CD markedly enhanced the solubility 
and dissolution rate [28]. Carbamazipine, an anticonvulsant drug, is reported to form 
inclusion complex with {3-CD resulting in its improved solubility and thus biological 
performance [29]. Ketoprofen, a non-steroidal anti-inflammatory drug with analgesic 
and antipyretic activity has poor aqueous solubility. The complexation of ketuprofen 
with [S-CD showed 15-fold increase in dissolution rate. Table 4 summarizes the 
solubility enhancement studies of variety of pharmaceutical compounds in presence of 
CDs. 
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Table 4. CDs used as solubilizing agent. 
Drug CD used Advantage Ref. 
Methotrexate 13-CD Enhanced solubility, bioavailability, decreased 30 photo sensitivity 
bnatinib li-. RM-13-CD 10-fold increase in solubility 31 
Bupivacaine HP-p-CD 1.5 to 4.5 fold increase in solubility 32 
Albendazole 13-CD Solubility enhancement 33 
Triclosan p-CD Higher solubilizing and complexing efficiency 34 
Bisphenol A u-, fi-, 7-CD Greatly enhanced solubilization ability 35 
Genistein (3-, y-CD Improved aqueous solubility 36 
Pyrimethamine P, ME-,HP-p- Solubility enhancement 37 
Meelizine (i-, HP-13-CD Solubility and dissolution rate enhancement 38 
Cefixime R-, HP-R-CD Solubility and dissolution rate enhancement 39 
Ketoconazole HP-(3-CD Stability and solubility enhancement 40 
Glycvrrhetic acid HP-3-CD Solubility increased by 54.6 fold 41 
Omeprazole p-, ME-O-CD 1.7 to 3.4 fold increase in solubility 42 
Rutin HP-a 'HP-p ' Solubility and stability enhancement, 43 HP-y-CD 
Nimesulide pip - p-, ME-  Solubility and bioavailability enhancement 44 
Natam cin Y P-, Y-, HP-f3-CD 
16 to 152-fold solubility enhancement with 
CDs 45 
Fasinopril P-  D,RM-p- Solubility and bioavailability enhancement 46 
12 
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1.3.2 Stability enhancement 
Peroxyacids are used as bleaching agents and their thermal stability and 
storage is a matter of concern. Its complexation with CDs not only improved storage 
and thermal stability but odor was also suppressed and complex was stable without 
the use of any dilutants [47]. CDs also play important role in the stabilization of 
oligonucleotides [48]. 
For the use as a drug, it is important for a pharmaceutical compound to 
maintain sufficient stability not only during storage but also in the gastrointestinal 
fluids, since reactions which result in pharmacologically inactive or less active 
products reduce the therapeutic effectiveness. The main concern in the 
pharmaceutical field is, therefore, the rate of deceleration. CDs have been used to 
stabilize pharmaceutical compounds [49.50] For instance, anthocyanin extract has 
important analgesic properties in addition to neuroprotective and anti-inflammatory 
activities. Its inclusion complex with [3-CD was more stable against oxidation then the 
free extract and the complex remained intact at 100 to 250 °C, whereas free extract 
was oxidized [51]. Nicardipine is a light sensitive drug and decomposes if exposed to 
light. The rate of photodegradation was reduced by complexing the drug with CDs. 
CD complexes of nicardipine were irradiated by UV light. Photo-degradation was 
slowed down by a factor of 10 with methylated-[3-CI), 8 with 2-HP-n-CD, 6.5 with a-
CD and 5 with y-CD [52]. Digoxin, one of the potent cardiac glycosides, is sensitive 
to light and gets hydrolyzed in the acidic medium. The acid catalyzed hydrolysis of 
the glycosidic bonds in digoxin is decelerated by the addition of CDs. The hydrolysis 
of the glycosidic linkage connecting the A-ring of digoxin - and the sugar was 
completely inhibited by 13-CDs [53]. Few examples of stability enhancement of 
pharmaceuticals in presence of CDs are summarized in Table 5. 
13 
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Table 5. Use of CDs for drug stability. 
Effect Drug CD used Ref. 
Methotrexate p-CD 30 
Rhein p-, HP-p-CD 54 
Photostability Piroxicam HP-(i-CD 55 
Tenoxicam p-CD 56 
Sufentanil HP-13-CD 57 
Increased shelf life Vanillin a-, [3-, y-CD 58 
Trimethoprim HP-13-CD 59 
Thermal stability Paeonol p-CD 60 
Citronellol, Citronellyl acetate a, (3-, y-CD 61 
Chemical stability Quinaril ]1-, HP-[1-CD 62 
Camptothesin PM-p-CD 63 
Stability against Melphalan, Carmustine SBE-p-,HP-p-Cl) 64 hydrolysis 
Paclitaxel HP-p-, y-CD 65 
Deacetylation or Spiranolactone SBE-a--,y-CD ,[3 66 degradation 
1.3.3 Enhancement of bioavailability 
Bioavailability is a measurement of the rate and extent to which a drug reaches 
the systemic circulation. When a medication is administered intravenously, its 
bioavailability is 100% but it generally decreases when a medication is administered 
via other routes. Enhancement of hioavailability is one of the most important 
applications of CUs [67]. The enhanced water solubility and stability of drug upon 
complexation results in enhanced oral hioavailability of the drug. This is achieved by 
making the drug available at the surface of the biological barrier, e.g., skin, mucosa. 
or the eye cornea, from where it partitions into the membrane without disrupting the 
lipid layers of the barrier [68]. In such cases, it is important to use just enough CD to 
solubilize the drug in the aqueous vehicle since excess may decrease the drug 
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availability [69,70]. In the case of water-soluble drugs, CDs increase the drug 
permeability by direct action on mucosal membranes resulting in enhanced drug 
absorption and bioavailability [71]. Bioavailability studies in humans showed that 
midazolam was rapidly absorbed after nasal administration [72). Glibornuride was 
complexed with [3-CD and stored for 1 year and the dissolution characteristics and 
bioavailability remained unchanged [73]. Table 6 summarizes various CDs which are 
successful in enhancing bioavailability of several drugs. 
Table 6. Examples of use of CDs for bioavailability enhancement. 
CD used Drug Ref. 
n-CD 
Flurbiprofen 74 
Glibenclamide 75 
y-CD 'y-Tocotrienol 
76 
[i-, HP-[3 -, RM-[3-CD Efavirenz 
77 
R-, y-• DM-~3-, HP-(3-CD Cilostazol 
78 
[i-, HP-[i-CD Lansoprazole 
79 
HP- -CD 
Dihydroartemisinin 80 
Lamotrigine 81 
1.3.4 Masking of ill effects 
Upon complexation with CDs the amount of guest which brings out a 
physiological effect become sufficiently reduced thereby masking certain properties 
like disgusting taste and odor, unwanted flavors in food, reducing the skin irritation 
effects, and side effects of various pharmaceutical products [82]. For instance, some 
food products have a peculiar smell such as, soybean milk and soy protein, which is 
suppressed upon complexation with CDs [83]. In cosmetic industry lotions have been 
developed in which a fragrant but irritation causing component is being complexed 
with CD in order to limit its direct physical contact with skin without affecting 
fragrance. Fixolide is a synthetic fragrance which is widely used to replace natural 
musk odor. It is semi-volatile and decomposes when exposed to light or high 
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temperature. Upon complexation with CDs, its stability against high temperature and 
UV exposure is increased [84]. 
With the growing popularity of orally disintegrating and chewable dosage 
forms, there is increased need to mask the taste and odor of unpleasant drugs. The 
bitter taste of drugs and food components can be masked by many taste-masking 
techniques such as physical barrier coatings. chemical modification and sensory 
masking method. Among chemical modification, the inclusion complexation of drugs 
with CDs can provide the effective bitter taste-masking effects without complicated 
formulation and/or delayed dissolution of drugs. Since, these inclusion complexes are 
strongly hydrated. they do not come in contact with the taste-bud receptors thus 
masking the bitter taste [85]. Some of the examples for elimination/reduction of 
bitter/irritating taste or unpleasant odors of orally administered drugs by complexation 
with CDs have been summarized in Table 7. 
Table 7. Examples of masking of bitter taste or unpleasant odor by CDs. 
Drug/food component 	 CD used 	Ref. 
Famotidine 	 CM-[3-CD 	86 
Diphenhydramine, Hydroxyzine. Cetirizine [3-, HP-[3-CD 	87 
Thiamine derivatives n-C D 88 
Naringin, limonin n-CD 89 
Fenbufen a-, [3-, y-CD 90  
Metronidazole benzoate y-CD 91  
Ibuprofen [3-CD 
92 
Benexate hydrochloride n-C D 93 
Carbetapentane citrate [3-CD 94  
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1.3.5 Process aid 
CDs have found invaluable and important roles as processing aids in food 
industry. CD has been used in the removal of cholesterol from animal products [95, 
96]. In one case, aqueous solution of CD was stirred with heated lard and tallow from 
which cholesterol was to be removed. The CD forms complex with cholesterol, which 
is insoluble in water or fat. The complex is removed by filtration or centrifugation. 
The CD-cholesterol complex is then suspended in water and heated which results in 
decomposition of complex causing CD to be solubilized in water and cholesterol to 
float on the surface. This way up to 80% of cholesterol was removed from some 
treated material and CDs and cholesterol are obtained as pure products. CD 
complexation of cholesterol has also been found useful in reducing dietary cholesterol 
intake [97]. CDs have been successfully used as anti-browning agents in fruit juices 
[98,99]. Fruit and vegetable juices were treated with a R-CD polymer to remove 
polyphenolics responsible for enzymatic browning [100]. Organic compounds need to 
be solubilized in water for bio-conversions and therefore, surfactants or solvents are 
used but these can be used in limited quantities because they affect the organism as 
well. By the use of ME-R-CD, a 6-fold increase in bio-conversion rate of phyllotoxin 
was achieved compared to bioconversion in the absence of CD [10 1 ]. 
1.3.6 Reduction of volatility 
Reduction of volatility is another important change observed in CD inclusion 
complexes. Involvement with guest provides a higher energy barrier to be overcome 
to volatize. Menthol, for example forms an odorless complex with p3-CD which can be 
dried at 100°C while free menthol will be completely volatilized under these 
conditions [102,103]. All the components of the fragrance have different volatility 
and some of the more highly volatile components are easily lost changing the 
composition of the fragrance but when these components are complexed with CDs 
their volatility is reduced and the character of the fragrance is not changed. Holland el 
al [ 104] have prepared long-lasting CD containing fragrances. The use of CD-
complexed fragrances in talcum powder stabilizes the fragrance against the loss by 
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evaporation and oxidation over a long period. The product also showed improved 
antimicrobial efficacy [105]. 
CDs are also effective in trapping pollutants and reducing their volatility, 
which helps in pollution control [l06]. The organic pollutants are trapped in water by 
CDs via the formation of inclusion complexes and dechlorinated by a supported 
heterogeneous palladium catalyst. Catalytic investigations demonstrate that CDs act 
as ellicient CCI4 solubilizers and more interesting, as protective molecules against 
side reactions [107]. 
1.3.7 Directing of chemical reactions 
CDs are also used for the mediation of specific organic reactions. The 
formation of host/guest complex, not only alter the physicochemical properties but 
inclusion of the part of the guest molecule into the CD cavity offers significant steric 
shielding. This concept has been utilized in many ways for highly selective synthesis 
[108]. 2,6-naphthalenedicarboxylic acid is an important monomer for liquid 
crystalline polymer synthesis. Synthesis of 2,6-naphrhaleHediearboxylic is difficult 
due to several reactive sites on the naphthalene ring leading to a range of products. It 
was found that when naphthalene was first complexed with CD then the yield of the 
desired 2,6-product was greatly improved [109]. The host CD sterically shielded the 
undesirable reaction sites on the naphthalene ring. In recent years CDs have been used 
as catalysts in organic reactions. The use of CDs in organic reactions as a 
supramolecular catalyst has also been investigated [1101. 
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1.4 C}-clodextrins in drug delivery systems 
A drug delivery system delivers the right quantity of drug at the targeted site 
for the required time period both efficiently and precisely. In this regard large 
numbers of carrier molecules are constantly being developed to overcome the 
undesirable drug properties [I11 ]. CDs have been found as potential candidates for 
this purpose also. 
1.4.1 Oral drug delivery system 
It is the most popular route for delivery of drugs. In this system the release of 
drug is either dissolution controlled, density controlled, pH controlled, osmotically 
controlled, or diffusion controlled [112]. In this system a rapid increase in the 
systemic drug concentration takes place along with the avoidance of systemic and 
hepatic first-pass metabolism [ 113]. CDs improve mucosal drug permeability by 
availing free drug at absorptive surface [ 114,115]. CD complexation provides better 
and uniform absorption of poorly water soluble drugs having poor and erratic 
absorption [116] and also enhances the drug activity upon oral administration [117-
119]. CDs can also be used to modify the time of drug release and therefore they find 
application for delayed drug release, prolonged drug release, modified drug release 
and immediate drug release. Chemically modified hydrophilic and hydrophobic CDs 
have been used as novel slow release carriers for water soluble drugs. Table 8 shows 
the use of CDs in oral drug delivery systems. 
1.4.2 Rectal drug delivery system 
It is ideal route to deliver drugs to unconscious patients, children, infants and 
for patients who have difficulties in swallowing or having nausea or vomiting. The 
rectal mucosa is potential site for delivering drugs having bitter and nauseous taste, 
having high first-pass metabolism and drugs that degrade at the gastrointestinal pH 
[130]. Application of CDs for rectal drug delivery is with respect to drug stabilization, 
improvement in release, bioavailability and alleviation of local irritation [131]. The 
use of CDs on rectal drug delivery is affected by partition coefficient of the drug and 
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its complex, magnitude of the complex stability, and nature of suppository base 
(oleaginous or hydrophilic) [68]. CDs enhance rectal drug stability either by inhibiting 
the drug/vehicle interaction (by making the drug insoluble in oleaginous base) or by 
inhibiting the drug bioconversion in the rectum. Table 9 shows the use of CDs in 
rectal drug delivery systems. 
Table 8. Application of CDs in oral drug delivery 
Drug 	 CD used 
Ketoprofen. Griseofulvin. Terfenadine 	(3-CD 
Albendaole. Ketoprofen HP-13-CD 
Phenytoin, Glicazide SBE-13-CD 
Spiranolactone DM-[i-CD 
Tacrolimus ME-13-CD 
Albendazole, Phenytoin ME-13-CD 
Terfenadine, Tolbutamide 13-CD 
Tolbutamide, Amylobarbitone HP-f3-CD 
Flutamide HP-13-CD 
Digoxin HP-13-CD 
Rutin y-CD 
Clomipramine, Testosterone HP-13-CI) 
Danazole SBE-13-C I) 
HP-(3-CD 
Ref. 
117,120,121 
120,122-124 
124 
116 
122 
123 
117.118 
118,119 
114 
125 
126 
114,127 
128, 
129 
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Table 9. Application of CDs in rectal drug delivery. 
Drug 	 CD used 	 Ref. 
Ethyl-4-biphenyl acetate (EBA) 	R-, DM-[3-. TM-[3-CD 	132 
Carmofur 	 R-, DM-3-CD 	 133 
Morphine, Cefmatazole 	 a-CD 	 134, 135 
Human chorionic gonadotrophin 	a-CD 	 136 
Morphine 	 a-CD 	 131 
AD-1590 	 3-CD 	 137 
1.4.3 Nasal drug delivery system 
It is a novel approach for systemic delivery of high potency drugs having low 
oral bioavailability due to extensive gastrointestinal breakdown and high hepatic first-
pass effect [ 130]. The nasal route avoids the first-pass elimination associated with oral 
drug delivery. Generally drugs opted for nasal deliveries are water based liquids or 
powders and they have tendency to flow down to throat soon after administration 
where they get mixed with nasal secretions. Small particle may sometime enter 
trachea while large particles into the non-villous anterior part of the nasal cavity. 
Therefore, loss of drug in this way makes frequent administration compulsory. Use of 
CDs provides very efficient nasal drug absorption [138]. Table 10 shows the use of 
CDs in nasal drug delivery systems. 
1.4.4 Trans dermal drug delivery system 
Administering drug through skin for local or systemic action is suitable for 
drugs having low therapeutic index [151]. Native CDs and chemically modified CD 
derivatives are used in transdermal drug delivery [1321. The transdermal drug 
transport is affected by permeation characteristics of stratum corneum. CDs are used 
in transdermal drug delivery for increasing drug release and/or permeation, enhancing 
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drug stabilization in formulation or at absorptive site, alleviation of drug-induced 
local irritation, sustaining drug release from vehicle, and alteration of drug 
bioconversion in the viable skin [68]. Table II enlists CDs used in transdermal drug 
delivery systems. 
Table 10, Application of CDs in nasal drug delivery. 
Drug CD used Ref. 
Glucagon DM,-[i-CD 139 
Insulin a-, [.3-, HP-a-, HP-13-. 140-  DM-a-, DM4-CD 143 
Calcitonin Me-[3-CD 144 
Buserelin DM-[i-CD 145 
Midazolam SBE-4-CD 146 
Dihydroergotamine RM-(3-CD 147 
Human granulocyte colony a-, fi-, DM-(3-CD 148, stimulating factor 149 
Estradiol DM-13-CD 150 
Table 11. Application of CDs in transdermal drug delivery. 
Drug CD used Ref, 
4-biphenyl acetate S-, DM4-, HP--CD 152 
Daxamethasone HP-p-CD 153 
Prednisolone II-, DM-3-CD 132 
Hydrocortisone HP-(l-CD 154 
Betamethasone -, 7-CD 155 
Beclamethasone dipropionate [3-, y-CD 156 
Indomethasin {i-, HP-p-CD 157 
Chlorpromazine HCI DM-4-CD 132 
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1.4.5 Ocular drug delivery system 
Eye diseases are treated by topical drug application in the form of eye drop, 
but after instillation in eye less than 5% of dose reaches the intraocular tissue. This is 
due to rapid loss of instilled solution from the pre-corneal area [ 158]. 
The ability of CDs to solubilize hydrophobic drugs and provide a hydrophilic 
exterior makes it ideal for ocular application. CDs enhance drug permeability by 
making the drug available at the ocular surface. The dissociation of drug-CD 
complexes depends more on the binding of drugs to precorneal proteins, absorption 
by corneal tissue, and displacement of drugs from CD complexes by precorneal fluid 
components [159]. Table 12 shows the use of CDs in ocular drug delivery systems. 
Table 12. Application of CDs in eye drop solutions. 
Drug CD used Ref. 
Acetazolamide HP-13-CD 160 
Anandamides HP43-CD 161,162 
Cyclosporine a-CD 163,164 
Dexamethasone HP-[i-CD 165 
Diclofenac HP-[3-CD 166 
Pilocarpine HP-[3-. SBE-R-CD 167,168 
Prostaglandins HP-R-CD 169 
1.4.6 Parenteral drug delivery system 
As a consequence of high water solubility and low toxicity. HP-13-CD and 
SBE-[i-CD are widely investigated for parenteral drug delivery. Since HP-3-CD has 
more water solubility, it is more frequently investigated for parenteral use. In 
parenteral drug delivery, the use of CD enhances the drug solubility and stability and 
reduces the irritation of drug at administration site [68]. Table 13 shows use of CDs in 
parenteral drug delivery systems. 
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Table 13. Application of CDs in parenteTal drug delivery. 
Drug CD used Ref. 
Itraconazole HP-p-CD 170 
McLphalan,Carmustine SBE-13-, HP-p-CD 64 
Ziprasidone mesylate SBE43-CD 171 
Dexamethasone Sugar branched CDs 172 
Phenytoin HP-(S-CD 173 
Miconazole HP-P-, SBE-p-CD 174 
DY-9760e SBE-R-CD 175 
1.4.7 Cyclodextrins in the design of novel drug delivery systems 
1.4.7.1 Liposomes 
The idea of entrapping drug into liposomes takes into account the advantages 
of both CD and liposome into single system and thus helps in preventing the problem 
associated with both systems [176,177]. Liposomes capture hydrophilic drug in 
aqueous phase and hydrophobic drug in Lipid bilayer en route to their targeted site. By 
forming water soluble complexes, CD helps in availing water insoluble drug in 
aqueous phase thus increasing drug to lipid mass ratio levels, extending the range of 
drug available for encapsulation, allowing drug targeting and reducing toxicity. 
Problems associated with intravenous administration of Cl) complexes such as their 
rapid removal into urine and toxicity to kidney after chronic use can be avoided by 
liposomes [68,177-181]. Pharmacokinetics of inclusion complexes are altered by 
liposomal entrapment. Liposomal entrapment greatly reduced the urinary loss of HP-
[3-CD/drug complex but boosted the uptake of the complex by liver and spleen, where 
after liposomal disintegration in tissue, drug tnatabolization takes place at rates 
dependent on complex stability [179]. Complexation with CD increases the capture of 
lipophilic drug and also improves the stability of liposomes [ 182-186], 
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1.4.7.2 Microspheres 
In the presence of high percentage of soluble hydrophilic excipients, the 
complexation with microspheres does not aid the dissolution rate. Release of 
nifedipine from chitosan microspheres was slowed down upon complexation with HP 
-p3-CD although drug-loading efficiency was enhanced. The observed slow release of 
nifedipine was reported due to lesser drug availability from the complex and also due 
to the formation of hydrophilic chitosan/CD matrix layer around the lipophilic drug 
that further reduces the drug matrix permeability [119.187-189]. Microspheres 
prepared by spray drying of water/oil emulsion containing CD provided constant 
insulin release up to 45 days without initial burst and maintained its stability during 
the entire release phase [190]. Microspheres prepared by cross linking of acidified 
aqueous mixture solution of polyvinyl alcohol and CDs (a-, I-  and y-CD) with 
gluteraldehyde displayed good affinity for drugs such as diclofenac, indomethacin, 
metronidazole and propranolol [191]. 
1.4.7.3 Microcapsules 
Cross linked a-CD microcapsules act as release modulators because they have 
the ability to slow down the release of water soluble drugs through semi-permeable 
membrane. A typical example is terephthaloyl chloride cross linked 3-CD 
microcapsules which rapidly complexed with p-nitrophenol and the amount of 
complexed drug increased as the size of microcapsule decreased, These microcapsules 
also retarded the diffusion of propranolol through dialysis membrane [192]. 
1.4.7.4 Nanoparticles 
The potential of nanoparticles in the area of pharmaceuticals is immense. They 
provide a mean of modifying the distribution of active substance in vivo and 
increasing its concentration in target tissue thereby increasing its bioavailability and 
efficacy [193]. Nanoparticles can be used for drug delivery but their application is 
limited due to low drug loading capacity and limited drug entrapment efficiency 
[194,195]. CDs are particularly useful in design of nanoparticles for two reasons; they 
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increase the loading capacity of nanoparticles and the nanocapsules or nanospheres 
are spontaneously formed by nanoprecipitation of amphiphilic CD diesters. Both 
these techniques are useful in oral and parenteral drug administration 1196,197). 
Drugs when delivered in combination of CD and nanoparticles increase the solubility 
and permeability as found in case of paclitexel [198]. The antiviral activity of 
acyclovir loaded into I3-CD-PALM ([i-CD-polv(4-acryloylmorpholine)) nanoparticle 
was found to be superior to that of free drug as well as soluble (3-CD-PACM complex 
[199]. Amphiphilie CDs derivatives we used to prepare nanocapsules and 
nanospheres having high drug loading capacity which do not require presence of 
surfactant [200]. Progesterone-p-CD nanosphere was shown to be very promising 
non-surfactant injectable system providing high quantity of water insoluble 
progesterone within 1 hour [201 ]. 
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1.5 Forces involved in cyclodextrin complexation 
The understanding of the driving forces involved in the inclusion 
complexation of CDs is fundamentally important not only for CD chemistry but also 
for supramolecular chemistry as a whole. A large number of studies have been carried 
out on the subject and have been reviewed earlier [204]. Nevertheless, it is often 
claimed that the driving forces leading to CD complexation still remain a 
controversial subject. In this section only the interactions between the substrate and 
the cavity wall of the CD is discussed. 
1.5.1 Electrostatic interactions 
Electrostatic interactions include all kinds of electrostatic forces between 
permanent charges, dipoles and higher dipoles, present in the system. Three types of 
electrostatic interactions are important, namely ion-ion, ion-dipole, and dipole-dipole 
interactions. As native CDs are neutral molecules, the ion-ion interactions do not 
occur in CD complexes, unless CD is appropriately substituted [205]. 
The ion-dipole interaction on the other hand, is expected to take place in CD 
complexation since they are polar molecules though the occurrence of this interaction 
is difficult to establish. The ion-dipole interaction should increase with increasing 
ionic charge of the guest. It can be expected that dianions such as S0,2- and CO12 will 
bind more tightly with CDs than ions such as C104 and NO3. However, though the 
complexation of Cl) with CI04 and NO3 has been observed experimentally no 
complexation could be detected for SO42 and CO32- ions [206]. The ion-dipole 
interaction, in aqueous solution, is not necessarily favorable since substrate-water 
interaction is also strong. Chujo et al [207] first calculated the dipole moments of CDs 
from the published X-ray structures, in the range 10-20 D suggesting that they are 
highly polarized. Later studies showed that dipole moments of CDs are highly 
susceptible to the chemical environment [208]. Smaller dipole moments in the range 
of 24 D were obtained for the CDs optimized by various theoretical methods. Since, 
CDs have modestly large dipole moments; this must play an important role in their 
complexation. 
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1.5.2 Dipole-dipole interactions 
Studies for the complexation of a-CD with several substituted benzene 
derivatives such as benzoic acid, p-hydroxybenzoic acid and p-nitrophenol were 
carried out and showed that dipoles of the guest are antiparallel to that of the host 
[209. 2101. Interestingly, as the magnitude of the guest dipole increases so does the 
value of the CD dipole but in opposite direction. Thus it was concluded that dipole-
dipole interaction plays an important role in stabilizing the complex as well as 
determining its orientation. 
The free energy relationship analysis also proves the importance of dipole-
dipole interactions in CD complexation. The correlation studies between the binding 
constants of u-CD with 4-substituted benzoic acids and the Hammett (a) constants of 
the substituents were carried out [211]. The results suggested that as the —COOH 
group always stays at the positive end of the dipole of the host, it is readily 
understandable that binding is enhanced by electron release from the pare 
substituents. However, in the case of complexation of a-CD with benzoate anions, it 
is the electron withdrawing pare substituent that favors the binding [212]. This is 
again caused by the dipole-dipole interaction, because in the anion complexes, the 
carboxylate group stays at the negative end of the dipole of the CD. Davis et al [212] 
also pointed out the importance of the dipole-dipole interaction in CD complexation 
on the correlation studies. The Hammett (a) values were used to reflect the electronic 
effects of the substituents in the 1, 4-disubstituted benzenes. It was observed that for 
neutral 1, 4- disubstituted benzenes the group with a larger a value is bound in the 
narrower end of the cavity because of the favorable dipole-dipole interaction energy. 
The conclusion has been successfully applied to a number of systems [21 3] and it was 
argued that the exceptions to the rule such as complexation of a-CD with pare 
substituted aromatic sulfides, sulfoxides. sulfones and ketones are caused by steric 
hindrance [214]. 
Hamai et al [215] studied the effect of CD complexation on the acidities of 
several phenol derivatives such as 4-nitrophenol, 4-cyanophenol, 4-bromophenol and 
4-methoxyphenol which also supported the above results. It was found that, except for 
4-methoxyphenol, the acidities of phenols enhanced as a result of CD complexation. 
The behavior was thought to be due to the dipole moments of the phenols, which are 
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usually directed from the hydroxyl group to the para substituent. Thus, the dipole-
dipole interaction was concluded to be an important factor in complexation. 
Yasuda el al [216] performed scanning tunneling microscopy studies on self 
assembled a-CD inclusion complexes with water, methanol and 4-nitrophenol. The 
observed structures of a-CD-water and a-CD-methanol complexes were different 
from that of a-CD-4-nitrophenol complex. It is believed that the difference reflects the 
important role of the dipole-dipole interaction in complexation. 
1.5.3 Van der Waals interaction 
The presence of van der Waals forces, which mean either the induction and 
dispersion forces combined or the dispersion forces alone, in CD complexation is 
reasonable. The involvement of van der Waals interactions in CD complexes has been 
claimed by many workers. It is generally believed that the hydrophobic interaction 
between two non-polar molecules is a positive enthalpy process, the observation of 
negative enthalpy change in CD complexation is often considered to indicate the 
dominance of van der Waals interactions instead of hydrophobic interactions [217]. 
However, since the complexation is a complicated process, the above argument is not 
always true. 
The correlation analysis between the binding strength and structural features 
of the substrate is a reasonable method to show the involvement of van der Waals 
interaction in CD complexation. For instance, both the induction and dispersion forces 
depend on polarizabiIity, which in turn is related to molecular size and electron 
density, and so to the correlation variables like molar refraction, molecular volume, 
surface area, molecular weight etc. Thus the correlation between the strength of 
binding and the above parameter is at least indicative of the importance of van der 
Waals interaction in CD complexation [218]. 
The involvement of van der Waals interaction in complexation can also be 
shown by the structure of the complexes. In fact, numerous studies have revealed that 
bulky guest molecules are in close van der Waals contact with the CD cavities [219]. 
Interestingly, sometimes van der Waals interaction might be so strong that the 
hydrophobic but the bulky side of the molecule can enter the CD cavity. Moreover, 
the fact that Cl) can form stable complexes with the guest molecules in pure organic 
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solvents such as DMF. DMSO and even heptanes evidently demonstrates that van Der 
Waals interaction is essentially important [220,2211. 
The involvement of van der Waals interaction in CD complexes has also been 
shown by molecular modeling [222] which is usually performed with molecular 
mechanic and molecular dynamic calculations. Most of the modeling studies were 
performed in the gas phase to avoid the solvent effect. Many authors concluded, from 
these calculations, that van der Waals interactions make major contribution to the 
formation of complexes. This conclusion is not unexpected because in the calculations 
the energetic contributions from the dehydration, hydration of the host, guest and their 
complex, and from the reorganization of the solvent molecules were not taken into 
consideration. Whether, or not, van der Waals interaction play a major role in CD 
complexation in solution is thus not clear. 
It should be mentioned that van der Waals interactions also exist between the 
solvent molecules and the substrate or CD. Thus, in the CD complexation the 
substrate is exchanging one set of van der Waals interaction (with the solvent 
molecules) for another set (with the CD cavity). In fact this type of exchange is the 
reason why the ion-dipole interaction is not significant in CD complexation. 
However, as the polarizability of water is much lower than that of the organic 
substrate lining the CD cavity, it is expected that van der Waals interaction should be 
stronger between CD and the substrate than between water and the substrate. As a 
result, van der Waals interactions have a positive contribution to complex stability. 
This effect can be shown by the complexation of CDs with inorganic ions such as 
C1O4 and NO3 [223]. Apparently. hydrophilic interaction might be stronger between 
water and the ions than between CD and the ions, the only possible driving force 
leading to complexation is van der Waals interaction. 
1.5.4 Hydrophobic interaction 
The role of hydrophobic interaction in CD complexation is a controversial 
problem. Traditionally, hydrophobicity was considered to be the result of enhanced 
structure of the water molecules in the near vicinity of the non-polar solute, which 
would bring about a usually large entropy loss during the hydration [224]. However, 
neither the neutron scattering measurements nor the computer simulations indicated 
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any evidence that structure of the water of hydration close to non-polar solute was 
more ordered than that of water in the bulk [225]. 
In the experimental studies, however, the association of non-polar molecules 
in water is usually found to be with positive enthalpy and positive entropy change. 
This has long been taken as the experimental signature of hydrophobic interaction. 
The fact that most of the experimental enthalpy and entropy changes of CD 
complexation are negative seems to indicate that the hydrophobic interaction is not an 
important driving force in CD molecular complexation. It was suspected that the 
above experimental observation was not representative enough, possibly, because all 
the guest molecules that had been studied were not sufficiently hydrophobic. Thus, 
the a-CD complexation with I -admantanecarboxylate was studied, and the observed 
positive entropy was believed to settle and issue [226]. Unfortunately, a 
reinvestigation of the system showed that the entropy change is actually negative 
[227].  
The above problem can be settled if we notice that in CD complexation many 
interactions other than the hydrophobic are also involved. For example, unlike 
aggregation of two small non-polar molecules, the van der Waals interactions between 
CD and the guest are quite strong. As the interaction is attractive in nature and tends 
to restrict the conformational freedom of the complex, it is possible that the total 
entropy and ettthaipy of the complexatioo are both negative in spite of the presence of 
hydrophobic interaction. Moreover, it is well known that the transfer of non-polar 
gases into water is associated with large positive heat capacity change. Therefore, the 
facts that CD complexation is often accompanied with a large negative heat capacity 
change also demonstrate that hydrophobic interaction is important in complexation 
[228].  
In addition to using the thermodynamic criteria, there are several other 
methods to show the involvement of hydrophobic interactions. The most compelling 
evidence in favor of the presence of hydrophobic interactions is the repeated 
observation that in the CD complexes the most non-polar portion of the guest 
molecules are usually enclosed into the CD cavities. 
The involvement of hydrophobic interactions in complexation can also be 
shown by the correlation analyses as, in general; increasing the hydrophobicity of the 
substituents of the guest enhances the complexation [229]. Parameters of 
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hydrophobicity including the partition coefficient log P and the hydrophobic surface 
area are frequently chosen. Sometimes, the correlation between the binding strength 
and the number of carbon atoms of a homologous series of substrate is also taken as 
evidence of hydrophobic interaction. As an increment of —3.0 KJ/mol in the standard 
free energy of complexation for each methylene group is observed, which is close to 
the value in the transfer of homologous organic compounds from water to 
hydrocarbon solvent, it is, therefore, repeatedly suggested that the binding mechanism 
is of hydrophobic nature [230]. Another evidence supporting hydrophobic nature of 
complexation is that the strength of the CD complexation is usually weakened upon 
the addition of organic co-solvents [231]. Addition of inorganic salts, on the other 
hand, tends to strengthen the binding, simply because it makes the bulk solution more 
polar. The binding constants of CD complexes also increase when D20 is used as 
solvent instead of 1-120 which might be caused due to the fact that hydrophobic 
interaction is stronger in D20 than in H2O [232]. 
1.5.5 Hydrogen bonding 
The role of hydrogen bonding in CD complexes has been well established for 
the complexes in the solid state [233]. The studies of a number of crystal structures of 
the complexes have clearly shown the well defined hydrogen bonding between the 
substrates and the hydroxyls of the CDs. Usually the host-guest hydrogen bonding is 
restricted to the primary 0(6)-H groups of CDs because they are flexible and can 
rotate, in contrast to the secondary 0(2)-H and 0(3)-H groups which are rigid due to 
the preferred 4C i form of glucose units. However, it should be mentioned that 
sometimes there are also C-H......0 [234]. C-H......N [235] and C-Fl......jr-interactions 
[236] between the cavity wall of CDs and the guest molecules. 
On the other hand, the role of hydrogen bonding in CD complexation in 
aqueous solution is still controversial. The primary reason for the problem is that 
water can compete with CDs to form hydrogen bonds with the substrate molecules. 
For example, molecular dynamic calculations on the complexation of a-CD with p-
chlorophenol and p-hydroxybenzoic acid in water clearly indicated that the hydrogen 
bond is rarely formed between CD and the substrates [237]. Thus, it was concluded 
that hydrogen bonding plays a minor role in complexation. Besides, it has been 
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demonstrated that although in the solid complex of a-CD with 4-flurophenol, the OH 
group of phenol is hidden inside the CD cavity [238]. In aqueous solution the F atom 
remains inside while OH group is outside the cavity [239]. 
Nevertheless, examples of hydrogen bonding in CD complexation in aqueous 
solution have been shown by some authors. For instance, in the study of the 
complexation of y-CD with pamoic acid, the large observed binding constants were 
thought to indicate the occurrence of hydrogen bonding between the carboxylate of 
the guest and a secondary, OH of CI) [240]. Sometimes, the occurrence of hydrogen 
bonding in CD complexation can be detected with spectroscopic methods. For 
example, Takahashi el al [2411 used the 'H and 15N NMR techniques to study the 
interaction of aspartame with R-CD in aqueous solution. It was concluded that the 
amide part of aspartame was hydrogen bonded in complexation in aqueous solution. 
Recently. Chan et al [242] studied the pH dependence of the complexation of 3-
hydroxynaphthalene-2-carboxylic acid with n-CD. It was found that with increasing 
pH (pH < 11), the binding constant decreases probably because the deprotonated 
substrate is more hydrophilic. However, at pH>I I the binding constant increases as 
the pH value rises. The behavior was thought to be due to the hydrogen bonding 
between the deprotonated secondary OH of CD and the hydroxyl group of the guest at 
pH range. After n-CD was permethylated. there was little change in the binding 
constant at pH > 11 with increasing pH value, presumably because permethylated [i-
CD cannot be deprotonated under the same conditions. Thus, it can be concluded that 
hydrogen bonding plays an important role in the CD complexation. 
1.5.6 Relief from conformational strain 
The conformation of CI)s in a solid state is usually less symmetrical than that 
in the solution. The crystalline packing and the presence of water molecules in the 
solid state are, probably. responsible for this behavior. Saenger and coworkers [243] 
assumed that the deviation from the symmetrical conformation of the CDs in the solid 
state constitutes a store of energy whose relief upon complexation is a driving force 
for the complexation. This was defined as an "induced fit" mechanism. However, [3-
and y-CDs exist in nearly symmetrical conformations in solid state, yet their 
complexes tend to be stronger than those of a-CD rendering the doubts about the stain 
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relief hypothesis. Actually, the hypothesis is not relevant to the complexation in 
solution. Though it is possibly true that a CD in the solid state has a higher 
conformational energy than that in solution, the thermodynamics of the CD 
complexation in solution does not involve the energy of a solid state CD. Eftink el al 
[244] pointed out that conversion of the a-CD from its distorted to symmetrical 
conformation must cost energy; the process cannot be a source of energy for the 
complexation. Thus there seems no support for the relief of conformational strain as a 
driving force for the CD complexation. 
1.5.7 Release of cyclodextrin cavity bound high energy water 
molecules 
Two water molecules are present in a-CD cavity in solid state. As the cavity is 
relatively non-polar, the water molecules included in the cavity should lack the 
complement of stabilizing hydrogen bonds that would be available to them in the bulk 
aqueous solution. Thus the water molecule in the cavity are energy rich than those in 
the bulk solution whose release upon complexation was postulated as a driving force 
leading to the complex formation 1245]. This hypothesis was largely developed 
around the observations on a-CD. 
Takagi et a! 12461 tried to estimate the thermodynamics of inclusion separately 
from solvent effect which supports this hypothesis but the problem with high energy 
water hypothesis is that it focuses on the water and neglects the CD or more generally 
it fails to consider the energetic of the entire system. The cavity bound water molecule 
may well be enthalpy rich but they should have more conformational freedom than 
the water molecules in the bulk solution because of the lack of hydrogen bonding. 
Although. the release of the cavity bound water molecule is accompanied with a 
negative enthalpy change. the free energy change of the process is not necessarily 
negative. The reorganization of the solvent molecules is actually a process of 
enthalpy-entropy compensation without any free energy contribution. As a result, the 
release of cavity bound high energy water is not considered a driving force for the 
complexation. 
34 
Chapter 1 
1.5.8 Charge transfer interaction 
Charge transfer interaction is usually considered a type of van der Waals 
interaction [247]. It needs to be discussed separately, however, since in the area of CD 
chemistry the term van der Waals interaction usually refers to the combination of 
induction and dispersion forces. In the CD chemistry, in addition to the charge 
transfer interaction between the substituent groups of CDs and the guest [248], charge 
transfer interaction between the CD skeleton and the substrate have also been 
observed and it has been recently suggested to be a driving force in CD complexation. 
The role of charge transfer interaction in the complexation can be shown by the fact 
that- 
(I) The binding constant of a-CD complex of the I.4-dicyanobenzene radical anion is 
4,5 times larger than that of neutral 1. 4-dicyarsobenzene-u-CD complex [249]. 
(2) The binding constants of the p-CD complex of neutral 10-methylphenothazine is 
3.5 times smaller than that of 10-methylphenothazine radical cation complex [250]. 
(3) The binding constant of a-CD with the singlet xanthone is much more stable than 
that with the triplet one [251 ]. 
It may be concluded that the inclusion complexation of CDs is mainly due to 
electrostatic interactions, van der Waals interactions, hydrophobic interactions, 
hydrogen-bonding and the charge transfer interactions. However, enthalpy-entropy 
compensation, release of conformational strain and release of cavity bound high 
energy water are not energetically contributing to the complex formation. 
Furthermore, van der Weals and hydrophobic interactions constitute the major driving 
forces for CD complexations, whereas electrostatic interactions and hydrogen-
bonding can significantly affect the conformation of a particular inclusion complex. 
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Part B - Structure determination of cyclodextrin inclusion complexes 
1.6 NMR spectroscopy 
Structure determination of host-guest complexes is of particular importance in 
supramolecular chemistry. It is the basis of most CD applications in medicine, 
catalysis, separation and sensor technology, and also in food chemistry. Many 
techniques are used for characterizing these inclusion complexes in solid as well as in 
solution states such as fluorescence, UV/visible spectroscopy, calorimetry etc. which 
play a major role in measuring the complexation energetics [252]. However, these 
techniques usually provide very indirect and qualitative information about inclusion 
mode and geometry of complexes. Nuclear magnetic resonance (NMR) spectroscopy 
has been well accepted as the most powerful tool for structural elucidation of 
inclusion complexes as it provides direct evidence for the inclusion phenomena, 
particularly in the solution stale. The obvious incentive to use NMR techniques for the 
investigation of CD complexes is the interest to understand the binding modes and 
driving forces involved in these non-covalent associations. Mostly, the CD application 
involve action in liquid matrix and also the driving forces involved are often of 
solvophohic nature, which emphasizes the role of NMR spectroscopy as the most 
important method for studies in solution [253]. 
The spectacular advances of NMR techniques have led to much more detailed 
structural information of CDs and their complexes. These tasks represent a fascinating 
challenge for the NMR spectroscopist in view of the high complexity of the 
underlying cycloamylose 'H NMR spin systems [254-256]. These are characterized 
by signals, which apart from the anomeric proton, absorb in a range of only 0.5 ppm 
and are strongly coupled. In addition, the shielding effects of the CD cavity on the 
included guest molecules are limited to a few tenths of a ppm at most as a 
consequence of a host framework being built up entirely of single. less polar and 
polarizable bonds. The advent of high field instruments and two-dimensional NMR 
(21) NMR) methods, in particular, has completely changed the scenario, and the 
possibilities of now available NMR techniques are far from being exploited. 
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1.6.1 Complexation induced chemical shift changes 
Demarco and Thakkar [257] were the first to notice highileld chemical shift 
changes (OS) in P-CD cavity protons. H-3' and H-5', in presence of an aromatic 
substrate in aqueous solution and envisaged that the aromatic ring is positioned inside 
the [I-CD cavity. This observation later became the basis for NMR spectroscopic 
studies of the CD inclusion complexes. In the beginning, they used 100 MHz 
instrument and realized that it is not well suited for this type of work as all the CD 
protons are not easily distinguished. Later, they established the assignments for each 
proton on the basis of analysis of individual splitting patterns, coupling constants at 
220 MHz, decoupling experiments and expected chemical behavior i.e. H-3' and H-5' 
being 1.3 diaxial to the C, axial oxygen should resonate at lower fields than the H-2' 
and H-4' protons. At magnetic fields above 9.4 T, corresponding to 400 MHz for the 
'H NMR spectra, the dispersion is high enough to locate, in conventional one 
dimensional spectrum, most of the CD protons eased by the high symmetry of the 
macrocycles [253]. 
The first evidence for inclusion process is the change in chemical shift values 
in the protons of host and guest. It is now well accepted that the signals of the CDs 
cavity protons (H-3' and H-5') generally move highfield [258], though exceptions are 
there [259], when the guest molecule or part of it enters the cavity, while the 
remaining CD protons generally undergo only marginal or no shift changes but again 
there are few exceptions (Fig. 4). Also, the inclusion complexation results in the 
concomitant chemical shift changes for the guest protons [260] (Fig. 5). The 
magnitude of the chemical shift changes for the CD cavity protons increases with an 
increase in the concentration of guest [258-2611 and vice versa [262]. 
Furthermore. the magnitude of the chemical induced shift changes in H-3' and 
H-5' also depends on the nature of the guest, these are high for aromatic guest and 
low if guest is aliphatic. For example, salbutamol forms a 1:1 inclusion complex with 
[3-CD by the entry of aliphatic part [2631 while N-acetyltyrosine forms a complex by 
the inclusion of aromatic ring into the [I-CD cavity [264]. Fig. 6 shows a comparison 
of chemical shift changes in the cavity protons upon inclusion of aliphatic 
(salbutamol) and aromatic (N-acetyltyrosine) guest. The magnitude of the chemical 
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shift changes observed in the presence of salbutamol is relatively small compared to 
those observed in the presence of N-acetyltyrosine. 
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Fig. 4. Partial 'H NMR spectra showing. (a) increasing upheld shift of the n-CD 
cavity protons with increasing concentration of ephidrine and (b) increasing 
downfield shift of y-CD cavity protons with increasing concentration of 
ferrocenium tetrafluoroborate. 
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IR spectra of (a) 1:1 mixture of (3-CD and vanillin showing 
'it y protons of n-CD and (b) downfield shift in aromatic 
protons of vanillin. 
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Salbutamol-[3-CD complex 	N-Acetyltyrosine-[3-CI) complex 
(b) 
H-5' 
3-CD 	H-6' 
4.0 	3.9 	3.8 	3.7 	3.6 
Fig. 6. Chemical shift changes observed in cavity protons upon 
inclusion of (a) aromatic part of N-acetyltyrosine and (b) aliphatic 
part of salbutamol with same H/G ratio. 
The relative chemical shift change data has also been used as evidence for the 
depth of inclusion of the guest as well as for predicting stability of the complexes. 
Rekharsky et al. [258] made a detailed 'H NMR study of the inclusion complexes of a 
variety of guests with a-, (3- and y-CDs. They suggested that higher magnitudes of 
AS11.3 and 	and their higher relative ratios (M1.5 /ô,.3) indicate higher stability 
of the complex and deeper inclusion of the guest into the cavity, respectively. 
However. higher OM, j.s ' values compared to O6F1..j, have also been reported upon 
shallow inclusion of guest from narrower side [265-267]. 
It is obvious from the above discussion that chemical shift changes in the 
cavity protons in the presence of a guest can only be taken as an evidence of 
formation of an inclusion complex. The relative magnitudes of the OSF,-s• and A611-y 
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are an indication of position of the guest inside the cavity. The higher magnitude of 
ASns compared to ASH-3  may be either due to deep inclusion of guest from wider 
side or shallow inclusion from narrower side of the cavity and vice versa. Moreover, 
higher magnitudes of ASH.r  and  ASna'  indicate more stable complexes. It is not 
always possible to predict which part of the guest is included and mode of penetration 
of the guest on the basis of chemical shift data only 
1.6.2 Nuclear overhauser effect (NOE) / Rotational overhauser effect 
(ROE) 
Beside the chemical shift changes, observed for hosts and guests, upon 
complexation relative to pure components, detection of the through-space dipole-
dipole interactions (NOE/ROE) between CD and the guest protons which are 4-6 A 
far from each other, is another important probe for the structure elucidation of 
complexes. NOEs have been used for studying CD structures since the pioneering 
work of Bergeron and Rowan [268]. Though the advent of high magnetic fields have 
greatly enhanced the dispersion of signals; at the same time, however, the unfavorable 
correlation times of the complexes with molecular weights around 103 have led to a 
drop of the observed NOEs, e.g. from 34% at 90 MHz to 9% at 250 MHz. To obtain 
sizeable NOEs at 400 or 500 MHz, application of spin-lock techniques such as ROEs 
are highly beneficial [269]. In the 2D ROESY spectra. artifacts which possess phase 
properties different from genuine cross-peaks are also frequently observed between 
resonances within a common J-coupling network, thus being easily distinguishable. 
Tntermolecularly, in case of CD complexes, the COSY (COrrelation SpectroscopY) 
type peaks are also observed. Moreover, false cross-peaks with the same phase as 
genuine interactions may arise from scalar transfer from H-3 and/or 11-5', the cavity 
protons being most prone to interact through space with the guest. Thus more detailed 
information of supramolecular structures is obtained by ROESY spectral data. 
The use of 2D ROESY data for the study of CD complexes is illustrated by 
taking an example of complexation of para-substituted phenol and CD. Various 
probable modes of inclusion of phenol derivatives are depicted in Fig. 7 which could 
easily be differentiated by use of their 2D ROESY data. For mode I with partial 
immersion of the phenyl ring into the cavity (OH group outside), there will be 
sizeable contact of H„ with only 11-3' and H. will come in contact with both the 
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cavity protons and thus intermolecular cross-peaks. H„/H-3', Hm/H-3' and Hm/H-5', 
will be observed in the ROESY spectrum. In case the aromatic ring is positioned in 
the center of the cavity (mode II) both the aromatic protons will come in contact with 
both the cavity protons and thus H()/H-3'. H,/H-5' and HR,/H-3', Hm/H-5' cross-peaks 
can be expected. In mode 11I, deep penetration of the phenyl ring, partially protruding 
outside narrow cavity, will bring H0 close to both the cavity protons while Hm will be 
in contact with only H-5' and ROESY spectrum will show 11jH3', H{/H-5' and 
Hm/H-5' cross-peaks. In case guest enters the cavity from OH side (Modes IV-VI), the 
ROESY contacts will be just reversed for Ho, and H,,,. Thus, ROESY data can 
ascertain the position of the guest inside the cavity but whether the guest approached 
cavity from wider or narrower side cannot always be confirmed. In cases where R 
group is large enough, not being able to enter the cavity, the mode of penetration can 
be speculated. The application of 2D ROESY in the structure elucidation of CD 
complexes is exemplified by few representative examples. 
OH 
H-S' HT 
Mode I 	 Mode 11 	 Mode III 
R 
Mode IV 	 Mode V 	 Mode VI 
Fig. 7. Six possible modes of inclusion of phenol derivatives into CD 
cavity from wider side. 
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Simova et a! [270] studied the complexation of'p-nitrobenzoic acid with a-CD 
using 'H NMR spectroscopy. The ROESY spectrum showed cross-peaks of both the 
cavity protons with H,, but cross-peak between Hm and H-3' only was observed 
suggesting the position of the aromatic ring inside the cavity as shown in Fig. 8. 
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Fig. 8. Partial expansion of the ROESY spectrum of p-nitrobenzoic acid with a-CD, 
along with schematic representation of the proposed geometry. 
Karpkird eta! [271 ] determined the structure of 4-methoxy-cinnamoyl-a-CD 
by 'H NMR spectroscopy. The ROESY spectrum displayed clear cross-peaks between 
H-3' of a-CD cavity with Hh protons of 4-methoxycinnamoyl moiety and that of H-5' 
with Ha as well as Hn protons. The ROESY data clearly established the deep inclusion 
of aromatic ring of 4-methoxycinnamoyl moiety inside the cavity (Fig. 9). 
Another interesting example is the structure elucidation of a 1:1 inclusion 
complex of 4-hydroxyazobenzene and O-CD [272]. Intermolecular cross-peaks were 
observed in ROESY spectrum between H-5' of [3-CD and H t, protons of 4-
hydroxyazobenzene, as well as between the H-3' and II  protons of 4-
hydroxyazobenzene. Moreover, the cross-peaks between the H-6' of O-CD and Ha as 
well as Hb of 4-hydroxyazobenzene were also observed. Possible inclusion 
complexation geometry on the basis of ROESY spectrum of 4-hydroxyazobenzene-[3-
CD was proposed as illustrated in Fig. 10. However, it was not possible to determine 
with certainty, from ROESY data, whether guest entered the cavity from wider or 
narrower side but since generally approach of the guest is more favorable from wider 
side, it can be assumed the mode of penetration. 
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Fig. 9. Partial expansion of the ROESY spectrum of 4-methoxycinnamoyl-a-CD 
along with schematic representation of proposed geometry. 
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Fig. 10. ROESY spectrum of 4-hydroxyazobenzene with a-CD in D20 and the 
possible structure of 4-hydroxyazobenzene-(3-CD complex in solution. 
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1.7 Stoichiometry and binding constant of inclusion complexes 
The determination of stoichiometry in host-guest system is strongly correlated 
with the estimation of binding constant. The stoichiometry of the complex tells us 
about the number of host and guest molecules present in the supramolecular system, 
the general representation being H.G.. The most common stoichiometry is 1:1 (H1G1) 
but other stoichiometries like H201, H202, 11)02, H3G1, H1G3 etc. are also known 
[273-277]. Most common approach to find stoichiometry is the supramolecular 
titration method. Here, one component (guest) is gradually added to the system (host) 
while monitoring a physical property such as specific chemical resonance (NMR) or 
absorption band (UV) that is sensitive to the supramolecular interaction(s) of interest. 
The resulting information is then compared and fitted to binding models to obtain 
information regarding stoichiometry, binding constant etc. 
Of all available methods, NMR titration are most employed NMR 
experiments for finding stoichiometry of the CD complexes and are based on changes 
in chemical shift values [278]. There are several methods to determine stoichiometry 
by NMR titration method namely continuous variation method (job's plot), mole ratio 
method and several 'H NMR modification of Benesi-Hildebrand method. 
1.7.1 Job's plot 
The method of continuous variation [279] involves preparing a series of 
solutions containing both host and guest in varying proportions so that a complete 
range of mole ratios is sampled (0<[H]/[H]+[G] <1) and where the total concentration 
of [H]+[G] is kept constant for each solution. The experimentally observed parameter 
is a host or guest chemical shift values that is sensitive to complex formation. The 
data is plotted in the form [H]/4S0b versus [H]/[H]+[G}. The position of the 
maximum indicates the stoichiometry of the complex (Fig. 11). 
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Fig. 11. A typical Job's plot for 1:1 complex. 
1.7.2 The mole ratio method 
In mole ratio method [280] a series of solutions are prepared in which the 
formal concentration of one of the components is held constant while that of the other 
is varied. A plot of the chemical shift change (M) versus mole ratio of the component 
is prepared if the formation constant is reasonably favorable, two straight lines of 
different slopes are obtained; their intersection occurs at a mole ratio corresponding to 
the combining ratio in the complex (Fig. 12). 
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Fig. 12. A typical molar ratio plot showing 1:1 stoichiometry of the complex. 
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1.7.3 Modification of Benesi-Hildebrand method 
The sloichiotuetry and association constant of the inclusion complex can also 
be determined by any of the following modification of Benesi-Hildebrand methods. 
Assuming that the composition of the complex is 1:1, the following expression can be 
written: 
G+H~GH 
The association constant of the complex (K,) is given by 
Ko = [GH]/[H][G] 
where [H], [G] and [GH] are equilibrium concentration of host, guest and complex 
respectively. 
Benesi-Hildebrand studied the complexation of iodine with aromatic hydrocarbons by 
W-visible spectroscopy [2R1] and derived the following linear equation (eqn. 1) for 
the calculation of K. 
sobs 	KvEa,lIll + t 
	(t)
pnn 
where, ^_-oss is the extinction of a layer of solution 1 cm deep containing m moles of 12 
and 0. is the molar extinction coefficient of the complex at the wavelength of 
maximum absorption. 
NMR version of the Benesi-Hildebrand equation was independently derived by 
Mathur et a7 [282] and Hanna and Ashbaugh [283]. 
1 _ I + r 	(2) 
TZv—s Kaddma+IB] Asm- 
where,  OSoe$ ° (SG—Sans) and ASma ° (SG—SGH). 
A plot of 1/aSoe, against I/[H] (often referred to as double reciprocal plot) should he 
linear for a 1:1 complex, with a slope I /KaA&IJX and intercept I 'Mm.' allowing the 
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determination of association constant (K,). This expression is valid when one species 
is observed in the presence of large excess of other species. 
An alternative solution of Benesi-Hildebrand equation has been proposed by 
Foster and Fyfe (eqn. 3) [284]. 
e6_e~ 
(NJ 
_ —Kn06nbs + KaMmax 	(3) 
This is a special form of more general Scatchard plot [285]. In the Foster-Fyfe 
procedure, a plot of ASobd[H] against Mobs (referred as an x-reciprocal plot) should 
be linear for a 1:l complex (Fig 13). The gradient is equal to -Ka and the intercept 
gives A8,,,a,. This modification requires an extrapolation to infinitely dilute solution 
and the K, is not dependant on the extrapolation. 
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Fig. 13. A typical Foster-fyfe plot showing 1:1 stoichiometry of the complex. 
Another modification of Benesi-Hildebrand equation is Scott's equation (eqn. 
4) [286]. 
[cnl _ JCDI + I 	 (4) 
esee: eas xaes~ 
In the Scott procedure, a plot of [CD]/ASS is plotted against [CD] (referred to as y-
reciprocal plot) which should be linear for a 1:1 complex with the slope 1/AS, and the 
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intercept with the vertical axis to I/KaAS0, allowing the estimation of association 
constant (K,). A typical scott's plot is shown in Fig. 14. 
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Fig, 14, A typical Scott's plot showing 1:1 stoiehiometry of the complex. 
The stoichiometry and association constant of the 1:1 tetramethrin and (i-CD 
inclusion complex were determined by spectrofluorometry [287] through double 
reciprocal plot (eqn. 5) [288] 
&Fops KudFm— [H] + LFm— 	 (5) 
where, AF denotes the change in fluorescence intensity of tetramethrin in the 
presence of (1-CD compared to pure tetramethrin and /Fmllx is change in fluorescence 
intensity of tetramethrin when all of its molecules are complexed with 13-CD, 
compared to pure tetramethrin while other symbols have their usual meaning. The 
equation is identical to the Hanna-Ashbaugh (eqn. 2) except that a different property 
of the complex is studied. 
Now, assuming the complex to be 1:2, the following expression can be written: 
G+2H~GH2 
The association constant of the complex (Ka) is given by: 
IGH21 
Ka = [H]2[G1 
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If [H]>>[GH2]>>[GH] then the following linear expression (eqn. 6) is obtained for 
calculating binding constant by fluorescence spectrometry; 
t 	1 	
(6) GFnbs KaAFinax[K]2 + AFmu 
where the symbols have their usual meaning. A plot of 1/Fobs against 1/[H]2  gives a 
straight line for L2 complex. Thus, the NNW version of this equation can be written 
as: 
1_ 	1  
48an, Kaadma:[N1' + AS,ao: 
A plot of 1/ASob, versus 1/[H]2 should be a straight line for 1:2 complex with a slope 
l/KaASmax and intercept 1/6 allowing the determination of association constant. 
Throughout the above discussion it is assumed that the guest molecule is the observed 
species. It does not matter which species is observed and the most readily observed 
and responsive molecule would normally he chosen. The data treatment for observed 
host is identical, with host and guest symbols switched. 
Throughout discussion the CD protons are numbered as H-1' to H-6'. 
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1.8 Computer simulation studies 
Computers started to be used in chemical research in the early sixties. 
Although initially used for storage and evaluation of experimental data, computers are 
now used for wide range of applications including implementation of theoretical 
chemical models, simulation of real chemical processes, and computation of chemical 
properties. In the area of chemical research, a specialization called computational 
chemistry that uses principles of computer science to assist in solving chemical 
problems developed stepwise. This specialization progressed tremendously in the past 
few decades and is now one of the main stays of modern industrial and academic 
chemistry. The computer serves as an instrument to solve real-world chemical 
research problems, much like the dif'ractometer is the tool of X-ray crystallography 
or the spectrometer is the tool of NMR spectroscopy [289]. Theoretical chemists, 
physicists and mathematicians develop algorithm and computer programs to predict 
atomic and molecular properties and reaction paths for chemical reactions. 
Computational chemistry has become a useful way to investigate materials that are 
too difficult to find or too expensive to purchase. It also allows one to investigate 
molecules that are unstable to be studied experimentally, analyze quantities (such as 
atomic charges) that are not experimentally observable, and to rectify incorrect 
experimental assignments. The principal branch of computational chemistry that 
encompasses all theoretical methods and computational techniques is molecular 
modeling which is used to model or mimic the behavior of molecules. Molecular 
modeling methods are now routinely used to solve a broad range of chemical 
problems, including structural chemistry. mechanistic studies, biotechnology (protein 
and drug design) and materials science (polymer, catalysis. metal, solid surfaces, etc). 
The molecular modeling techniques enable the calculation of molecular geometries, 
energies and physical properties with varying accuracy, depending on the calculation 
method and theory. It is a collection of mathematical approximations and algorithms 
that allows scientists to generate and present molecular data including geometries 
(bond lengths, bond angles and torsion angles). energies (heat of formation, activation 
energy. etc.) and physical properties (volumes, surface areas, diffusion, viscosity, 
etc.). It also helps chemists to make predictions before running the actual experiments 
so they can be better prepared for making observations. 
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Molecular modeling techniques range from highly accurate to very 
approximate; highly accurate methods are typically feasible only for small 
systems. For instance, Ab initio methods that are based entirely on theory from first 
principle quantum mechanics while other methods that are empirical or semi-
empirical employ experimental results, often from acceptable models of atoms or 
related molecules, to approximate some elements of the underlying theory. For 
studying the supramolecular complexes of CDs, various methods of molecular 
modeling have been utilized to represent three-dimensional structures of complexes. 
In contrast to other methods, that are extremely time-consuming and expensive, 
molecular mechanics (MM) and molecular dynamics (MD) are the most commonly 
used methods as they are simple and easy to handle, available with high 
computational speed. and economically inexpensive [290]. These methods have the 
advantage of giving a direct picture of the interacting groups and they provide a better 
and practical clue for the chemist to understand and to design CD inclusion 
complexes. Generally MM2, MM3, CFF, AMBER, AMI and PM3 force fields are 
used for studying host-guest interactions. [290] 
Currently two common modeling strategies are being utilized to investigate, 
interpret, and explain the molecular properties using three dimensional structures in 
combination with experimental studies. One approach is to fmd a geometry that 
satisfies some geometric constraints and is also a good chemical match of the 
experimentally derived model that is reflected by numerous studies employing 
theoretical modeling methods in support of the experimental data. Another approach 
is to design and resolve the three-dimensional structure of the complex where 
experimental measures failed to explain the complete detail of the geometry and 
hence, theoretical methods are used to corroborate the experimental data. Some of the 
examples are discussed here highlighting the use of molecular modeling studies in 
attaining the three-dimensional model for the inclusion complexes. 
Recently, Sohajda et al computed the structure of aspartame--CD exploiting 
ROESY and molecular modeling technique [291]. On the basis of 'II NMR 
complexation shifts and intermolecular cross-peaks observed in 2D ROESY, the 
authors proposed a geometric model of the supramolecular complex with aromatic 
ring of aspartame including through the wider rim of (3-CD. Intense cross-peaks 
between ortho-protons (H-2 and H-6) of phenyl ring with H-3' of n-CD cavity 
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protons and ROESY interactions between para-proton (H-4) and H-5 of a-CD cavity 
suggested that inclusion is deep and proceeded from the wider side of the cavity. The 
three-dimensional structure of aspartame-(3-CD complex obtained from molecular 
modeling was found to be in good agreement with the experimental ROESY data 
(Fig. 15). 
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Fig. 15. Schematic structure of aspartame (left) and aspartame-[3-CD 
complex based on MD (right). 
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Fig. 16. ROESY spectrum of an aqueous sample containing aspartame 
and a-CD at 2:1 molar ratio. 
An unambiguous structural elucidation of nitrooxoisoaporphine complex with 
DM-[3-CD was assessed by means of experimental and theoretical methods by Perez-
Curl et al [292].The ROESY spectrum (Fig. 17) confirmed the inclusion of 
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nitrooxoisoaporphine in DM-R-CD which was further corroborated with molecular 
modeling. Molecular modeling results suggested a preferred final relative orientation 
for the complex where the heterocycle was inserted in the DM-~3-CD cavity with the 
nitro and dimethylamino groups oriented near the secondary rim. The nitro group was 
partially positioned within the cavity whilst the dimethylamino group was exposed to 
the outside (Fig. 18). Thus, molecular modeling results gave a three-dimensional space 
perspective about the complex of nitrooxoisoaporphine with DM-(3-CD which was in 
complete agreement with ROESY experimental results. 
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Fig. 17. 2D ROESY spectrum of nitrooxoisoaporphine in presence 
of DM-~3-CD in D20. 
Fig. 18. Interaction mode for nitrooxoisoaporphine-DM-0-CD obtained from 
molecular docking studies from frontal (left) and secondary rim (right) perspective. 
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The structure of pyrimethamine complex with HP-[3-CD, Cl-in cavity 
orientation of the drug, was proposed on the basis of simulation studies (AM 1, PM3 
and MM3) by Gaspar de Araujo el a! (Fig. 19) [293]. The structure proposed by 
molecular modeling was further confirmed by ROESY spectral data (Fig. 20). In the 
ROESY spectrum of the pyrimethamine and HP-[3-CD inclusion complex, it was 
possible to observe correlations of Hm protons of the p-chlorophenyl moiety with both 
H-5' and H-3' while Ho showed contact with only H-5' of HP-(3-CD protons. The 
proposed ROESY inclusion mode was found in good agreement with the theoretical 
structure proposed on the basis of molecular modeling studies demonstrating that a 
combination of experimental and theoretical studies is better tool for establishing the 
geometry of these types of complexes. 
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Fig. 19. Pyrimethamine structure (left) and complex of 
pyrimethamine-HP-¢-CD in Cl in orientation (right). 
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Fig. 20. 2D ROESY spectrum of pyrimethamine in presence of HP-[3-CD. 
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The spatial configuration of 2-(2-nitrovinyl) furan inside HP-[-CD cavity was 
investigated using NMR spectroscopy and molecular modeling studies by Ruz et al 
[294]. Cross-peaks in ROESY spectrum suggested complexation of 2-(2-nitrovinyl) 
furan with HP-R-CD. However, due to overlapping of cavity protons signals it was 
difficult to retrieve three-dimensional structure of complex on the basis of ROESY. 
Molecular modeling established the unambiguous geometry of 2-(2-nitrovinyl) furan 
complex HP-P-CD (Fig. 21). 
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Fig. 21. (a) Chemical structure of 2-(2-nitrovinyl) furan (G-0) in 2D ROESY 
spectrum of G-O/HP-~3-CD complex and schematic representation of the 
inclusion complex (top), (b) front and side view of HP-(3-CD with a G-0 
molecule after MD simulation. 
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1.9 Quantitative NOEIROE analysis 
The NOE is undoubtedly one of the most important discoveries in NMR 
spectroscopy, It is widely used in solving structural and conformational problems of 
small organic molecules to macromolecular systems alike [295]. The intensities of 
cross-peaks in NOE correlated spectra primarily depend on the inter-proton distances 
but they also depend to a substantial extent on several other experimental parameters 
including spin diffusion, additional cross-relaxation pathways, selective polarization 
transfer, accuracy of signal integration, and conformational flexibility [295]. The 
analyses of NOE data are generally for the purpose of qualitative (NOE/no NOE) or 
semi-quantitative (strong/medium/weak) when applied to stereochemical 
determination of small molecules [295]. 
Of all factors which affect the cross-peak intensities in a NOE spectrum, 
mixing time (i.) used in the pulse sequence of NOESY is of particular importance. 
During this time, magnetization transfer occurs between protons coupled through 
dipolar interactions (D). If the system consists of only two cross-relaxing protons, 
then the intensity of the cross-peak increases with mixing time till a steady state is 
reached. However, when the system consists of more than two spin systems, it 
constitutes a network of D-coupled spins and a more complicated diffusion of 
magnetization occurs which is referred to as spin diffusion. Under such conditions, 
the relative intensities of NOE cross-peaks are not a true measure of the distances 
between the protons they connect. Another important factor which affects intensities 
is the line shape. The line shapes are distorted when complex data manipulation 
procedures are employed, and in the event of poor multiplet resolution, component 
intensities cancel each other, resulting in poor overall intensities. 
For last several years, researcher are making efforts to obtain precise inter-
proton distances, from NOE intensities data, which are extremely valuable in the 
configurational and conformational analyses of small-to-medium sized organic 
molecules in solution and the method has potential for examining solution structures 
in much greater detail than before, with a resolution approaching (but probably not 
equaling) that of X-ray crystallography. 
Procedures have been evolved to overcome these problems and some success 
has been achieved in getting reasonable estimates of inter-proton distances. On the 
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other hand, improvements in NMR hardware (non-quadrature detection, improved RF 
generation, and digital receivers, etc.), NOE experimental methods (e.g., ID-DPFGSE 
sequences, [296-2981) zero-quantum suppression [299]), and data analysis, such as the 
PANIC method of Macura [300,301] have made quantitative measurements of NOEs 
more reliable [301-303]. Though methodologies are still being developed for 
obtaining more accurate distance estimates, there are numerous examples in the 
literature for the semi-quantitative and quantitative estimation of NOESY data [304-
306]. 
Macuet eta! [300] demonstrated that employing relative, rather than absolute, 
intensities of NOEs from within a single experiment can be used to correct for 
relaxation in 2D-NOESY experiments-effectively extending the period during which 
the initial rate approximation holds for the absolute values of NOE enhancements. 
When initial rate (and thus Isolated Spin Pair) approximation holds true, there are 
negligible negative (transferred) NOEs (<0.1% of intensity of the inverted resonance) 
and all relative NOE intensities are essentially constant with mixing time (up to -600 
ms), i.e. each NOE builds up at a rate proportional to its initial intensity during this 
time. 
Under these conditions one can assume that a pair of protons (I and S) give 
rise to a buildup of NOE intensity which, for a given mixing time, is proportional only 
to the I—S cross-relaxation rate (ors) according to eqn (8) where r)ls is the intensity of 
the NOEs between land S and Tm is the experimental mixing time [295,307]. A more 
complete description of this equation and their use in determining interproton 
distances can be found in references [295,308]. 
Ills = aisTm 	 (8) 
Further, in the fast tumbling regime. the cross-relaxation rate is proportional to 
the inter-nuclear distance (rfs 6) as described by eqn (9). 
Thus, 
'Its = kriS6 	 (9) 
Its = krts Tm 	 (10) 
where, k = l4n) fiID It+a~,=r — T 
The values of Po, y, o are essentially fixed for a given experiment, and thus if we 
assume r, is comparable for each spin pair in a given selective inversion experiment 
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then k can be assumed to be constant (and identical) for each spin pair within a given 
selective inversion experiment. If k is also constant, as described above, then the ratio 
of the intensities of a pair of NOE signals 1I,rs:or2, within that spectrum can be 
assumed to be proportional to their ratio of inter-nuclear distances (eqn (10)) and this 
ratio will be independent of mixing time (within the Initial Rate Approximation). 
Since in a given experiment NOE intensity will build-up for a fixed tm. 
1Jfis __ rji% 
711zS 	r12S 
Thus, if all of the above assumptions are valid then the calculation of inter-
proton distances is very straight forward. By measuring tl j s and TIPS we only need to 
know one distance, e.g. rji s. in order to calculate the second distance, rp5 and so on. 
Using above relationship (eqn. (10)) Butt and coworkers have shown that 
inter-proton distances can be accurately determined by a simple analysis of transient 
NOE intensities fitting extremely well with crystallographic and DFT calculated 
structures for both rigid as well as flexible small molecules suggesting that many of 
the perturbations highlighted above do not contribute significantly under the 
conditions reported. They calculated the inter-proton distances and there from 
established the absolute configuration of strychnine in solution and also confirmed the 
presence of a minor conformer (2.5%) [308.309]. They also demonstrated that using 
(eqn. (10)) inter-proton distances can also be calculated with extremely high accuracy 
for small flexible molecules e.g. 4-propylaniline (Fig. 22) [310]. 
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Fig. 22. Molecular structure of strychnine and 4-propylaniline. 
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Later, they demonstrated the application of combined accurate ROE-distance 
analysis with OFT calculations of NMR chemical shifts to achieve the relative 
configuration assignment of a marine natural product, conicasterol F (Fig. 23), a new 
polyhydroxylated steroid isolated from the marine sponge Theonella swinhoei [311). 
L 
m 
Fig. 23. Molecular structure of conicasterol F. 
It becomes obvious from above discussion that NMR spectroscopy and 
computational studies are complimentary to each other. NMR studies confirm the 
existence of inclusion complex and are also used to determine the stoichiometry and 
binding constant. From ROESY spectrum, it is established which part of the guest is 
encapsulated into the CD cavity and the mode of entry is also sometimes indicated. 
The results of computational studies show the feasibility of formation of complex and 
the favored mode of entry of guest into the cavity. 
If results of computational studies are well matched with NMR data, the 
minimum energy configuration is then analyzed in light of ROESY data. In case, all 
the intermolecular contacts obtained in the ROESY spectrum are well explained by 
this minimum energy structure, it is considered most likely to be present in solution, 
But these structures are highly ambiguous because ROESY peak intensities depend 
primarily on inter-proton distances and very insignificant change in the conformation 
of inclusion complex will affect ROESY peak intensities drastically. The quantitative 
estimation of ROE data for structure elucidation is very good tool to avoid ambiguity 
of inclusion structures. It has been used successfully in rigid as well as flexible 
molecules, although its use for structure elucidation of CD supramolecular system is 
still in its young stage. 
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Study of Enalapril-j9- Cyclodextrin and 
Enalapril- y'-Cyclodextrin Inclusion 
Complexes 
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ENALAPRIL MALEATE 
I UPAC name: (2S)-1-[(2S)-2- { [(2S)-1-ethoxy-l-oxo-4-phenylbutan-2-
yl]amino, propanoyl]pyrrolidine-2-carboxylic acid . (Z)-butenedioic acid 
Molecular mass: 492.5 g/mol 
Melting point: 143-144.5 °C 
Solubility: sparingly soluble in water, soluble in ethanol, and freely soluble in 
methanol 
Structural formula: C20H28N205 . C4H404 
Color/appearance: white to off-white, crystalline powder 
Enalapril (ENA) is the ethyl ester of the angiotensin converting enzyme 
(ACE) inhibitor, used for the treatment of hypertension and some types of chronic 
heart failures [312]. ACE converts the peptide hormone angiotensin Ito angiotensin II 
which is responsible for narrowing the arteries and consequently leads to hypertension 
[313]. Since, the oral absorption of ENA is superior to that of enalaprilat, the former 
is used in oral dosage form [312]. The therapeutic application of ENA has certain 
limitations [314]. ENA has stability problem since it suffers degradation in the solid 
state as a consequence of its interaction with excipients. The formation of maleate 
salt, which reduces the attacking ability of the nitrogen atom, was an attempt to 
overcome this problem [315J. By this strategy, the stability of ENA formulations 
improved a lot but this was not sufficient enough to assure long term stability of the 
formulations that are currently in use [313]. Attempts have also been made to mask 
the bitter taste of the drug by forming sugar containing or sugar free liquid oral 
suspensions but this undertaking also lacks durability [316]. 
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The complexation studies of ENA with a-CD have been carried out earlier 
[317] and the formation of a 1:2 R-CD-ENA complex was reported in which aromatic 
ring and proline ring of ENA were reported included in the cavity. The aromatic ring 
entered via narrow side while part of proline ring penetrated the cavity through wide 
side. Later. Longhi and coworkers [318] reported the formation of 1:1 [13-CD-ENA] 
complex in which only the aromatic ring was trapped inside the cavity through wide 
side and their results were also supported by molecular modeling studies. Therefore, 
the structure of ENA-[i-CD inclusion complex was reinvestigated and complexation 
of ENA with y-CD was studied. 
2.1 Experimental studies 
2.1.1 Materials: 
ENA was gifted by Nebula Healthcare, India. while [3- and 'y-CD were 
obtained from Geertrui Haest, Cerestar Application Centre, Food & Pharma 
Specialities. France, and these were used without further purification. 
2.1.2 One-dimensional NMR experiments: 
All the 'H NMR spectra were recorded on a JEOL 500 MHz instrument in 
D20 at 298 K. No external indicator was used. Chemical shift values (S) are reported 
in ppm and HDO signal at 4.800 has been used as internal reference throughout this 
work. 1 H NMR spectra were recorded for pure ENA as well as six mixtures of each (3-
CD and ENA and y-CD and ENA having molar ratios 1:0.25. 1:0.50, 1:0.75, 1:1.00, 
1:1.50 and 1:2.00. NMR samples of ENA and CD mixtures were prepared by taking 9 
mg of CD ([3- or y-) and adding calculated amount of ENA in 0.5 ml D20. All the 
mixtures of the drug and CD as well as pure ENA and CD were shaken and/or 
sonicated till clear solutions were obtained. The chemical shift change was calculated 
according to the formula: Ai = 6(cOmpjex) _ 6(f«,). Distinct peaks for bound and free 
form of ENA or CD were not observed in any of the spectrum, indicating a rapid 
exchange of guest between free and bound state on the NMR time scale. 
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2.1.3 Two-dimensional NMR experiments: 
For the purpose of unambiguous assignments of 'H NMR signals COSY 
spectra of 1:1 mixtures of ENA and p-CD and ENA and y-CD were recorded. The 
COSY spectra of ENA and p-CD mixture and ENA and y-CD mixture were recorded 
with gradient ratio of 1:1 and relaxation delay of 1.5 s. A total of 1280 data points in 
F2 and 256 data points in Fl over a spectral width of 5000 Hz were collected. 
ROESY spectrum were acquired in phase sensitive mode for 1:1 mixtures of both 
ENA and n-CD as well as ENA and y-CD with a spin lock power of 21 dB, 
relaxation delay of 1.5 s and mixing time of 0.5 s. ROESY spectrum of ENA and (3-
CD mixture was measured by acquisition of 1024 (F2) x 39 (Fl) data points, with 
5000 Hz spectral window in both dimensions while spectrum of ENA and y-CD 
mixture was measured by acquisition of 1024 (F2) x 51 (Fl) data points, with 5000 
Hz spectral window in both dimensions. The experiment was stopped as soon as 
crosspeaks appeared between ENA and CD cavity protons. 
2.1.4 Computational methodology: 
Computational studies were performed using Allinger's MM2 program of CS 
Chem 3D Pro (Cambridge Soft Corp.) in vacuum, at 298 K. The geometries of [3- and 
y-CD were obtained from the crystallographic structure as determined by X-ray 
diffraction and deposited in the Cambridge databank [319] after removal of water 
molecules because final product does not contain water molecules inside CD cavity. 
The structure of the ENA was drawn and its geometry was then minimized to a root 
mean square (RMS) value 0.1 kcalmol'' A' under the MM2 force field. This geometry 
was used in all calculations of inclusion complexes. MM2 studies were carried out by 
keeping the optimized structure of ENA molecule into the CD cavity in a 
perpendicular manner of its diameter and allowed for full geometry optimization at 
the corresponding level of calculation. Energy minimizations were performed in two 
ways; with constraints and no constraints on the movement of CD. With the optimized 
geometries as the initial structures, the molecular dynamics (MD) simulations studies 
were performed by placing the aromatic ring of ENA near the mouth of CD cavity 
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along z-axis from wider rim side (Fig. 24) at an iteration step of I fs. In simulation 
studies, only the guest molecule was allowed to move. The conformations were 
recorded after every 10 iterations with 5000 and 6000 steps of equilibration for ENA-
13-CD and ENA-y-CD complex, respectively. 
x-axis 
Y 
o 	0 
'N 
Fig. 24. Coordinate system used to define the complexation process. 
63 
Chapter 2 
Part A: study of enalapril-B-cyclodextrin 
inclusion complex 
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Fig, 34. ROESY spectnim for a mixture of ENA and f •CD having molar ratio [F.AA1'[[3•CDj =1.00:1.00. 
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2.2 Results and Discussion 
2,2.1 1H NMR spectroscopic studies 
To clearly ascertain the geometry of ENA-R-CD complex and to establish 
which part of ENA is interacting with CD, an unambiguous resonance assignment of 
ENA protons in free and complexcd state is required, which was made with the help 
of COSY spectral data obtained for 1:1 mixture of ENA and p-CD (Fig. 33). A triplet 
which appeared in the aromatic region at 7.3978 (2H, J= 7.45 Hz) was ascribed to H-
3,5 of the aromatic ring while H-2,4,6 were found resonating around 7.3200 as a 
multiplet (Fig. 25). The signals for H-12 and H-14 protons appeared most upfield at 
1.3135 and 1.5746 respectively. The signals for methylenic protons at H-17 and H-8 
were merged and were found resonating at 2.3287. The peak at 2.0246 was ascribed 
to H-18 and the peak at 2.8159 was assigned to H-7 since both of them showed 
coupling with 1-1-8/17 signal. As expected the signal for methylenic protons at 11-19 
appeared downfield at 3.6010 due to the presence of electron withdrawing group 
while signal for methylenic proton at H-11 was found merged with H-13 signal at 
4.2R94. The peak at 4.4380 was assigned to H-16 as it showed interaction with H-
17/H-R signal. The signals for H-9 and H-19 protons were found centered at 3.9339 
and 3.6010 respectively. The total integrated peak area very well rationalized the total 
number of protons present in ENA molecule. 
The assignment of proton resonances of -CD was achieved by examining the 
scalar interactions by means of COSY experiment. The part of COSY spectrum 
showing cross connection peaks of (3-Cl) protons is given in Fig. 35. The assignment 
of 13-CD protons matched very well with the reported data [320]. 
A cursory examination of 1 H NMR spectra of the mixtures of RNA with (3-CD 
(Fig. 27-32) revealed prominent upfield shift changes, compared to pure. in both the 
cavity proton resonances, while remaining CD protons showed only trivial changes. 
Moreover, the chemical shift change observed for H-5' was more pronounced 
compared to H-3'. In the presence of p-CD recordable downfield shifts changes were 
observed for ENA aromatic hydrogens. The shift change observed in H-3,5 was 
greater than 13-2,4,6. 
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The upfield shift changes observed for cavity protons of 13-CD and 
concomitant downfield shift changes for aromatic protons of ENA in the spectra of 
mixtures are evidence of formation of inclusion complex in solution, since the 
screening environment is sensed only by the hydrogens of the inner surface but not by 
the hydrogens located on the outside surface of 13-CD. The chemical shift change 
observed in the signals of cavity protons of 13-CD in the presence of ENA (H/G = 1:2) 
were 0.0541 (H-3') and 0.1256 (H-5') respectively. (Fig. 36). 
H-6' 
H-3' 
HS' 	
H2 
li H-4' 
I1c   
4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 
Fig. 35. Part of COSY spectrum showing the interaction of 13-CD protons. 
~~ H.6' 
W1 	 H.2• 
J j) 4t J 
4.0 	3.9 	32 	3.7 	3.6 	3.5 
Fig. 36. Expansion of 'H NMR spectra of 13-CD as well as mixture of 13-CD 
and ENA showing CD region: (A) 13-CD/ENA 1:2 mixture (B) pure 13-CD. 
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2.2.2 Stoichiometry and binding constant of ENA-f3-CD complex 
Stoichiometry and binding constant of ENA-[3-CD complex were determined 
by Scott's method which is the modified form of Benesi-Hildebrandt method. Scott's 
equation for 1:1 ENA-[3-CD complex can be written as: 
[ENA] _ [ENA] + 1  
Sobs A6S KQ ASS 
where [ENA] is the concentration of ENA. A&,s is the observed chemical shifts= 
changes for a given [3-CD concentration with varying concentrations of ENA, and ASs 
is the chemical shift difference between pure sample of complex and the free 
component at saturation and Ka is binding constant. Chemical shift change data 
(Table. 14) for H-3' and H-5' of (3-CD was plotted in the form of [ENA]/ASohs versus 
[ENA] which gave excellent linear fits. confirming 1:1 stoichiometry of the ENA---
CD complex (Fig. 37). The overall binding constant was found to be 74.3 M"'. 
Table: 14 1 H NMR titration data used for Scott's plot. 
SAMPLES 
(13-CD:ENA) 
[ENAI 
(mM) 
AS}i.3. 
(ppm) 
Mn_5. 
(ppm) 
[ENAI/A6H.3• 
(mM/ppm) 
[ENAJ/OSH_5• 
(mM/ppm) 
1:0.25 3.96 0.0182 0.0576 217.58 68.75 
1:0.50 7.93 0.0280 0.0637 283.21 124.49 
1:0.75 11.89 0.0340 0.0731 349.71 162.65 
1:1.00 15.86 0.0390 0.0877 406.67 181.46 
1:1.50 23.79 0.0460 0.1092 517.17 217.86 
1:2.00 31.72 0.0541 0.1256 586.32 252.55 
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W 
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Fig. 37. Scott's plot for 1:1 ENA-(i-CD complex. 
2.2.3 ROESY spectroscopic studies of ENA-fl-CD complex 
The ROESY spectrum (Fig. 34) clearly gave evidence for interaction of 
aromatic protons of ENA with p-CD cavity protons. Proton dipolar contacts 
correlations in the ROESY spectrum are shown in Fig. 38, All the aromatic protons of 
ENA showed contacts with both the cavity protons, i.e. H-3' and 11-5', in the ROESY 
spectrum of ENA-(i-CD mixture confirming that inclusion phenomenon has indeed 
taken place and aromatic ring is embedded into the p-CD cavity. The wide side entry 
of guest molecule was indicated by observation of cross peaks between H-3' cavity 
proton and benzylic protons (H-7) of ENA (Fig. 34). 
Though it is very clear that aromatic ring enters the cavity from wider side and 
is fully positioned in the CD cavity, it is not possible to predict the exact mode of 
penetration of aromatic ring in the cavity. Two probable geometries (Modes I and II) 
(Fig. 39) can be considered for orientation of ENA into D-CD cavity. Of the two 
probable geometries for this complex, Mode I seemed more favorable due to steric 
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factors but needed further confirmation. In order to fully establish the structures of 
these complexes, molecular modeling studies were performed. 
H-2.4.6 	 H-6 
H-3.5'' H-3' 
i 
ENA  
	
-CO N 	 ENA 
11  
M 	 _ U 
O
____ 
Z 
Q) 	 -= t. 	 W 
o 	 c''
14) 
7.5 7.4 7.3 7.2 	 4.0 3.9 3.8 3.7 3.6 
Fig. 38. Portions of ROESY spectrum of 1:1 mixture of ENA and n-CD showing 
intermolecular interaction of aromatic protons of ENA with n-CD cavity protons on 
both sides of diagonals. 
Mode I 	 Mode 1I 
Fig. 39. Two probable geometries (Modes I and II) depicting the 
orientation of ENA inside the n-CD cavity. 
2.2.4 Energy minimization (MM2) studies 
The MM2 energy minimization studies were carried out for three potential 
binding sites (the aromatic ring, proline part and ethoxycarbonyl group) present in 
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ENA molecule. The MM2 calculations for the process of inclusion of ENA into the (3-
CD cavity through both the rims were carried out for these binding sites of ENA. A 
total of six possible orientations for each binding site were studied; three each through 
the wider (W) as well as narrower (N) rim side. The guest was placed near the rim 
partially inside (S), in the center of the cavity (C) or deep inside the cavity partially 
outside the bottom rim (B) (Fig. 40). Two possible modes (Fig. 39) of penetration of 
aromatic ring were studied. Both the ENA and n-CD were allowed to move freely 
during energy minimization. 
Wide-to-surface (WS) Wide-to-Centre (WC) Wide-to-Bottom (WB) 
tj 	I 
Narrow-to-Surface (NS) Narrow-to-Centre (NS) 
I 
Narrow-to-Bottom (NB) 
Fig. 40. Orientations of ligands used for MM2 calculations. 
The results of the MM2 minimization studies are summarized in Table. 15. 
The results indicated that the lowest energy complex (Fig. 41. steric energy 85.8396 
kcal/mol) was obtained when the aromatic ring was placed in the center of the CD 
cavity, as shown in mode I, (Fig. 40) from wider rim side (WC). 
The positioning of the aromatic ring from wide side (Mode I) near the mouth 
of the cavity (WS) or deep inside the cavity (WB) gave quite unstable complexes 
having energies 112.6862 and 100.0263 kcallmol, respectively. Similar pattern was 
observed when the aromatic ring (Mode 1) entered from the narrower rim. In this case 
two complexes NC and NB having very close energies were obtained. The complexes 
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formed by penetration of aromatic ring (Mode II) into the CD cavity from either side 
of the cavity were found to be less stable compared to those obtained by penetration 
by Mode I. 
Table: 15 Steric energies (kcal/mol) obtained with MM2 
energy minimizations for ENA-f3-CD complexes. 
Ligand WS WC WB NS NC NB 
Ar(Model) 	112.6862 85.8396* 100.0263 107.0926 91.3152 92.3973 
Ar (Mode II) 
	97.4973 	101.7070 659.4723 111.8197 113.4087 654.9920 
Ethoxycarbonyl 115.6140 108.93 75 100.2895 109.9016 112.5257 109.1344 
Proline 	118.3423 96.1943 90.7769 102.6312 99.3079 94.7300 
* The most stable complex 
Fig. 41. Side and top view of ENA-~3-CD complex (WC, 85.8396 kcal/mol). 
The entry of aromatic ring was through mode I. 
(Colors: red — (3-CD, green — ENA carbon atom, purple — ENA hydrogen 
atom, blue — ENA nitrogen atom, orange — ENA oxygen atom) 
The complexes formed by penetration of the ethoxycarbonyl group into the -
CD from either side of the cavity were least stable. These complexes were found to 
have high energies and were neglected. However, complexes obtained by penetration 
of the proline ring deep into the cavity were found to have relatively low energies 
90.7769 kcal/mol (WB) and 94.7300 kcal/mol (NB). These results support the 
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ROESY results that the aromatic ring is positioned in the center of the cavity and that 
the aromatic ring enters from wider side of cavity. 
The complex with lowest energy (Fig, 41) was assumed as the most probable 
structure for ENA-[i-CD complex and the results were published [321]. Later ROESY 
data was quantitatively analyzed and it was found that calculated peak intensities were 
not in agreement with the experimental ROESY data. Therefore, the structure of 
complex was further investigated. 
2.2.5 Quantitative ROESY analysis 
To confirm the structure of ENA-p-CD complex, the quantitative analysis of 
ROESY data was done by the use of distance — intensity relationship. 
I1 	ri 6 
12 T2 6 
Using the above equation the referenced cross peak intensities of H-2,4,6 and 
H-3,5 of ENA with cavity protons of [3-CD were calculated from the interproton 
distances obtained from ENA-13-CD complex. The distances of each aromatic proton 
to fourteen (3-CD cavity protons (seven H-3' and seven H-5') were taken for the 
complex having energy 85.R396 kcal/mol (Fig. 41, Table. 16). The referenced peak 
intensities for each aromatic proton with all the cavity protons (IH.2.0-3 , IH-2-H-s, '1-1-3-H-
3. IH-3-H-5', 'I-I-4-H-3  IH-4-H-51 IH-s-Ha', IH-5-11-5', IH-6-Ha', II{-6-H-5') were calculated. These 
were then summed up to give total referenced intensities i.e. IIH-2,4,6-Ha' (IHa-Ha'+IH- 
441J'+IH4Hd'), ZIH-2,4,6-H-5' (IH-2-H-5'+IH4-H-9'+IH-6-H•5'), ~IH-35-H-3' (IH-3-H3'+IH,5-H-3'), 
(4H-3,5-H-5' (IH-3-rI-5'+III-5.II-5').. The summation of 1111-2,4,6-II-3- and jIH-2,4,6-H-5' as well 
as /F!-35-H-3 and LIH-3,5-H-5' gave the total referenced intensities, 'H_2,4,6 and IH.3,s 
respectively. Similarly the summation of ZhH-2,4,o-u-3 and LIH-3,5-H-3' as well as 
2.4,6-H-5 and FIH3.5-H-5' gave total referenced intensities, IH_3. and IH_s'- The calculated 
relative peak intensities for the M'M2 complex did not match well with peak 
intensities in the ROESY spectrum. 
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Table: 16(a) Interproton distances between ENA and R-CD H-3' protons of MM2 
complex (WC. 85.8396 kcal/mol) and their corresponding intensities. 
r 	1r 
11-2i1I-3 
I 
11-3 11-3' 
r 	I 
H-4.1-1-3' 
r 	I 
H-5/H-3' 
r 	1 
11-6/11-3' 
2.356 5.85 4.834 0.08 6.077 0.02 3.425 0.62 2.366 5.70 
3.180 0.97 5.908 0.03 6.572 0.02 5.407 0.04 3.259 0.84 
5.016 0.07 6.640 0.02 6.538 0.02 4.029 0.24 4.702 0.10 
4.127 0.21 4.444 0.13 6.288 0.02 7.043 0.01 4.486 0.13 
6.575 0.02 7.658 0.01 6.596 0.02 7.160 0.01 6.064 0.03 
6.135 0.02 7.070 0.01 6.335 0.02 6.258 0.02 6.083 0.02 
7.294 0.01 5.325 0.05 5.575 0.04 5.427 0.04 5.230 0.05 
All distances are reported in A unit. 
Table: 16(b) Interproton distances between ENA and n-CD H-5' protons of MM2 
complex (WC, 85.8396 kcal/mol) and their corresponding intensities. 
r 	Jr 
11-2/H-5' H-3.'H 
I 
-5' 
r 	1 
H-4/H-5' 
r 	1 
H-5/H-5' 
r 	1 
H-6/H-5' 
2.712 2.52 2.683 2.68 3.754 0.36 2.494 4.16 3.665 0.42 
2.366 5.70 2.652 2.88 4.468 0.13 3.574 0.48 3.804 0.33 
4.142 0.20 5.908 0.03 5.071 0.06 5.729 0.03 5.772 0.03 
4.247 0.18 6.243 0.02 5.125 0.06 6.540 0.03 6.423 0.02 
5.304 0.05 4.061 0.23 4.321 0.16 6.032 0.03 6.033 0.03 
6.766 0.02 6.226 0.02 4.297 0.16 3.821 0.33 4.106 0.21 
6.772 0.02 5.042 0.07 4.326 0.15 2.304 6.69 3.489 0.56 
All distances are reported in A unit. 
MM2 energy minimization studies were then performed again by allowing the 
movement of guest only. Since ROESY data evidenced the inclusion of aromatic part 
of ENA, the MM2 minimization studies were performed for phenyl ring only and 
modes I and II were studied. The results of MM2 minimization studies are 
summarized in Table 17. Lowest energy complex (Fig. 42) was obtained when 
aromatic ring was placed in the centre of n-CD cavity (mode I). The relative peak 
intensities for this complex (Fig. 42, 103.7408 kcal/mol), were calculated from 
interproton distances which are listed in Table 18. The experimental and calculated 
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ROESY peak intensities for ENA-~i-CD complexes obtained during MM2 energy 
minimization studies are given in Table 19. 
Table: 17 Steric energies (kcal/mol) obtained with MM2 energy minimizations for 
ENA-13-CD complexes performed by constraining [i-CD. 
Orientation Aromatic 
(Mode 1) 
Aromatic 
(Mode 11) 
WS 131.9399 123.7399 
WC 103.7408* 109.9101 
WB 116.0624 648.0994 
NS 127.9037 119.5834 
NC 119.0063 112.0510 
NB 111.5565 113.0596 
" The most stable complex 
Fig. 42. Side and top view of the ENA-~3-CD complex (103.7408 kcal/mol). 
(Colors: light purple — R-CD, pink — ENA carbon atom, green — ENA 
hydrogen atom, blue — ENA nitrogen atom, red — ENA oxygen atom) 
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Table: 18(a) Interproton distances between ENA and 3-CD H-3' protons of MM2 
complex (103.7408 kcal/mot) and their corresponding intensities. 
r 	I 
H-2/H-3' 
r 	I 
H-3/H-3' 
r 	Jr 
H-4/11-3' H-5/H-3 
Jr I 
H-64i-3' 
2.678 2.71 4.139 0.20 6.838 0.01 7.363 0.01 6.657 0.02 
4.230 0.17 4.299 0.16 5.304 0.04 6.099 0.02 6.064 0.02 
5.796 0.03 4.914 0.07 3.830 0.32 3.846 0.31 4.939 0.07 
7.180 0.01 6.102 0.02 3.778 0.34 2.420 4.98 4.504 0.12 
6.142 0.02 5.524 0.04 3.867 0.30 2.571 3.46 3.705 0.39 
4.726 0.09 5.171 0.05 5.387 0.04 5.168 0.05 4.705 0.09 
2.428 4.88 4.012 0.24 5.839 0.03 6.454 0.01 5.601 0.03 
All distances are reported in A unit. 
Table: 18(b) Interproton distances between ENA and n-CD H-5' protons of MM2 
complex (103.7408 kcallmol) and their corresponding intensities. 
r 	I r 	I 
H-3/H-5' 
r 	I 
H-4'H-5' 
r 	I 	l 
H-5/H-5' 
r 
11.6,71-5' 
3.271 0.81 2.831 1.94 5.233 0.05 7.029 0.01 7.223 0.01 
4.853 0.08 3.571 0.48 4.532 0.12 6.265 0.02 7.087 0.01 
6.587 0.01 4.775 0.08 3.640 0.43 4.955 0.07 6.732 0.02 
6.819 0.01 4.917 0.07 2.515 3.95 3.322 0.74 5.781 0.03 
6.234 0.01 4.778 0.08 3.208 0.92 3.726 0.37 5.462 0.04 
4.818 0.08 4.129 0.02 4.549 0.11 5.517 0.04 6.040 0.02 
3.750 0.36 3.724 0.37 5.745 0.03 7.225 0.01 7.234 0.01 
All distances arc reported in A unit. 
Table: 19 Experimental and calculated relative ROESY crosspeak intensities. 
13' f5' I=A6 135 
Experimental 1.84 1 1.70 1.15 
(Fig. 34) 
MM2 model 0.53 1 0.88 0.65 
(85.83% kcal/mol) 
MM2 model 1.70 1 1.47 1.23 
(103.7408 kcal/mol) 
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2.2.6 Molecular dynamics (MD) studies 
The MI) simulation studies were performed by placing the phenyl ring of 
ENA near the wide opening of cavity since it has been shown by ROESY and MM2 
minimization studies that guest enters from wide side. The MD simulation studies 
evidenced that the inclusion of aromatic ring of ENA into n-CD cavity is 
energetically favored given that complex formation resulted in a net decrease in 
energy. Fig. 43 depicts the potential energy-time plot of MD simulation studies. 
0 	1000 	2000 	3000 	4000 	5000 	6000 
Time (fs) 
Fig. 43. The time evolution of the potential energy calculated from MD run in 
vacuum from wide side entry of ENA into R-CD cavity. 
The approach of aromatic ring towards the cavity was quick when simulation 
started. Aromatic ring started penetrating the cavity after 780 fs and was inside the 
cavity after 1970 fs. After 2710 fs the aromatic ring was pushed outside slightly 
towards the surface but it again entered the cavity and remained inside till the end. 
During the entire course, the ENA molecule occupied various orientations by moving 
sideways, rotating, tilting or twisting. Undergoing various changes in conformation 
the ENA molecule was positioned in the centre of the cavity after 4780 fs and yielded 
lowest energy conformation. Fig. 44 shows some pivotal snapshots of MD simulation 
studies. 
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780 fs 
• 
1 fs 
• 
;sow • 
1970 fs 
2710 fs 	 4780 fs 	 5000 fs 
Fig. 44. Snapshots showing the inclusion of ENA into the p-CD cavity as 
obtained in the MD trajectory from wide side. 
The lowest energy conformation (4780 fs, Frame 478) was then quantitatively 
analyzed. The interproton distances and corresponding calculated peak intensities for 
the above mentioned conformation are listed in Table. 20. The relative ROESY peak 
intensities 1,r_,;'. 1fl_5•,1//_2,4.b and 1,,_3,5 were calculated from these values as described 
earlier and were found to be 0.39, 1, 0.76 and 0.63 respectively. 
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Table: 20(a) Interproton distances between ENA and n-CD H-3 protons of 478 
frame MD model (112.2007 kcal/mol) and their corresponding intensities. 
r 	1 
11-2/ti-3' 
r 	I 
11-31H-3' 
r 	I 
1i-4lti-3' 
r 	Jr 
}i-511-3'  
I 
2.836 1.92 5.087 0.06 6.836 0.01 7.038 0.01 5.724 0.03 
5.315 0.04 6.575 0.02 7.352 0.01 7.144 0.01 6.227 0.02 
6.615 0.01 7.004 0.01 6.398 0.02 5.374 0.04 5.112 0.06 
7.176 0.01 6.972 0.01 5.243 0.05 3.1110 1.11 3.676 0.41 
6.469 0.01 6.153 0.02 4.525 0.06 2.467 4.44 3.017 1.33 
4.793 0.08 5.113 0.06 5.065 0.12 4.485 0.12 3.890 0.29 
2.695 2.61 4.592 0.11 6.118 0.02 6.356 0.02 5.072 0.06 
All distances are reported in A unit. 
Table: 20(b) Interproton distances between ENA and n-CD H-5' protons of 478 
frame MD model (112.2007 kcal/mol) and their corresponding intensities. 
r 	1 
H-2/H-5' 
r 	I 
H-3/H-5' 
r 	1 
H44'Ii-5' 
r 	fir 
H-5/H-5' 
I 
H-6/H-5' 
2.828 1.95 3.869 0.30 6.058 0.02 7.164 0.01 6.715 0.02 
4.692 0.09 4.956 0.70 5.778 0.03 6.048 0.02 6.382 0.02 
6.169 0.02 5.670 0.03 4.884 0.07 4.803 0.08 5.576 0.03 
6.481 0.01 5.439 0.04 3.312 0.76 2.336 6.15 4.300 0.16 
6.285 0.02 4.922 0.07 2.742 2.35 2.364 5.73 4.442 0.13 
3.866 0.30 2.991 1.40 3.069 1.20 3.841 0.31 4.387 0.14 
2.095 11.83 2.680 2.70 4.935 0.70 6.152 0.02 5.855 0.02 
All distances are reported in A unit. 
2.3 Conclusion 
The outcome of the inclusion studies of ENA with n-CD can be summarized 
as follows: The formation of ENA-~i-C D inclusion complex in solution was evidenced 
by comparative study of chemical shifts of 3-CD cavity protons in the 'H NMR 
spectra of pure components and their mixtures. The stoichiometry of the complex was 
determined using 'H NMR titration data. ROESY data confirmed the encapsulation of 
aromatic ring from wider side into n-CD cavity but two inclusion modes could be 
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considered. Mode I in which the orientation of aromatic ring was perpendicular to the 
CD z-axis and mode 11 in which the aromatic ring was tilted. The MM2 minimization 
studies performed by allowing the movement of both host and guest supported the 
wide side entry of aromatic ring via mode I. Relative cross peak intensities, calculated 
for the intermolecular crosspeaks observed in ROESY spectrum for lowest energy 
conformation obtained by MM2 minimization studies, performed by allowing free 
movement of all atoms, ruled out this conformation but supported MM2 minimized 
conformation obtained by allowing the movement of guest only. 
However, the steric energy of the complex obtained when both host and guest 
were allowed to move freely was very low (85.8396 kcal/mol) compared to when 
only guest was allowed to move (103.7408 kcal/mol). It was observed that during 
energy minimization process, the cavity of CD collapsed a bit when allowed free 
movement which brought the cavity protons closer to the included guest part which 
resulted in lowering of energy. This loss in flexibility of cavity can be expected 
because computational studies were performed in vacuum which is not perfect 
simulation of experimental condition. CDs have numerous free hydroxyl groups on 
its exterior which are hydrogen-bonded to surrounding water molecules in aqueous 
medium which should help in retaining the symmetry of CD cavity, When 
simulations are performed in vacuum, the interactions between water molecules and 
part of the guest outside cavity as well as between water molecules and hydroxyl 
groups present on CD surface are neglected. These results suggest that energy should 
not be the only criterion unless experimental conditions are fully simulated. 
As MM2 minimization yielded good results when only guest molecule was 
allowed to move, the MD simulation was done by allowing the movement of guest 
only. MD results also verified the formation of inclusion complex from wide side 
entry' of aromatic ring. All the MM2 minimized and minimum energy MD complex 
could agree with ROESY data qualitatively. The lowest energy complex obtained 
from MD studies was also quantitatively analyzed and the calculated peak intensities 
were not as good in agreement as MM2 model (Fig. 42) which was the most probable 
geometry of the complex. The results of the present study demonstrated that by 
combining quantitative ROESY analysis and computational studies, highly accurate 
and reliable conformation of the inclusion complex can be obtained which can only be 
obtained by MD studies simulating experimental conditions perfectly. 
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Part B: study of enalagril-Y-cyclodextrin 
inclusion complex 
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;cussion 
6-trosconic studies 
;signment of ENA protons has already been discussed earlier 
of y-CD were assigned with the help of COSY data (Fig. 51). 
t he assignment of y-CD matched very well with the reported data [320]. 
In the presence of y-CD, downfield shifts changes were observed for the 
aromatic hydrogens of ENA. Noticeable shift changes in H-7. H-8/H-17 of ENA were 
also observed while negligible shift change was observed for other guest protons. 
Similarly in presence of ENA prominent upfield shift changes. compared to pure, 
were observed in both the cavity protons of y-CD. All the remaining CD protons 
showed only trivial shift changes except H-6 which also shifted significantly 
hightield. The chemical shift change (MS) observed in the signals of cavity protons of 
y-CD in the presence of ENA (H/G = 1:2) was 0.0390 (H-3') and 0.0483 (H-5') (Fig. 
53), respectively. The magnitude of chemical shift changes for y-CD in the presence 
of ENA was smaller compared to [3-CD but the trend was similar. 
Ham' 
4.0 	3.9 	3.8 	3.7 	3.6 	3.6 
Fig. 53. Expansion of H NMR spectra of y-CD and mixture of y-CD 
and ENA showing CD region: (A) y-CD/ENA 1:2 mixture (B) y-CD. 
The observed upfield shift changes in internal cavity protons of y-CD and 
concomitant downfield shift changes in ENA protons indicated the formation of 
inclusion complex between ENA and y-CD. 
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2.4.2 Stoichiometry and binding constant of ENA-Y-CD complex 
Stoichiometry and binding constant of ENA-y-CD complex was determined by 
Scott's method. The Scott's equation for 1:1 complex can be written as: 
[ENA] _ [ENA] + 1 
Mobs M5  KaASS 
where [ENA] is the concentration of ENA, 4S0 is the observed chemical shifts 
changes for a given y-CD concentration with varying concentrations of ENA, and A8, 
is the chemical shift difference between pure sample of complex and the free 
component at saturation and K. is binding constant. [he plot of chemical shift change 
data for H-3' and H-5' (Table. 21) of y-CD protons in the form of [ENA]/AS0 versus 
[ENA] was found to be linear, confirming 1:1 stoichiometry of the complex (Fig. 54). 
The binding constant (K,) was calculated to he 199.21vf W. 
Table: 21 'H NMR titration data used for Scott's plot. 
SAMPLE 
(y-CD:ENA) 
(ENA] 
mM 
AS(H-3') 
ppm 
AS(H-5') 
ppm 
[ENAI/AS,u• 
mM/ppm 
[ENA]/ASn.s' 
mM/ m 
1:0.25 3.47 0.0199 0.0220 174.37 157.73 
1:0.50 6.94 0.0263 0.0307 263.88 226.06 
1:0.75 10.41 0.0298 0.0366 349.33 284.43 
1:1.00 13.88 0.0335 0.0397 414.33 349.62 
1:1.50 20.81 0.0367 0.0440 567.03 472.95 
1:2.00 27.75 0.0390 0.0483 711.54 574.53 
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Fig. 54. Scott's plot for 1:1 ENA-y-CD complex. 
2.4.3 ROESY spectroscopic studies of ENA-y-CD complex 
Aromatic protons of ENA showed close contacts with both the cavity protons, 
i.e. H-3 and H-5', in the ROESY spectrum of ENA/y-CD 1:1 mixture (Fig. 55) 
confirming the inclusion of aromatic ring into the y-CD cavity. The entry of guest 
molecule from wide side of cavity was established by observation of cross peak 
between H-3' and benzylic protons (H-7) of ENA (Fig. 51). Since, H-6', which is 
positioned near the narrow rim of the Cr) also showed intermolecular contact with 
aromatic protons in the spectrum of ENA-y-CD mixture, it can be said with great 
certainty that penetration of aromatic ring is deeper in case of ENA-y-CD complex. 
Though it is very clear that aromatic ring enters the cavity from wider side and 
is fully embedded in the y-CD cavity, the exact mode of penetration of aromatic ring 
needs to be confirmed. Two probable geometries (Modes I and 1I) were considered for 
the ENA-y-CD complex as was the case with 13-CD (Fig. 56). 
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Fig. 55. Portions of ROESY spectrum of 1:1 mixture of ENA and y-CD showing 
intermolecular interaction of aromatic protons of ENA with y-CD cavity 
protons on both sides of diagonal. 
Fig. 56. Two probable geometries (Modes I and 11) depicting the 
orientation of ENA inside y-CD cavity. 
2.4.4 Energy minimization (MM2) studies 
A total of six orientations, two each for three potential binding sites present in 
ENA molecule were considered for MM2 energy minimization studies as depicted in 
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Fig. 40. The results of MM2 studies of the ENA-y-CD complexes were quite different 
from those of ENA-~i-CD. MM2 minimization studies of the ENA-y-CD complexes 
showed that most stable complexes were formed when the guest enters deep inside the 
cavity either from narrow or wide side. Moreover, complexes obtained from the entry 
of guest via wider rim side were more stable than those resulting from narrow side 
entry. The results of MM2 energy minimization studies are outlined in Table. 22. The 
most stable complex (116.9530 kcal/mol) was obtained when aromatic ring entered 
deep into the cavity (Mode 1) from wider rim side (Fig. 57). Complexes involving 
aromatic ring via Mode II, were found to be least stable while those involving proline 
ring were found to be more stable than those involving ethoxycarbonyl group. 
Table: 22 Steric energies (kcal/mol) obtained with MM2 
energy minimizations for ENA-y-CD complexes. 
Ligand WS WC WB NS NC NB 
Ar (Mode I) 149.7940 128.1628 116.9530* 132.7524 136.2366 124.5135 
Ar (Mode Il) 135.61 1 1 133.0817 131.7741 142.9356 131.0508 139.3523 
Ethoxvcarbonv I 144.7725 132.5763 126.8047 143.1152 129.8977 130.3165 
Proline 141.7355 130.0426 123.1286 128.4737 125.2259 126.3302 
* The most stable complex 
Fig. 57. Side and top view of ENA-'j-CD complex (WB. 116.9530 kca(/mol). 
(Colors: orange - ~3-CD. brown - ENA carbon atom, green - ENA hydrogen 
atom, blue - ENA nitrogen atom. red - ENA oxygen atom) 
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Since, the complex obtained on energy minimization involving aromatic ring 
via Mode I (WB) had lowest energy (Fig. 57), it was assumed to be the most probable 
structure of ENA-y-CD complex and the results were published [321]. However, 
when ROESY data was quantitatively analyzed, it was found that calculated ROESY 
peak intensities for this complex were not in compliance with the experimental data 
2.4.5 Quantitative ROESY analysis 
The referenced peak intensities for each aromatic proton with the y-CD cavity 
protons (1H-2.a,e-Ha. IH-2.4,64i4', '11-3,541-3. Ix-3,5-H-5) were calculated. These were then 
summed up to give total referenced intensities as was done for ENA-p-CD complex. 
The summation Of jIH-2,4,&H-3' and ~IIIdS-H-I' as well as IH-2,4,6-H-5' and EIH-3,5-H-5' 
gave the total referenced IH_3, and /H.5, while the summation of VH-2.4.6-H- and FIx- 
2,4,6- 1-5' as well as LIH3,s-01a' and Y_IH 3,s-H-s' gave the total referenced I11-2.4,6 and I11-3,5 
respectively. 
The referenced peak intensities for the intermolecular cross peaks observed in 
ROESY spectrum were determined for WB, MM2 minimized ENA-y-CD complex 
(116.9350 kcal/mol energy. Fig. 57). The interproton distances of aromatic protons of 
ENA and cavity protons of 7-CD for this complex are listed in Table. 23. The 
calculated peak intensities obtained for this complex did not match well with the 
experimental ROESY data. In light of this observation, energy minimization was 
performed again by restricting the movement of y-CD. Since, only aromatic part of 
ENA was included in the y-CD cavity, the MM2 minimization studies were performed 
for phenyl ring only and both modes (land II) were studied. The results of this MM2 
minimization studies are summarized in Table 24. The measured interproton distances 
and corresponding intensities of most stable complex (121.3773 kcal/mol, Fig. 58) are 
given in Table. 25. The experimental and calculated ROESY peak intensities for 
complexes obtained by MM2 energy minimization process are given in Table. 26. 
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Table: 23(a) Interproton distances between ENA and y-CD 11-3' protons of MM2 
complex (WB. 116.9350 kcal/mol) and their corresponding intensities. 
r 	1r 
H-211-3' 
I 
11-3 11-3' 
r 	I 
H-4/H-3' 
r 	I 
H-5/H-3 
r 	I 
H-6/11-3' 
4.724 0.09 5.885 0.02 6.577 0.01 6.288 0.02 5.230 0.05 
3.654 0.42 5.342 0.04 7.346 0.00 8.011 0.00 7.006 0.01 
4.033 0.23 5.923 0.02 8.101 0.00 8.787 0.00 7.639 0.01 
5.851 0.02 7.322 0.01 8.588 0.00 8.617 0.00 7.397 0.01 
7.467 0.01 8.471 0.00 8.573 0.00 7.676 0.00 6.535 0.01 
8.739 0.00 9.476 0.00 18.683 0.00 6.873 0.01 5.799 0.03 
7.177 0.01  8.028 0.00 7.087 0.01 4.777 0.08 3.137 1.05 
5.983 0.02 6.984 0.01 6.481 0.01 4.706 0.09 3.041 1.26 
All distances are reported in A unit. 
Table: 23(b) Interproton distances between ENA and y-CD H-5' protons of MM2 
complex (WB. 116.9350 kcal/mol) and their corresponding intensities. 
r 	I 
11-2/11-5' 
r 	I 
11-3H-5' 
r 	I 
11-4/11-5' 
r 	I 
H-5/11-5' 
r 	I 
11-6/11-5' 
3.558 0.49 3.772 0.35 4.186 0.19 4.390 0.14 4.217 0.18 
2.373 5.60 2.909 1.65 5.035 0.06 6.279 0.02 6.052 0.02 
2.433 4.82 3.654 0.42 5.889 0.02 6.963 0.01 6.402 0.01 
4.978 0.07 5.622 0.03 6.765 0.01 7.276 0.01 6.777 0.01 
7.072 0.01 7.321 0.01 7.227 0.01 6.849 0.01 6.576 0.01 
7.335 0.01 7.476 0.01 6.329 0.01 3.602 0.46 4.609 0.10 
7.695 0.01 7.729 0.01 6.057 0.02 2.764 2.24 3.519 0.53 
5.897 0.02 5.991 0.02 4.727 0.09 4.849 0.08 2.562 3.54 
All distances are reported in A unit. 
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Table: 24 Steric energies (kcal/mol) obtained with MM2 energy minimization 
for ENA-y-CD complexes performed by constraining y-CD. 
Orientations Aromatic ring 
(Mode 1) 
Aromatic ring 
(Mode 11) 
WS 154.8203 135.7391 
WC 147.9713 121.3733* 
WB 141.9084 125.7854 
NS 146.2044 139.0171 
NC 141.8587 132.1270 
NB 144.7099 124.2606 
* Lowest energy complex 
Fig. 58. Side and top view of ENA-y-CD complex (121.3773 kcal/mol). 
(Colors: green -13-CD. deep pink - ENA carbon atom, dark blue - ENA 
nitrogen atom, red - ENA oxygen atom, light blue - ENA hydrogen atom) 
Table: 25(a) Interproton distances between ENA and y-CD 11-3' protons of MM2 
ENA-y-CD complex (121.7337 kcal/mol) and their corresponding intensities. 
r 	I 
H-2/H-3' 
r 	I 
H-3/H-3 
r 	I 
H-4/H-3' 
r 	I 
I1-5/H-3' 
r 	I 
H-6/H-3' 
4.303 0.16 5.304 0.04 5.330 0.04 4.292 0.016 2.963 1.48 
3.827 0.32 3.140 1.02 3.995 0.25 5.128 0.05 5.569 0.03 
4.587 0.11 2.511 3.99 4.011 0.24 6.381 0.01 7.440 0.01 
5.965 0.02 4.576 0.11 5.558 0.03 7.504 0.01 8.417 0.00 
7.438 0.01 7.067 0.01 7.483 0.01 8.291 0.00 8.604 0.00 
7.299 0.01 7.886 0.01 7.926 0.01 7.456 0.01 6.827 0.01 
6.595 0.01 7.868 0.01 7.436 0.01 6.222 0.02 4.503 0.12 
6.174 0.02 7.672 0.01 7.701 0.01 5.536 0.03 3.145 1.03 
All distances are reported in A unit 
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Table: 25(b) Interproton distances between ENA and y-CD H-5' protons of MM2 
ENA-y-CD complex (121.7337 kcal/mol) and their corresponding intensities. 
r 	I 
11-2ti-5' 
r 	I 
H-3M-5' 
r 	Jr 
H-4/H-5 
I 
H-51H-5` 
r 	I 
H-6!H.5' 
5.646 0.03 5.582 0.03 4.432 0.13 2.881 1.75 3.004 1.36 
4.923 11.07 3.406 0.64 2.349 5.95 3.425 062 4.935 0.07 
5.592 0.03 3.115 1.09 2.654 2.86 5.115 0.06 6.904 0.01 
6.853 0.01 4.992 0.06 4.703 0.09 6.499 0.01 8.013 0.00 
7.333 0.01 6.464 0.02 5.989 0.02 6.567 0.01 7.421 0.01 
7.832 0.00 7.875 0.00 7.112 0.01 6.286 0.01 6.230 0.01 
7.871 0.00 8.489 0.00 7.527 0.01 5.625 0.03 4.624 0.10 
6.359 0.01 7.009 0.01 5.958 0.02 3.611 0.45 2.090 12.0 
All distances are reported in A unit. 
Table: 26 Experimental and calculated relative ROESY crosspeak intensities. 
111.3' 111-5' 111-1,4.6 	iii-i 
Experimental 3.12 - 1.60 2.10 	1 
(Fig. 52) 
MM2 model 0.27 3.70 3.33 	1 
(116.9350 kcallmol) 
MM2 model 0.92 2.68 2.60 	1 
(121.3773 kcal/mol) 
2.4.6 Molecular dynamics (MD) studies 
The MD simulation studies carried out by allowing movement of guest only 
revealed that formation of ENA-y-CD inclusion complex is energetically favorable 
process since the complexation resulted in a net decrease in energy as can be seen in 
energy-time plot (Fig. 59). 
The aromatic ring of ENA started moving towards y-CD cavity and was 
completely inside the cavity after 2200 fs and stayed there till the end. During its stay 
in the cavity the aromatic ring of ENA underwent changes in depth and orientation 
moving along the wall of the cavity and simultaneously rotating and tilting. The 
aromatic ring went deep in the cavity after 3370 fs protruding outside from narrow 
opening and after 3870 fs maximum part of phenyl ring was outside the cavity from 
narrow end. After this the ring moved back to the cavity and after 5730 fs the lowest 
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energy complex was obtained. The entire MD trajectory describing complexation 
process is represented with the help of crucial snapshots in Fig. 60. The referenced 
ROESY peak intensities were calculated from the intermolecular interproton distances 
(Table 27) for the lowest energy MD conformation (Fig. 61). 
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Fig. 59. The time evolution of the potential energy calculated from MD run in 
vacuum from wide side entry of ENA into y-CD cavity. 
I fs 	 2200 fs 	 3370 fs 
Fig. 60. Snapshots showing the inclusion of ENA into the y-CD cavity as 
obtained in the MD trajectory from wide side. 
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Table: 27(a) Interproton distances between ENA and y-CD H-3' protons of 573 
frame MD model (132.904 kcallmol) and their corresponding intensities. 
r 	I 
H-2/H-3' 
r 	I 
H-3.11-]' 
r 	I 
11-4/7{-3 
r 	I 
H-51n-3' 
r 
(-6/I-)' 
3.844 0.31 3.305 0.77 4.076 0.22 4.858 0.08 5.194 0.05 
4.394 0.14 2.339 6.11 3.976 0.25 6.248 0.01 7.250 0.01 
5.736 0.03 4159 0.15 5.485 0.04 7.561 0.00 8.434 0.00 
7.279 0.01 6.937 0.01 7.435 0.01 8.515 0.00 8.824 0.00 
7.262 0.01 7.878 0.00 7.933 0.00 7.768 0.00 7.185 0.01 
6.690 0.01 7.976 0.00 1 	7.766 0.01 6.511 0.01 4.815 0.08 
6.373 0.01 7.871 0.00 7.548 0.01 5.655 0.03 3.273 0.81 
4.504 0.12 5.539 0.03 5.459 0.03 4.155 0.19 2.569 3.48 
All distances are reported in A unit. 
Table: 27(b) Interproton distances between ENA and y-CD H-5' protons of 573 
frame MD model (132.904 kcal/mol) and their corresponding intensities. 
r 	I 
H-21H-5'' 
r 	I 
H-3111-5' 
r 	I 
H-441-5' 
r 	I 
H-5,H-5' 
r 	I 
tl-6/H-5' 
4.916 0.07 3.482 0.56 2.415 5.04 3.105 1.12 4.624 0.10 
5.434 0.04 2.923 1.60 2.555 3.59 4.994 0.06 6.765 0.01 
6.659 0.01 4.767 0.09 4.594 0.11 6.577 0.01 8.066 0.00 
7.196 0.01 6.329 0.01 5.926 0.02 6.810 0.01 7.656 0.00 
7.802 0.00 7.854 0.00 7.108 0.01 6.629 0.01 6.618 0.01 
7.949 0.00 8.569 0.00 7.578 0.01 5.954 0.02 5.074 0.06 
6.502 0,01 7,162 0.01 6,054 0,02 3.787 0.34 2.343 6.04 
5.775 0.03 5.755 0.03 4.546 0.11 2.661 2.82 2.669 2.77 
All distances are reported in A unit. 
The relative intensities JH..3 , Ira -s, 7H-2.4,6 and ly_3 s were calculated for 573 frame 
(Fig. 61) from interproton distances as described above and were found to be 0.93, 
1.75, 1.98 and 1, respectively. 
When the crosspeak intensity values for all the three complexes obtained by 
computational studies were matched with the experimental values it was found that 
there is probability of two structures being present in solution since the relative 
crosspeak intensity values were comparable to the experimental values for two 
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complexes. These two complexes were, MM2 model obtained by only moving guest 
molecule and MD 573 frame complex. A close examination revealed that these two 
complexes have very similar structures. It was also noticed that there was large 
difference in calculated 1,f_; intensity value when compared with experimental value 
(Table. 26) which was due to the merging of TOCSY peaks with intermolecular 
ROESY crosspeaks resulting in large difference. 
• 
• 
Fig. 61. Side and top view of 573 frame MD ENA-y-CD complex (132.904 kcal/mol). 
(Colors: brown — y-CD, purple — ENA carbon atom, dark blue — 
ENA nitrogen atom, red — ENA oxygen atom, light blue - ENA hydrogen atom) 
2.5 Conclusion 
The formation of 1:1 ENA-y-CD inclusion complex was indicated by 
comparative study of 'H NMR spectra of pure components and their mixtures and by 
NMR titration experiments. ROESY experiments confirmed the entry of aromatic ring 
from wide side into the y-CD cavity. Two modes of insertion of aromatic ring were 
envisaged as was the case with ENA and n-CD complex. MM2 minimization studies 
were carried out in two ways: by allowing movement of both host and guest and guest 
only. Minimization studies, in both the cases, suggested that aromatic ring was locked 
in the cavity via mode II. The quantitative ROESY analysis of most stable complexes 
suggested that minimization studies gave better results when only guest molecule was 
allowed to move. The MD simulations were performed by allowing movement of 
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only guest and the lowest energy MD complex was also quantitatively analyzed. The 
calculated peak intensities for lowest energy MD complex (Fig. 61) were in better 
agreement to experimental values compared to MM2 models and were the most 
probable structure of the ENA-y-CD complex. The results also show that by 
efficiently combining computational studies (MM2 or MD) done in vacuum and 
quantitative ROESY analysis highly accurate structural information can be obtained. 
These results again show that when computational studies are carried out in vacuum, 
the energy cannot be taken as the only deciding parameter for determining the 
solution structure of inclusion complex. 
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XYLAZINE 
IUPAC name: N-(2,6-Dimethylpheny1)-5,6-dihydro-4H-1,3-thiazin-2-amine 
Molecular mass: 220.33 g/mol 
Melting point: 165-168°C 
Solubility: freely soluble in water, very soluble in methanol and chloroform, 
practically insoluble in hexane and ether 
Structural formula: C121116N2S 
Color/appearance: white or almost white crystalline substance 
Xylazine (XZ) is a non-narcotic sedative, analgesic and muscle relaxant [322]. It was 
developed for use as an antihypertensive agent. It was found to have excessive central 
nervous system depression effects and was subsequently introduced for veterinary 
use, Today it is widely used in veterinary and animal science either alone or in 
combination with other drugs such as tranquilizers or barbiturates [323,324]. 
XZ has numerous other pharmacological effects. Most of these effects consist of 
bradycardia and hypotension. XZ is believed to act as an agonist on the a2-
adrenoreceptors [325]. These receptors. located primarily at presynaptic sites on 
sympathetic neurons, inhibit norepinephrine release when stimulated by XZ, resulting in 
muscle relaxation. the use of a specific antagonist (e.g. yohimbine, idazoxan, or 
tolazoline) to reverse XZ's sedative effect has also become popular and is a valuable tool 
in the management of anesthesia where XZ is used as an adjunct. Ketamine with XZ is a 
generally accepted anesthetic for laboratory rats [326]. XZ is a supplement drug used to 
minimize the side effects of using ketamine alone such as tremor, muscle rigidity and 
excitement during recovery [327]. 
XZ molecule has two rings, one substituted benzene ring and the other heterocyclic 
ring. Due to the presence of two methyl groups at or! ho position on the aromatic ring, 
the partial entry of XZ into n-CD cavity was expected while the other ring was 
expected to stay in the aqueous medium outside the [1-CD cavity. Apart from 
structural attributes, the interesting feature of the chosen guest was its conformational 
flexibility. This flexibility favors the host-guest interaction since the guest can modify 
its conformation to ensure better complexation. 
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3.1 Experimental studies 
3.1.1 Materials: 
XZ was gifted by Bachem AG. Switzerland, while p-CD was obtained from Geertrui 
Haest. Cerestar Application Centre, Food & Pharma Specialities, France. and these 
were used without further purification. 
3.1.2 One-dimensional NMR experiments: 
The 1 H NMR spectra of pure n-CD and mixtures of XZ and n-CD were recorded on a 
JEOL 500 MHz instrument in D20 at room temperature while the pure XZ spectrum 
was obtained on a 400 MHz BRUKER AVANCE I1 spectrometer at 298 K. No 
external indicator was used and chemical shift values (S) are reported in ppm. The 
HDO peak at 4.800 ppm was used as internal reference. NMR samples of mixtures of 
n-CD and XZ having molar ratios 1:0.25. 1:0.50, 1:0.75. 1:1.00, 1:1.50 and 1:2.00 
were prepared by taking 9 mg of R -C D and adding calculated amount of XZ in 0.5 ml 
D20. All the mixtures of the drug and n-CD as well as pure XZ and [i-CD were 
shaken or/and sonicated till clear solutions were obtained. The chemical shift change 
was calculated according to the formula: OS = S0,)fl,p jCX  - 	No new peak appeared 
in the spectra of six studied mixtures, that could be assigned to complex, indicating a 
rapid exchange of XZ between free and bound state on the NMR time scale. 
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3.1.3 Two-dimensional NMR experiments: 
For the purpose of unambiguous assignments of '11 NMR signals, COSY spectrum of 
1:1 mixture of XZ and p-CD was recorded on 400 MHz BROKER AVANCE 11 
spectrometer using pulse program cosygpq. ROESY was acquired in phase sensitive 
mode for 1:1 mixture of XZ and 3-CD with a spin lock power of 21 dB, relaxation 
delay of 1.5 s and mixing time of 0.5 s on a 500 MHz JEOL spectrometer. A total of 
1024 data points in F2 and 1024 data points in Fl over a spectral width of 4000 Hz 
were collected. ROESY spectrum was measured by acquisition of 1024 (F2) x 44 (Fl) 
data points, with 5000 Hz spectral window in both dimensions. The experiment was 
stopped as soon as cross peaks appeared between XZ and 13-CD cavity protons. 
3.1.4 Computational methodology: 
Computational studies (MM2 and MD) were performed using Alfinger's MM2 
program of CS Chem3D Pro (Cambridge Soft Corp.) in vacuum, at 298 K. Initial 
coordinates for p-CD were obtained from the Cambridge databank [3191. The 
published X-ray coordinates for hydrated n-CD were used as starting point after 
excluding water molecules. The structure of the XZ was drawn and then minimized to 
a root mean square (RMS) value 0.1 kcalmol-' A-' under the MM2 force field. This 
geometry was used in all calculations of inclusion complexes. MM2 studies were 
carried out by accommodating the optimized structure of XZ molecule into the 3-CD 
cavity and allowed for full geometry optimization at the corresponding level of 
calculation. MD simulations were performed by placing the substituted aromatic ring 
of XZ new the mouth of [i-CD cavity along z-axis from both wide and narrow rim 
side in vacuum, at an iteration step of I fs. The conformations were recorded after 
every 10 iterations with 4000 steps of equilibration. In these studies, only the guest 
molecule was selectively moved while the motion of-CD cavity was restricted, 
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3.2 Results and Discussion 
3.2.1 'H NMR spectroscopic studies 
To fully establish the structure of any inclusion complex, an unambiguous resonance 
assignment of guest protons in the free as well as complexed state is required which 
was made with the help of COSY spectroscopy performed on a 1:1 mixture of (3-CD 
and XZ (Fig. 69). The three aromatic protons. two H-1 and one H-2 of XZ were 
observed in the aromatic region as a distorted doublet at 7.1303 (2H, J = 9 Hz, H- I ) 
and a doublet of doublet at 7.2039 (1 H. J,=J2=9 Hz, 11-2) (Fig. 62). Signal for the six 
protons of two methyl groups substituted at ortho position of benzene ring was 
merged with H-4 of heterocyclic ring and was found resonating at 2.1033. The peak 
for H-3 and H-5 protons of heterocyclic ring was observed at 3.2486. The assignment 
of [3-CD protons was good agreement with the reported data [320]. 
In 'H NMR spectra of mixtures (Fig. 63-68) , small downfield shift changes (AS) were 
observed for aromatic protons of XZ while upfield shift changes were observed for 
the peak assigned to methyl and H-4 protons. The detailed inspection of the [i-CD 
protons in the spectra of mixtures of XZ and n-CD revealed upfield shift changes, 
compared to pure component, in the H-3' and 1-1-5' cavity protons resonances which 
increased with increasing concentration of XZ. The magnitude of OSE{.3- was slightly 
higher than MSEi_s- Slight highfield shift was also observed in the resonance of H-2' 
and 1-1-4' signals (Fig. 71) but these were not affected by change in concentration of 
XZ. No appreciable shift change was observed for H-6' proton. 
The downfield shift changes observed for aromatic protons of XZ and the highfield 
shift changes observed for the cavity protons of-CD in the spectra of mixtures of 
XZ and n-CD confirmed the formation of inclusion complex. 
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Fig. 71. Expansion of the part of 'H NMR spectra showing n-CD protons 
in the presence and absence of XZ. 
3.2,2 Stoichiometry and binding constant of XZ-B-CD complex 
The Scott's version of Benesi-Hildebrand equation was used in the present study for 
determining the stoichiometry of the complex. Scott's equation for 1:1 XZ-[3-CD 
complex can be written as 
[XZ]_ [XZ] 	1 
Mobs ~Ss + X.ASs 
where [XZ] is the concentration of XZ. 4ii„b, is the observed chemical shifts changes 
for a given [3-CD concentration with varying concentrations of XZ, and A8, is the 
chemical shift difference between pure sample of complex and the free component at 
saturation and Kn is binding constant. Chemical shift change data for H-3' and H-5' of 
(3-CD protons (Table. 28) was plotted in the form of [XZ]/4Sobs versus [XZ] which 
gave a straight line confirming 1:1 stoichinmetry of the complex (Fig. 72). The 
binding constant of XZ-(i-CD inclusion complex was calculated to be 86.45 M''. 
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Table: 28 1 H NMR titration data used for Scott's plot. 
SAMPLE 
-CD:XZ 
JXZJ 
M 
ASH.3' 
ppm 
[XZJ/LSti_3• 
M/ppm 
Abli_5' 
ppm 
[XZJ/ASH.i' 
M/ppm 
1:0.25 0.004 0.041 0.098 0.032 0.125 
1:0.50 0.008 0.064 0.125 0.053 0.150 
1:0.75 0.012 0.078 0.154 0.065 0.185 
1:1.00 0.016 0.090 0.178 0.074 0.216 
1:1.50 0.024 0.104 0.230 0.087 0.276 
1:2.00 0.032 0.115 0.278 0.097 0.323 
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Fig. 72. Scott's plot for 1:1 XZ-J3-CD complex. 
3.2.3 ROESY spectroscopic studies of XZ-13-CD complex 
To clearly establish which of the two rings of XZ was involved in complexation 
process, a ROESY spectrum was obtained for a 1:1 mixture of XZ and n-CD (Fig. 
70). The region showing intermolecular peaks contained no TOCSY artifacts on one 
side of the diagonal but artifacts interfered with intermolecular peaks on the other side 
of the diagonal. The spectrum exhibited strong cross correlation peaks between 
cavity protons of n-CD and aromatic protons of guest confirming the penetration of 
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aromatic ring into (.3-CD cavity. Since, no crosspeak was observed between methyl 
groups and cavity protons; the shallow insertion of aromatic ring was evidenced. As 
expected, the heterocyclic ring being hydrophilic preferred to stay in solution given 
that no intermolecular crosspeaks involving H-3, H-4, and or H-5 were observed, 
Expansion of part of ROESY spectrum, where crosspeaks are obtained on one side of 
diagonal is shown in Fig. 73. From ROESY spectrum, nothing could be said with 
regard to regioselection of host-guest binding i.e. whether guest entered into the 
cavity from wide or narrow side. Two structures could be considered on the basis of 
ROESY contacts for XZ-p-CD inclusion complex which are shown in Fig. 74. The 
structure of X7-fl-CD complex was established using this ROESY data and 
combining the results of computational studies carried out in vacuum. 
H-1 
Y 
F  
Fig. 73. Expanded part of ROESY spectrum of 1:1 mixture of XZ and (3-CD 
depicting intermolecular crosspeaks obtained on one side of diagonal. 
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Fig.74. Possible structures of XZ-13-CD inclusion complex considered 
on the basis of ROESY data. 
3.2.4 Energy minimization (MM2) studies 
MM2 minimizations were performed only for inclusion of substituted aromatic ring 
into the n-CD cavity since it was established unequivocally that only this part is 
involved in complexation process. The studies were carried out from both the wide 
(W) and narrow (N) openings of the cavity for aromatic ring only in view of the 
ROESY data. The energy minimization was carried out for six different orientation of 
aromatic ring (Fig. 40). The aromatic ring was placed at the mouth of cavity from 
wide side partially inside (WS, wide-to-surface), in the centre of cavity (WC, wide-to-
center) and deep inside (WB, wide-to-bottom). In a similar manner, these three 
orientations were studied from narrow rim side (NS, narrow-to-surface. NC, narrow-
to-centre, NB, narrow to bottom) also. The steric energies (in kca/lmol) of the studied 
complexes are listed in Table. 29. It was observed that energy values were smaller 
when minimization was done from wide side suggesting that the approach of the 
substituted aromatic ring towards the n-CD cavity was more favorable from the wide 
side of the cavity. Fig. 75 depicts the two complexes, obtained from wide side, having 
very close energies. It was observed that the aromatic ring was pulled inside the 
cavity on energy minimization when it was placed at the mouth of the cavity from 
wide side (WS) while the aromatic ring was pushed outside when it was placed in NS 
orientation. In NS complex, the orientation of aromatic ring was slightly tilted. 
Detailed structural information about the inclusion complex was obtained by 
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quantitative ROESY data analysis. The peak intensities were calculated from the 
interproton distances of WS and WC complexes for the intermolecular contacts 
observed in ROESY spectrum. 
Table: 29 Steric energies (kcal/mol) obtained with MM2 
minimizations for XZ4i-CD complexes. 
Orientation Steric energy 
WS 98.7986 
WC 98.2215* 
WB 112.9711 
NS 101.4393 
NC 106.7033 
NB 107.4037 
* Lowest energy structure. 
(a)  
., 
c 
(b) 
Fig. 75. Side and top view of MM2 energy minimized XZ-(i-CD complexes 
(a) WS complex, 98.7986 kcal/mol (b) WC complex, 98.2215 kcal/mol. 
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3.25 Quantitative ROESY analysis 
The interproton distances between aromatic protons of XZ and R-CD cavity protons 
were obtained for the WS and WC energy minimized models (98.7986 kcal/mol, 
98.2215 kcaUmo1). These distances are listed in Table. 30 and 31 respectively. From 
these distances. ROESY peak intensities IF1-1 and IH.2 were calculated using 
following relationship as discussed earlier, 
'1 	rib 
I2 r2 
After obtaining the H-H distances of each aromatic proton (two H-1 and one H-2) 
with seven H-3 and seven H-5' protons, their referenced peak intensities (lE1_i3', IH. 
-H-S'. /H-2-H-3', IH.2-H-5') were calculated. 
Table: 30 Interproton distances between XZ and n-CD protons of MM2 complex 
(WS, 98.7986 kcallmol) and their corresponding intensities. 
r 	I 
H-1 /H-3' 
r 	I 
H-2/H-3' 
r 	1 
H-1 !H-5' 
r 	I 
H-2/H-5' 
2.340 6.09 4.397 0.14 3.326 0.70 4.287 0.16 
4.296 0.16 4.333 0.15 2.319 6.43 3.026 1.30 
5.992 0.02 4.621 0.10 4.583 0.11 3.522 0.52 
7.367 0.01 5.698 0.03 6.415 0.01 4.331 0.15 
6.640 0.02 5.595 0.03 6.860 0.01 4.603 0.11 
5.001 0.06 5.375 0.04 6.357 0.02 4.756 0.09 
2.848 1.87 4.848 0.08 6.624 0.01 4.326 0.15 
6.098 0.02 6.478 0.01 
4.674 0.10 5.327 0.04 
2.899 1.68 4.422 0.13 
3.280 0.80 3.299 0.78 
4.318 1.15 2.944 1.54 
5.776 0.03 4.199 0.18 
6.441 0.02 3.395 0.65 
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Table: 31 Interproton distances between XZ and (i-CD protons of MM2 complex 
(WC, 98.2215 kcal/mol) and their corresponding intensities. 
r 	I 
H-1/H-3' 
r 	I 
H-2/H-3' 
r 	Jr 
11-1/1-1-5' 
I 
1-1-2/H-5' 
2.576 3.42 4.886 0.07 2.331 6.23 3.617 0.45 
3.546 0.50 3.934 0.27 3.539 0.51 2.798 2.08 
5.587 0.02 4.256 0.17 6.868 0.01 4.627 0.10 
6.833 0.01 5.218 0.05 6.108 0.02 4.739 0.09 
6.901 0.01 6.002 0.02 5.298 0.05 5.292 0.05 
5.589 0.03 6.069 0.02 3.718 0.38 4.964 0.07 
3.382 0.67 5.298 0.05 5.290 0.05 3.095 1.14 
6.572 0.02 5.974 0.02 
4.673 0.10 4.337 0.15 
2.668 2.77 3.099 1.13 
2.834 1.93 4.304 0.16 
4.807 0.08 6.250 0.02 
6.332 0.02 6.941 0.01 
6.666 0.02 2.284 7.04 
These referenced intensifies were then summed up to give referenced £'H-l_H-3 , FJH.1. 
0.5 , E4I-2-n-3'. EIH-2-11-5 - The summation of 11H.1.0.3' and Eln.i.i I.  as well as EIH.2.H.3.  
and 17µ2.H.5, gave total referenced intensities /H.1 and 111-2,  respectively, which are 
given in Table. 32. As can be seen, the peak intensities of H-1 and H-2 with cavity 
protons are close to experimental ROESY intensities for lowest energy WC model 
(Fig. 75 (b)). 
Table: 32 Experimental and calculated relative ROESY crosspeak intensities. 
IH-1 	IH-2 
Experimental 4.7 	1 
(Fig. 70) 
WS model 6.78 	1 
(98.7896 kcallmol) 
WC model 4.12 	1 
(98.2215 kcat/mol) 
131 
Chapter 3 
3.2.6 Molecular dynamics (MD) studies 
MD simulation was performed from wide as well as narrow opening of n-CD cavity. 
The results of MD simulations provided evidence that complexation of n-CD and XZ 
is energetically favorable since complex formation resulted in a net decrease in 
energy. As can be seen in Fig. 76, the total potential energies of the inclusion 
complexes were less than the sum of the potential energies of XZ and 13-CD. when the 
MD simulations were performed by placing XZ near the mouth of 13 -CD cavity either 
from wide side and narrow side. 
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Fig. 76. The time evolution of the potential energy calculated from the MD run in 
vacuum from (a) wide side and (b) narrow side of 13-CD cavity. 
When the XZ molecule was placed near the wider opening, it entered the cavity 
quickly and remained in the cavity during the entire simulation time of 4000 fs. 
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Aromatc ring of X7. molecule was near the opening of cavity after 720 fs and was 
patially inside the cavity after 1120 fs. After 1320 fs, the lowest energy inclusion 
complex was recorded. The maximum inclusion depth was obtained after 1430 fs, 
after which the ring moved all along the wall of cavity occupying various orientations. 
Methyl groups of aromatic ring remained outside the cavity during the entire 
simulation time. In Fig. 77, the wide side MD simulation trajectory is depicted with 
the help of series of pivotal snapshots. 
Fig. 77. Snapshots showing the inclusion of XZ into the R-CD cavity as 
obtained in the MD trajectory from wide side. 
In case of narrow side simulation, the aromatic ring partially entered the cavity, with 
methyl groups staying outside, but left the cavity after 2000 iterations and never 
returned. The aromatic ring touched the surface after 650 fs and after 990 fs it was 
partially within the cavity. After 1500 fs the maximum penetration of aromatic ring 
was observed. And then the aromatic ring slowly started coming outside the cavity. 
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Fig. 78 shows series of pivotal snapshots of the MD simulation trajectory carried out 
by placing aromatic ring at narrow side. 
Fig. 78. Snapshots showing the inclusion of XZ into the n-CD cavity as 
obtained in the MD trajectory from narrow side. 
I 	 The lowest energy conformations obtained by two MD simulations i.e. one frame 
from wide side (frame 132. 1320 fs, 100.7288 kcal/mol) and two frames from narrow 
sides (frame 105, 1050 fs. 97.8276 kcal/mol : frame 118 , 1180 fs, 97.3679 kcal/mol) 
were quantitatively analyzed to gain more insight into complex structure. The 
interproton distances for the three aforementioned MD frames are given in Table. 33, 
34 and 35 respectively. From these interproton distances the relative intensities of H-1 
and H-2 protons were calculated which are given in Table. 36. 
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Table: 33 Interproton distances between XZ and 3-CD protons of 132 frame MD 
(wide side) model (100.7288 kcal/mol) and their corresponding intensities. 
r 	I 	r 	I 	r 	I r 	I 
H-I,'H-3' 	H-2/H-3' 	H-i/H-5' H-2/H-5' 
2.833 	1.74 	4.726 	0.09 5.362 	0.04 3.549 	0.50 
4.415 	0.13 	5.878 	0.02 4.370 	0.14 2.768 	2.22 
5.812 	0.02 	5.730 	0.02 3.229 	0.88 4.094 	0.21 
4.449 	0.13 ! 	5.277 	0.05 3.385 	0.16 4.347 	0.15 
3.483 	0.56 	4.010 	0.24 4.261 	0.66 5.016 	0.06 
5.710 	0.03 	! 	4.144 	0.20 5.093 	0.06 4.962 	0.06 
6.214 	0.02 	4.501 	0.12 6.309 	0.02 4.609 	0.10 
2.227 	8.20 3.414 	0.63 
4.446 	0.13 4.728 	0.09 
6.210 	0.02 6.563 	0.01 
7.500 	0.02 7.156 	0.01 
6.703 	0.02 6.774 	0.01 
4.889 	0.07 4.951 	0.07 
2.544 	3.70 2.65I 	2.90 
Table: 34 Interproton distances between XZ and R-CD protons of 105 frame MD 
(narrow side) model (97.8296 kcal/mol) and their corresponding intensities. 
r 	I 
H- I /H-3 
r 	I 
H-2/H-3' 
r 	I 
H-1 /H-5' 
r 	I 
H-2/H-5' 
4.136 0.20 4.416 0.13 2.178 9.37 3.431 0.13 
4.431 0.13 5.149 0.05 2.242 7.87 3.327 0.73 
6.179 0.02 5.513 0.03 4.649 0.10 4.385 0.14 
7.860 0.00 6.051 0.02 6.362 0.02 5.013 0.06 
7.871 0.00 5.262 0.05 7.321 0.01 5.321 0.04 
7.364 0.00 4.456 0.13 6.304 0.01 4.498 0.12 
5.697 0.03 4.023 0.04 4.066 0.22 3.148 1.03 
4.217 0.12 3.148 1.03 
5.650 0.03 4.224 0.17 
6.370 0.01 5.273 0.05 
6.757 0.01 j 5.494 0.03 
6.267 0.01 5.406 0.04 
5.234 0.05 3.507 0.53 
4.173 0.19 2.591 3.31 
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Table: 35 Interproton distances between X7. and [s-CD protons oil18 frame MD 
(narmw side) model (97.3679 kcal/mol) and their corresponding intensities. 
r 	I 
H-I/H-3' 
r 	Jr 
H-2/H-3' 
Jr 
H-I/H-5' 
I 
H-2/H-5' 
4.180 0.19 4.584 0.12 2.248 7.75 3.763 0.35 
3.778 0.34 4.149 0.20 2.179 9.34 3.907 0.28 
5.202 0.05 4.241 0.17 3.689 0.40 3.222 0.89 
6.776 0.01 4.645 0.10 5.874 0.02 4.228 0.17 
7308 0.00 4.958 0.07 6.827 0.01 4.989 0.06 
7.420 0.00 5.673 0.03 6.064 0.02 4.850 0.08 
5.867 0.02 5.148 0.05 4.525 0.12 4.524 0.12 
3.834 0.31 2.418 5.00 
3.601 0.46 2.742 2.35 
5.314 0.04 4.088 0.21 
6313 0.01 5.508 0.04 
6.897 0.01 5.809 0.03 
6.457 0.01 5.808 0.03 
5172 0.05 3.700 0.39 
Table: 36 Calculated relative crosspcak intensities obtained for MD models. 
1H-1 I 2 
Frame 132 (WS) 5.0 1 
100.7288 kcal/mol 
Frame 105 (NS) S.7 1 
97.8296 kcal/mol 
Frame 118 (NS) 10.2 1 
97.3679 kcal/mol 
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Fig. 79. Side and top view of MD (wide side) 132 frame XZ-~3-CD complex 
(100.7288 kcal/mol). (Green - ~3-CD, red - XZ carbon atom. blue - XZ hydrogen 
atom, dark green - XZ nitrogen atom, magenta - XZ sulphur atom.) 
3.3 Conclusion 
The formation of XZ--CD inclusion complex was established by noticing the upfield 
shift changes in the n-CD cavity protons in the presence of XZ. The stoichiometry of 
the complex was determined as 1:1 from NMR titration data. ROESY data in this case 
only confirmed the partial entry of aromatic ring of guest in the n-CD cavity but could 
not provide any information about the mode of inclusion. Results of MM2 
minimization and MD studies, performed by allowing the movement of guest only. 
also verified the partial entry of aromatic ring. MM2 calculations revealed that XZ 
exhibited preference for inclusion through the wide rim. MD simulations revealed that 
complexation of XZ and 3-CD is energetically favorable. However, the energy of 
most stable conformation was smaller when MD was performed by placing the guest 
at the narrow opening compared to when guest was placed at wider opening. All the 
lowest energy complexes obtained from computational studies could satisfy the 
ROESY data qualitatively. A comparision of calculated relative ROESY intensities 
obtained for five structures (two MM2 models and three MD models) with the 
experimental ROESY data showed that two conformations, which were very similar 
in appearance. could be considered. Of these. MD minimum energy (Fig. 79) 
conformation is the most probable structure of the complex. 
137 
Chapter 3 
The results of the present study further substantiated that energy cannot be taken as 
the only criteria for predicting geometry of inclusion complexes when computational 
calculations are performed in vacuum. The results again illustrated that by 
combination of quantitative ROESY analysis and computational studies in vacuum, 
highly accurate structural information regarding the conformation of the inclusion 
complex can be obtained. 
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ISONIAZID 
IUPAC Name: isonicotinohvdrazide 
Molecular mass: 137.139 glmol 
Melting point: 171.32°C 
Solubility: freely soluble in water. sparingly soluble in alcohol, very slightly soluble 
in ether 
Structural formula: C(,H7N3O 
Color/appearance: white to off-white. crystalline powder 
Isonicotinic acid hydrazide or isoniazid (INH) is an important drug used for 
treating tuberculosis - the most common infectious and contagious disease worldwide. 
It is estimated that about one third of the world's population is affected by 
tuberculosis and more than 5000 people die from its infection every day [328]. INH is 
a prodrug and is activated by mycobacterial catalase-peroxidase [3291. It acts by 
preventing the biosynthesis of mycolic acid by inhibiting 2-trans-enoyl-acyl carrier 
protein reductase (InhA) that belongs to the FAS-I1 (fatty acid synthetase 11) system 
[ 330]. INH is poorly absorbed from the stomach because at acidic pH (PKa = 2) it is 
present in the protonated form, although it is well absorbed from all the three 
segments of the intestine [331 ]. 
INH is vulnerable to hydrolysis and oxidation and it interacts with excipients, 
particularly reducing sugars to form hydrazones. The hydrazone formed by the 
reaction of INH with lactose (pH 1.0-6.0) is I -isonicotinoyl-2-lactosylhydrazine [332, 
333]. Several hospitals have also reported stability problem of INH tablet/capsule that 
their colors were changed during storage [334]. Since liquid INH formulation is not 
present in market, it is generally administered to children or in cases where tablet is 
not suitable as mixture prepared from commercially available tablets instead of INH 
powder as recommended by British Pharmaceutical Codex (BPC) without considering 
the possible presence of lactose, an excipient present in the tablet, and with which the 
incompatibility of INN is very well documented. There are many detailed reports on 
the formulation and stability evaluation of various extemporaneously prepared INH 
mixtures from INH powder as well as INH tablets [335,336] emphasizing the 
implication of stability consideration of these formulations. 
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4.1 Experimental studies 
4.1.1 Materials: 
D-CD was obtained from Geertrui Haest, Cerestar Application Centre, Food 
& Pharma Specialities, France. and INH was gifted by Lincoln Pharmaceuticals Ltd., 
India and these were used without further purification. 
4.1.2 One-dimensional NMR experiments: 
All the 'II NMR spectra were recorded on a BRUKER AVANCE 11 400 MHz 
instrument at room temperature. Chemical shift values (S) are reported in ppm with 
the HDO signal being used as internal reference. Samples of Is-CD and drug mixtures 
having molar ratios 1:0.77, 1:1.05, 1:1.47, 1:2.10, 1:2.41 were prepared by keeping 
the concentration of [3-CD constant at 9 mg and varying the concentration of INH. All 
these mixtures as well as pure INH were dissolved in D20 by shaking/sonicating till 
clear solutions were obtained. The chemical shift changes were calculated according 
to the formula: AS=S(,npkx)_ S(f).No separate signals of bound and free form of 
INH or p-CD were observed indicating a rapid intermolecular exchange between free 
and complexed form on NMR time scale. 
4.13 Two-dimensional NMR experiments: 
COSY spectrum of 1:1 mixture of INH and 3-CD was recorded on 400 MHz 
BRUKER spectrometer using pulse program cosygpqf. A total oil024 data points in 
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F2 and 1024 data points in Fl over a spectral width of 4000 Hz were collected. 
ROESY spectrum of 1:1 mixture of INH and 3-CD was am on a 500 MHz BRUKER 
spectrometer. ROESY was attained in phase sensitive mode with a spin lock power of 
17.92 dB, relaxation delay of 2.5 sand mixing time of 0.35 s with 5000 Hz spectral 
window in both dimensions. The spectrum was measured by acquisition of 2048 (F2) 
x 400 (Fl) data points. 
4.1.4 Computational methodoloey: 
All computational studies were performed using CS Chem3D Pm (Cambridge 
Soft Corp.) in vacuum, at 298 K. Initial coordinates for p-CD were obtained from 
Cambridge data bank. The published X-ray coordinates for hydrated n-CD [319] were 
used as starting point after removing water molecule coordinates. The structure of 
INI1 was minimized to a RMS value of 0.1 kcalmol-*" using Allinger's force field. 
In all the calculations, the cavity of 13-CD was kept static and INH molecule was 
selectively allowed to move. MM2 minimisation studies were carried out by keeping 
the optimized structure of INH molecule into the p-CD cavity and allowed for full 
geometry optimization at the corresponding level of calculation. MD calculations 
were performed by placing the pyridine ring of INH molecule near the mouth of (I-CD 
cavity along z-axis from wider rim side. An iteration step of t ft was used and 
conformations were recorded after every 10 iterations with 10000 steps of 
equilibration. 
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R spectroscopic studies 
NMR spectrum of INH displayed only two peaks in the aromatic 
loublet at 7.5730 (2H, J= 4.6 Hz) and protons H-2 as distorted doublet 
at 8.5609 (2H. J = 4.72 Hz) (Fig. 80). The assignment of n-CD proton was made with 
the help of COSY spectral data obtained for 1:1 mixture of INH and n-CD (Fig. 86). 
The obtained spectrum was in good agreement with the reported data (3201. 
In the 'H NMR spectra of mixtures of INI I and D-CD (Fig. 81-85), small 
upfield shift changes were noticed for the signals of aromatic protons of INH while 
significant upfield shift changes were displayed in the signals of cavity protons, 
namely H-3' and H-5'. These shift changes (M) increased with increasing 
concentration of INH. The magnitude of ASF1_y was slightly larger than OSff_3'. H-2' 
and H-4' protons, present outside the cavity underwent negligible shift change. Fig. 88 
compares the n-CD region of pure a-CD and 1: 2.10 molar mixture of -CD-1NH. 
rNZ/13-CD = 2.10 
H-6' 
H-3' A 
H-2' H-4' 
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H-6' 
Pure 13-CD 
H-3'  H-2' 
H _5' 	i, .. H-4' 
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Fig. 88. Expansion of the part of 'H NMR spectra showing n-CD protons 
in the presence and absence of INH. 
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The observed shifts in the signals of H-3' and H-5' protons in the spectra of INH and 
13-CD mixtures was indicative of inclusion occurrence, especially as the variation in 6 
values for the external 13-CD protons (H-2' and H-4') were negligible. The upfield 
shift displacement of aromatic protons of INH further evidenced the formation of 
inclusion complex. 
4.2.2 Stoichiometry and binding constant of INH-f3-CD complex 
The stoichiometry of INH-13-CD complex was determined by Scott's version 
of Benesi-Hildebrand equation. For 1:1 complex, the Scott's equation can be written 
as: 
[INH] _ [INH] 	1 
Sobs 	16s  + KaI 6s 
where [[NH] is the concentration of INH, A6„n, is the observed chemical shift changes 
for a given 3-CD with varying concentrations of INH, and OS, is the chemical shift 
difference between pure sample of complex and the free component at saturation and 
K3 is binding constant. A plot was constructed in the form of [INH]/OS versus 
[INH] by making use of A6H _3- and MSH _5• data (Table. 37). The obtained straight lines 
(Fig. 89) confirmed the 1:1 stoichiometry of the complex. The binding constant was 
also calculated from this plot and was found to be 18.49 W. 
Table: 37'H NMR titration data used for Scott's plot. 
SAMPLE 
(5-CD:INH) 
[INH] 
(M) 
ABfi_3• 
m) 
[INH]/AS1i-3. 
(M/ 	m) 
ASN_5' 
m) 
[INH]/ASH_r. 
(M/ 	m) 
1:0.77 0.0123 0.0105 1.1714 0.0363 0.3388 
1:1.05 0.0162 0.0136 1.1911 0.0383 0.4229 
1:1.47 0.0233 0.0189 1.2328 0.0500 0.4660 
1:2.10 0.0332 0.0259 1.2818 0.0619 0.5363 
1:2.41 0.0388 0.0301 1.2890 0.0686 0.5655 
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Fig. 89. Scott's plot for 1:1 INH-0-CD complex. 
4.2.3 ROESY spectroscopic studies of INH-f-CD complex 
The ROFSY spectrum of the 1:1 mixture of INH-~i-CD (Fig. 87) shows the 
existence of intermolecular crosspeaks between the H-3' and H-5' protons of a-CD 
and the pyridine ring protons (H-1 and H-2) of INH. This is in agreement with the 
chemical shift data, confirming inclusion of pyridine ring of INH in the n-CD cavity. 
The partial expansion of ROESY spectra showing intermolecular crosspeak is 
shown in Fig. 90. Following conclusions can be drawn by close inspection of ROESY 
spectrum: The H-1 protons of INH are more close to a-CD ring protons as compared 
to H-2 INH protons since the intensity of crosspeak of 1-1-1 and cavity protons of -
CD was higher as compared to the crosspeak intensity obtained between H-2 and H-3' 
and H-2 and H-5'. It was also noticed that the crosspeak intensity of H-1 with H-3'as 
well as with H-5' was almost equal suggesting that 11-1 is positioned in between H-3' 
and I1-5'. Moreover the intensity of crosspeak of H-2 with H-5' was higher than with 
11-3' implying that protons H-2 are farther from H-3' compared to H-5'. These results 
compiled together indicated, that guest enters the cavity from wider side. Since, the 
0.3 
0.010 
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complexation geometry obtained by wide side penetration of pyridine ring of INH can 
only justify the obtained ROESY spectra. 
PM 
9.2 9.1 9.0 8.9 82 8.7 86 8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 ppm 
Fig. 90. Partial ROESY spectrum of 1:1 mixture of INH and n-CD 
showing intermolecular crosspeaks obtained on one side of diagonal. 
The proposed inclusion structure of INH-~i-CD on the basis of ROESY data is 
shown in Fig. 91. In this structure the protons H-1 are equidistant from H-3'and H-5' 
and protons 11-2 are near to H-5' and far away from H-3'. The ROESY spectrum 
pertaining to this structure will show cross peaks for H-I/H-3', H-1/H-5' and H-2/H-
5'. No cross peak will be obtained for H-2/H-3' as H-2 is far away from H-3'. The 
intensities of cross peaks of 11-1/11-3' and 1-1-1/11-5' would be almost same. Also, the 
intensity of H-2/H-5' would be comparable to H-l/H-3' and H-I/H-5'. But, in our 
case this is not so. The intensity of H-2/H-5' is smaller than H-1/H-3' and H-1/H-5' 
and very weak cross peak spot is obtained for 1-1-2/11-3'. This suggests that the 
orientation of INH inside n-CD cavity may be slightly tilted. 
It can be seen in Fig. 87 that the crosspeaks on one side of the diagonal are not 
visible due to the presence of TOCSY artifacts. The structure of INH-~i-CD was 
further quantitatively analyzed. 
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NH2 
Fig. 91. Structure of TNH-(i-CD inclusion complex on the basis of ROESY data 
4.2.4 Enerey minimization (MM2) studies 
The MM2 minimization studies were carried out for pyridine ring of [NH 
molecule since its involvement in inclusion process was proved by ROESY spectrum. 
Two orientations were studied: orientation 1, in which the pyridine ring was placed 
perpendicular to the CD cavity and orientation 11 in which the pyridine ring was kept 
slightly tilted, For both these orientations three different modes were studied from 
wide side as well as narrow side. The pyridine ring was placed near the rim partially 
inside (S), in the center of the cavity (C) or deep inside the cavity partially outside the 
bottom rim (B) (Fig. 40). 
The results of MM2 minimization studies are presented in Table 38. It was 
observed that orientation II is preferred over orientation I since in all the three studied 
modes either from wide or narrow side; the steric energy for orientation II was lower 
as compared to orientation I except for WB mode. Lowest energy complex was 
obtained when pyridine ring was placed in the centre of the cavity in tilted orientation 
from wide side. The steric energy of this complex was 90.3739 kcal/mole (Fig. 92). 
The energy minimization from narrow side gave most stable complexes having steric 
energy 88.0912 kcal/mole and 89.0618 kcal/mole which were not considered since 
these structures could not explain the ROESY contacts. The most stable inclusion 
complex obtained by MM2 energy minimization studies was quantitatively analyzed. 
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Table: 38 Steric energies (kcal/mol) obtained with MM2 
minimizations for 1NH-~i-CD complexes. 
Modes Steric energy 
(Orientation I) 
Steric energy 
(Orientation II) 
WS 97.7583 93.4610 
WC 96.5371 90.3739* 
WB 92.3973 94.1971 
NS 95.7025 94.0914 
NC 95.7333 92.8147 
NB 89.0618 88.0912 
* Lowest energy complex 
Fig. 92. Side and top view of INH-13-CD complex (WC, 90.3739 kcal/mol). 
(Colors: orange - P-CD, green - INH carbon atoms, red - INH hydrogen 
atoms, pink - INH oxygen atom, blue -- INH nitrogen atom) 
4.2.5 Quantitative ROESY analysis 
The tine structure of the inclusion complex was determined by use of distance 
-intensity relationship: 
The interproton distances between pyridine ring and cavity protons (H-l/H-3', H-I/H-
5', H-2.'H-3', H-2/H-5') for MM2 energy minimized WC complex (Fig. 92) were 
obtained. From these distances the corresponding referenced intensities Iti.i.11_z-, l~i_~_E{ _ 
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5-_'H.2.}i_3- .111-2.11-5- were calculated (Table. 39). These intensities were then summed to 
get total referenced intensities. i.e. 	IEl_i.fI_3 , FJH_i_gi.s EIII-2-fH-Y_ Y-1E1_2_H_Y. It was 
observed that these calculated relative intensities did not match with the experimental 
ROESY intensities. A series of complexes were then obtained by refinement of this 
conformation and were quantitatively analyzed. The procedure was continued until 
calculated peak intensity data was in good agreement with the experimental ROESY 
data. The interproton distances and corresponding intensities for the obtained complex 
(Fig. 93. 101.202 kcal/mol) are listed in Table. 40. The relative crosspeak intensities 
calculated for MM2 minimized models are given in Table 41. 
Table: 39 Interproton distances between INH and n-CD protons of MM2 complex 
(WC. 90.3739 kcallmol) and their corresponding intensities. 
r 	I 
H-1 /1-1-3' 
r 	I 
H-2/H-3' 
r 	I 
H- I /H-5' 
r 	I 
H-2/H-5' 
2.306 6.65 3.912 0.28 3.884 0.29 2.918 1.62 
3.512 0.53 5.218 0.05 2.166 9.68 2.272 7.27 
5.913 0.02 5.751 0.03 3.327 0.74 3.476 0.57 
6.391 0.02 6.623 0.01 5.274 0.05 5.181 0.05 
6.639 0.01 6.706 0.01 6.753 0.01 5.552 0.03 
5.815 0.03 5.311 0.04 6.451 0.01 5.203 0.05 
3.408 0.64 4.509 0.12 5.259 0.05 4.638 0.10 
6.058 0.02 7.126 0.01 4.178 0.19 2.267 7.37 
5.776 0.02 6.148 0.02 3.782 0.34 2.615 3.13 
3.624 0.03 4.980 0.07 4.963 0.07 4.244 0.17 
2.570 3.47 2.529 3.82 5.866 0.03 5.810 0.03 
3.697 0.39 2.883 1.74 6.443 0.02 6.431 0.01 
4.756 0.09 5.108 0.06 6.268 0.02 6.295 0.02 
6.143 0.02 6.222 0.02 5.812 0.03 4.221 0.18 
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Fig. 93. Side and top view of refined MM2 INH-~i-CD complex (101.202 kcal/mol). 
(Colors: green - n-CD. pink - INH carbon atoms, magenta - INH hydrogen 
atoms, red - IN1I oxygen atom, blue - [NH nitrogen atom) 
Table: 40 Interproton distances between INII and n-CD protons of 
refined MM2 complex (101.202 kcal/mol) and their corresponding intensities. 
r 	I 
H- I /H-3' 
r 	I 
H-2/H-3' 
r 	I 
H- I /H-5' 
r 	I 
H-2/H-5' 
3.056 1.22 5.233 0.05 2.495 4.14 2.559 3.56 
5.064 0.06 6.039 0.02 4.881 0.07 3.335 0.72 
7.200 0.01 7.138 0.01 6.614 0.02 4.848 0.08 
7.364 0.01 6.692 0.01 7.468 0.01 5.731 0.03 
7.001 0.01 6.247 0.02 6.075 0.02 5.975 0.02 
4.681 0.10 4.784 0.08 4.093 0.21 4.464 0.13 
2.008 15.24 4.009 0.24 2.057 13.19 3.018 1.32 
4.558 0.11 5.657 0.03 5.934 0.02 6.005 0.02 
5.627 0.03 6.692 0.01 5.902 0.02 6.185 0.02 
4.987 0.06 5.959 0.02 5.700 0.03 5.619 0.03 
4.702 0.09 4.739 0.09 5.306 0.04 4.229 0.18 
3.871 0.03 2.120 2.47 5.359 0.04 3.154 1.08 
4.200 0.18 3.043 1.26 4.799 0.08 2.613 3.14 
4.156 0.19 4.321 0.15 5.147 0.05 4.301 0.16 
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Table: 41 Experimental and calculated relative ROESY crosspeak intensities. 
IH`2/H-5 	'1r-21H-3' IH-I/H-3' IH-I/1I-5' 
Experimental 2.83 	1 59Ø* 5.90 
(Fig. 87) 
MM2 model 1.78 	1 1.03 0.54 
(90.3739 kcal/mol) 
MM2 model 2.36 	1 3.90 4.02 
(101.202 kcal/mol) 
* H- I /H-3' and H-1/1-I-5' crosspeaks are merged. 
4.2.6 Molecular dynamics (MD) studies 
When INH molecule was placed at the wider mouth of the cavity and 
simulation started, it started approaching the cavity. The molecule entered the cavity 
after 500 fs and after 1230 fs the H-2' of pyridine ring was past H-3' proton of cavity. 
After attaining this position the INH molecule rotated and moved swiftly outside the 
cavity. It stayed at the wider opening withstanding conformational changes and after 
3000 fs it re-entered the cavity and after 3790 fs it was placed centrally in the cavity. 
The pyridine ring underwent rotation at this juncture and it located itself at the mouth 
of cavity after 5180 fs. Undergoing tilting and simultaneous rotation the pyridine ring 
invaded the cavity such that after 7000 fs the N atom of pyridine ring was at the 
narrow opening. The INII molecule underwent further penetration till the entire 
pyridine ring was protruding outside from the narrow end. After 8650 fs the INH 
molecule pulled itself inside the ring and occupied various positions in the cavity till 
the end. The lowest energy conformation of INI1- 3-CD inclusion complex was 
obtained after 6920 fs. The entire MD trajectory is depicted with the help of some 
crucial snapshots in Fig. 94. 
The time-potential energy plot depicting the inclusion process is shown in Fig. 
95. Lowering of potential energy confirms that inclusion of INH into n-CD is 
energetically favorable. The lowest energy conformation obtained by the MD 
simulation was quantitatively scrutinized. The interproton distances between 
pyridine ring protons of INH and n-CD cavity protons (H-3' and H-5') for this 
complex (Fig. 96, frame 692, energy 88.3149 kcal/mol) are given in Table 42. From 
these distances the referenced intensities were evaluated as discussed above. The 
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relative intensities 'H. 	, I}i-mw', 	and 41.1/ UU_5 for this complex were found 
to be 19.36. 1, 14.41 and 59.49, respectively. 
I fs 	 1230 fs 
	 3 790 fs 
7000 fs 8650 fs 	 10000 fs 
Fig. 94. Snapshots depicting the inclusion process of INII into the n-CD cavity as 
obtained in the MD trajectory from wide side. 
104 
102 
0100  
11 	 .V1 
W u 
1 	 692 *me 
0 	2000 	4000 	60C 	8000 	10000 	12000 
Time (fs) 
Fig. 95. The time evolution of potential energy calculated from MD run in vacuum 
from wide side entry of INH into f3-CD cavity. 
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Fig. 96. Side and top view of MD 692 frame [NH-n-CD complex (88.3149 kcaUmol). 
(Colors: blue - n-CD, pink - [NH carbon atoms, yellow - INH 
hydrogen atoms, red - INH oxygen atom, magenta - [NH nitrogen atom) 
Table: 42 Interproton distances between INH and n-CD protons of 692 frame MD 
model (88.3149 kcaUmol) and their corresponding intensities. 
r 	I 
H-1 /H-3' 
r 	I 
H-2/H-3' 
r 	I 
H-1 /H-5 
r 	I 
H-2/H-5' 
2.669 2.77 4.513 0.12 2.406 5.15 2.553 3.61 
4.410 0.14 5.288 0.05 3.451 0.59 3.035 1.28 
5.841 0.02 6.461 0.02 5.163 0.05 4.784 0.03 
7.166 0.01 7.932 0.00 6.087 0.02 6.039 0.02 
6.211 0.02 7.503 0.01 6.241 0.02 6.652 0.01 
5.120 0.06 6.918 0.01 4.694 0.09 5.553 0.03 
3.700 0.39 5.758 0.03 2.701 2.58 3.718 0.38 
6.703 0.01 7.567 0.01 6.472 0.02 6.451 0.02 
6.918 0.01 7.582 0.01 5.958 0.02 5.805 0.03 
5.400 0.04 6.285 0.02 4.722 0.09 4.578 0.11 
4.170 0.19 5.644 0.03 2.842 1.90 3.151 1.02 
2.867 1.80 5.190 0.05 2.098 11.73 3.274 0.81 
4.363 0.14 6.290 0.02 3.239 0.87 4.295 0.16 
6.271 0.02 7.526 0.01 4.983 0.07 5.451 0.04 
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4.3 Conclusion 
The internalization of INH molecule in the (1-CD cavity was evidenced by 
noticing the chemical shift changes in the (3-CD cavity protons in the presence of 
INH. From NMR titration experiments, formation of 1:1 inclusion complex was 
authenticated. The observed intermolecular crosspeaks in the ROESY spectrum 
suggested total penetration of pyridine ring of INH into p-CD cavity from wide side. 
MM2 calculations performed by only moving INH molecule, via two modes, revealed 
that tilted orientation of pyridine ring had significant preference over the orientation 
where the pyridine ring was placed perpendicular to 13-CD z-axis. MD simulations 
performed by wide side entry of the guest and selectively moving only guest molecule 
confirmed that complexation process was energetically favorable. More clear picture 
of inclusion structure was obtained from quantitative analysis of ROESY data which 
showed that MM2 complex (Fig. 93) was the most probable structure of tNH-0-CD 
complex. As can be seen, of all the possible conformations, the relative intensities 
calculated for the complex having highest energy were found in good agreement with 
experimental intensities. It was observed that when hydrazide protons of the drug 
came in contact with the hydroxyl groups of n-CD it resulted in lowering of energy of 
the complex. As already discussed earlier, the presence of water outside the cavity 
will make these interactions self compensatory. The results again show that energy 
can be taken as the only criteria when the simulations are performed in water. 
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CHLORDIAZEPDXIDE 
IUPAC name: 7-chlory-2-methylainin-5-phenyl-311-1,4-benzodiazepine-4-oxide 
Molecular mass; 299.75 g/mol 
Melting point: 236.2 °C 
Solubility: solubility in water - 160 mg/ml, sparingly soluble in alcohol 
Structural formula: C16H14CIN30 
Color/appearance: almost white or light yellow crystalline powder 
Chlordiazepoxide (CDZ) belongs to the class of medications called 
benzodiazepines which act on the central nervous system to produce a calming effect. 
In clinical practice benzodiazepines are usually prescribed for longer period ranging 
from weeks to months even years. CDZ was discovered by accident when tests 
revealed that the compound had anxiolytic, sedative-hypnotic, tranquilizer, and 
antidepressant effects [337]. It works by slowing down the movement of chemicals in 
the brain resulting in reduction in nervous tension (anxiety) and muscle spasm, and 
also causes sedation. 
CDZ is used to treat anxiety and acute alcohol withdrawal. It is helpful in 
relieving fear and anxiety before surgery. It enables the treatment of emotional 
disturbances without a loss of mental acuity or alertness and also assists persons 
burdened by compulsive behavior. CDZ is rapidly hydrolyzed in solution to the active 
ketone product demoxepatu which possesses a reduced activity at the GABAA 
receptor which is the main inhibitory receptor in the central nervous system known to 
be closely involved in stress and anxiety processes [338]. 
3 
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The CDZ molecule has three rings: one heterocyclic ring and two aromatic 
rings. Out of two aromatic rings, one ring has one of its H atom substituted by Cl 
atom. It was expected that heterocyclic ring stays in solution during inclusion 
complex formation due to presence of nitrogen atoms and steric hindrance while the 
two aromatic rings may compete with each other for occupying CD cavity space. 
5.1 Experimental studies 
5.1.1 Materials: 
CDZ was gifted by P. 1. Pharmaceuticals (P) Ltd., India while p-CD was 
obtained from Geertrui Haest. Cerestar Application Centre, Food & Pharma 
Specialities, France, and these were used without further purification. 
5.1.2 One-dimensional NMR experiments: 
NMR spectra were recorded at 298K on a JEOL 500 MHz spectrometer in 
D20 and referenced to the residual signal of HDO at 4.800 ppm. NMR samples of 
pure CDZ and mixtures having (3-CD:CDZ molar ratios 0.25:1, 0.50:1, 0.75:1, 1:1, 
1.50:1, 2.00:1 and 2.50:1 were prepared. NMR samples of CDZ and (3-CD mixtures 
were prepared by taking 1.188 mg of CDZ and adding calculated amount of (i-CD in 
0.5 ml DO, All the mixtures of the drug and 13-CD were shaken and/or sonicated till 
clear solutions were obtained. The chemical shift change was calculated according to 
the formula: AS = S(u,,hie,) S(G ). On NMR time scale, rapid intermolecular exchange 
takes place between free and bound form of 3-CD and CDZ, as a consequence of 
which no separate signals were observed for free and complexed form of CDZ or 3-
CD. 
5.13 Two-dimensional NMR experiments: 
The COSY and ROESY spectra were recorded on JEOL 500 MHz 
spectrometer in D20 at room temperature for 1:1 mixture of CDZ and n-CD. In 
COSY spectrum, a total of 1280 X points and 256 Y points were collected over a 
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spectral window of 5000 Hz with relaxation delay of 1.5 s. ROESY spectrum was 
measured by acquisition of 1024 (F2) x 51 (Fl) data points with 5000 Elz spectral 
window in both the dimensions. ROESY was acquired in phase sensitive mode with 
spin lock power of 21 dB, relaxation delay of 1.5 s and mixing time of 0.5 s. 
5.1.4 Computational methodology: 
All computational calculations were carried out with CS Chem3D Pro 
(Cambridge Soft Corp.) using Mlinger's MM2 force field in vacuum at 298 K. Initial 
coordinates for (3-CD were obtained from the Cambridge databank [319] after 
excluding water molecules. CDZ structure was drawn and minimized to a root mean 
square (RMS) value 0.1 kcalmof' A'' under the MM2 force field. MM2 studies were 
carried out by keeping the optimized structure of CDZ molecule into the [i-CD cavity 
and allowed for full geometry optimization. MD simulations were performed by 
placing the phenyl ring of CDZ molecule near the mouth of (1-CD cavity along z-axis 
from wide rim side in vacuum, at an iteration step of 1 fs. The conformations were 
recorded after every 10 iterations with 6000 steps of equilibration. In computational 
studies, only the guest molecule was selectively moved while the motion of (3-CD 
cavity was restricted. 
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Fig. 106. ROESY spectrum of a mixture of CDZ and P•CD having molar ratio [CDZ],'[I•CD] 
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5.2 Results and Discussion 
5.2.1 1 H NMR spectroscopic studies 
To establish the structure of inclusion complex, an unambiguous resonance 
assignment of CDZ protons was needed which was made with the help of COSY 
spectrum of 1:1 mixture of CDZ and n-CD (Fig. 105). The signal for five protons of 
phenyl ring (Ph-H) and H-6 proton of Cl-substituted ring appeared as a broad 
complex multiplet centered at 7.5317. H-4 signal appeared as doublet at 7.2431 (1 H. J 
= 2.3 Hz) and H-5 signal was observed as double doublet at 7.6571 (111, J = 2.3 Hz, J 
8.6 Hz). Methyl protons were found resonating at 3.1811 while peak for 1-1-7 proton 
appeared at 2.0211. The total peak area rationalized the total number of CDZ protons 
(Fig. 97). The assignment of 3-CD protons has already been discussed earlier. 
In the spectra of mixtures of CDZ and n-CD (Fig. 98-104) it was observed that 
H-3' and H-5' protons of n-CD undergo significant upfield shift change compared to 
pure p-CD. Very small shift change was also noticed for H-6 proton, while negligible 
shift change was obtained for H-2' proton and no shift change was noticed in H-4' 
proton signal. The shielding effect on the H-3' proton was higher than 11-5' i.e. (M113• 
> Odt1.5) (Fig. 107). In case of drug protons, downfield shift change was noticed for 
multiplet signal corresponding to H-1,2,3/H-6 and also there was change in shape of 
the peak and splitting of peak with increasing concentration of a-CD. Upfield shift 
change was noticed for H-5 and H-4 proton signals while no shift change was 
observed for 1-1-7 and H-8 protons. A change in peak shape was also noticed for H-4 
proton signal with increasing concentration of 13-CD. These shift changes in host and 
guest protons strongly suggested that CDZ formed inclusion complex with 13-CD. 
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H-3' 
H-S• 
H-3' 
1 	H-S' 
.0 	3.9 	3.8  
C[ DX] 
(p-CD] - 
H-4' 
H-2' 
PURE p-CD 
H-2' H-4' 
3.7 	3.6 	35 
Fig. 107. Expansion of the part of 'H NMR spectra showing [3-CD protons 
in the absence and presence of CDZ. 
5.2.2 Stoichiometry of CDZ-Q-CD complex 
The stoichiometry of the complex was determined by Scott's method which is 
modified form of Benesi-Hildebrandt method. Scott's equation for 1:1 CDZ-[3-CD 
complex can be written as: 
[R- CDC - [R -C]+ 1 
Sobs 	ASS 	Kass 
where, [ — CD] is the concentration of [3-CD. M is the observed chemical shift 
changes for a given CDZ with varying concentrations of n-CD, and 06, is the 
chemical shift difference between pure sample of complex and the free component at 
saturation and Ka is binding constant. The quantity [[3 — CD] was plotted against 
[[i — CDJ/ 	by making use of chemical shift change data obtained for H-4 proton 
i.e. ASFi4 (Table. 43) obtained from 'H NMR titration experiments. The obtained 
straight line (Fig. 108) confirmed the formation of 1:1 complex between CDZ and P-
CD. 
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Table: 43 '11 NMR titration data used for Scott's plot. 
SAMPLE 
(COZ: n-CD) 
1P-CDl 
(M) 
68x4 
(ppm) 
I D-CDI/ASa4 
(M/ppm) 
1:0.25 0.00198 0.0057 0.3473 
1:0.50 0.00396 0.0109 0.3633 
1:0.75 0.00595 0.0159 0.3742 
1:1.00 0.00793 0.0205 0.3868 
1:1.50 0.01189 0.0320 0.3715 
1:2.00 0.01586 0.0362 0.4381 
1:2.50 0.01982 0.0430 0.4609 
0.000 0.002 0.004 0.006 0.008 0.3W 0.012 0.014 0.016 0018 0.020 0.022 
[13-CD] M 
Fig. 108. Scott's plot for 1:1 CDZ-P-CD complex. 
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5.2.3 ROESY spectroscopic studies of CDZ-1-CD complex 
The 1i-1,2,3/H-6 protons of CDZ showed intermolecular contacts with H-3' 
and H-5' in the ROESY spectrum of 1:1 mixture of CDZ, and a-CD (Fig. 106) while 
no correlation peaks were found for H-4 and H-5 protons and cavity protons. Hence, it 
was concluded that only phenyl ring (Ph-H) participated in the inclusion process and 
11-6 proton of Cl-substituted ring has no contribution to the intermolecular crosspeak 
intensities. The entry of guest molecule from wide side of cavity was established by 
studying cross peak intensities between H-3'/Ph-H and H-5'/Ph-H. Proton dipolar 
contacts correlations obtained in the ROESY spectrum on both side of the diagonal 
are shown in Fig. 109. It was observed that intensities for H-3' and Ph-H was greater 
than H-5' and Ph-H. 
Fig. 109. Portions of ROESY spectrum of 1:1 mixture of CDZ and 1i-CD showing 
intermolecular interaction of phenyl ring protons of CDZ with n-CD cavity 
protons on both sides of diagonal. 
Computational studies were carried out to further confirm the complex 
structure. These studies became more significant due to the fact that ROESY 
spectrum exhibited TOCSY artifacts on one side of the diagonal incorporating certain 
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degree of ambiguity. The structure of the inclusion complex deduced on the basis of 
ROESY is shown in Fig. 110. 
0 
Fig. 110. Structure of CDZ-(3-CD inclusion complex on the basis of ROESY data. 
5.2.4 Energy minimization (MM2) studies 
MM2 minimization studies were carried out to gain insight into the structural 
conformation of the CDZ-(3-CD complex, the preferential binding sites on the host 
and the preferred orientation of the CDZ inside the cavity. MM2 energy minimization 
was performed for both phenyl ring and Cl-substituted aromatic ring of CDZ. A total 
of six orientations were studied for phenyl ring. Phenyl ring was placed at the mouth 
of cavity from wide side partially inside (WS, wide-to-surface), in the centre of cavity 
(WC. wide-to-center) and deep inside (WB. wide-to-bottom). In a same way, these 
three orientations were studied from narrow side (NS, narrow-to-surface, NC, narrow-
to-centre. NB, narrow to bottom) (Fig. 40). Only four orientations viz. WS, WC, NS, 
and NC could be studied for Cl-substituted aromatic ring because of steric hindrance. 
The steric energies of complexes obtained in all studied orientations are listed in 
Table 44. 
It can be concluded from energy minimization studies that wide side entry of 
guest is more preferred as compared to narrow side. It was also noticed that binding of 
phenyl ring is more favorable than ring Cl-substituted aromatic ring. It was observed 
that when the phenyl ring was placed at bottom of the cavity either from narrow side 
or wide side, the ring was pushed towards the centre of the cavity implying that 
central position of guest is best suited for inclusion. WC complex was found to have 
lowest energy followed by WB complex. The difference in energy of these two 
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complexes was very small. The two lowest energy complexes from wide side (Fig. 
I11) were further quantitatively analyzed. 
Table: 44 Steric energies (kcallmol) obtained with MM2 energy 
minimizations for CDZ-(3-CD complexes. 
WS 102.4974 106.3009 
WC 96.8571 102.7283 
WB 97.0237 - 
NS 108.4007 106.8371 
NC 105,7198 105.3456 
NB 100,5824 - 
'Lowest energy 
(a)  
(b)  
Fig. 111. Side and top view of MM2 energy minimized CDZ-(3-CD complexes 
(a) WC complex, 96.8571 kcalhnol (b) WB complex, 97.0237 kcallmol. 
(Colors: blue — (3-CD, pink — CDZ carbon atoms, dark green — CDZ hydrogen 
atoms, light green — CDZ chlorine atom, orange — CDZ nitrogen atom) 
Chapter 5 
5.2.5 Quantitative ROESY analysis 
To estimate the solution structure of complex of CDZ with 3-CD, the energy 
minimized MM2 complexes were quantitatively analyzed in light of ROESY data 
using distance-intensity relationship: 
11 	rl-6  
-6 I2 rz  
Two complexes. predicted by MM2 (Fig. 111) studies were quantitatively estimated. 
The interproton distances between phenyl ring and cavity protons (H-1/H-3', H-1/H-
5'. H-2/H-3', H-2/H-5'. H-3/H-3', H-3/H-5') for WC (Table. 45) and WB (Table. 46) 
MM2 complexes were obtained. 
Table: 45 Interproton distances between CDZ and 3-CD protons of MM2 complex 
(WC, 96.8571 kcal/mol) and their corresponding intensities. 
r 	I 
H- l /H-3' 
r 	I 
11-2/11-3' 
r 	I 
l l-3/H-3' 
r 	I 
H- l /H-5' 
r 	I 
H-2/11-5' 
r 	I 
H-3/H-5' 
2.086 12.14 3.628 0.44 5.901 0.02 3.414 0.63 2.874 1.77 5.162 0.05 
2.833 1.93 3.655 0.42 5.351 0.04 3.339 0.73 2.194 8.97 4.009 0.24 
5.096 0.06 5.128 0.05 4.901 0.07 4.875 0.07 3.621 0.44 2.894 1.70 
6.021 0.02 5.964 0.02 4.501 0.12 6.565 0.02 5.770 0.03 3.796 0.33 
6.741 0.02 6.889 0.01 5.518 0.04 5.898 0.02 5.371 0.04 4.682 0.09 
5.666 0.03 6.199 0.02 6.026 0.02 4.535 0.11 4.124 0.20 5.086 0.08 
4.504 0.12 5.496 0.04 6.808 0.01 6.640 0.01 5.549 0.03 3.312 0.76 
6.195 0.02 6.856 0.01 3.741 0.36 6.919 0.01 
5.935 0.02 6.261 0.02 4.351 0.15 5.852 0.02 
4.897 0.07 4.770 0.08 6.454 0.02 3.924 0.27 
2.721 2.46 2.500 4.10 5.218 0.05 2.226 8.35 
2.748 2.32 3.249 0.85 6.280 0.02 4.427 0.13 
4.295 0.16 5.123 0.06 7.166 0.01 6.075 0.02 
6.304 0.02 7.127 0.01 4.911 0.07 2.288 6.97 
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Table: 46 Interproton distances between CDZ and n-CD protons of MM2 complex 
(WB. 97.0237 kcal/mol) and their corresponding intensities. 
r 
H- I /H-3 
Jr 
H-2'H 
1 
-3' 
r 	I 	 j 
H-3/H-3' 
r 	1r 
H- l /H-5' 
I 
H-2/H-5' 
r 	I 
H-3/H-5' 
2.217 8.42 3.546 0.50 5.505 0.04 3.363 0.69 2.500 4.10 4.354 0.15 
2.576 3.42 3.852 0.31 5.994 0.02 3.024 1.31 2.210 8.58 4.390 0.14 
4.887 0.07 5.529 0.04 6.354 0.02 4.613 0.10 3.958 0.26 4.377 0.14 
5.973 0.02 6.393 0.02 5.819 0.03 6.520 0.01 5.906 0.02 4.708 0.09 
6.855 0.01 7.218 0.01 5.911 0.02 6.595 0.01 6.031 0.02 4.073 0.22 
5.907 0.02 6.323 0.02 5.408 0.04 6.036 0.02 5.428 0.07 3.713 0.38 
4.781 0.08 5.408 0.04 5.829 0.03 4.673 0.10 , 3.929 0.27 3.693 0.39 
5.648 0.03 6.294 0.02 6.414 0.02 6.014 0.02 
6.478 0.01 6.986 0.01 6.594 0.02 6.170 0.02 
6.289 0.02 6.646 0.01 6.027 0.02 5.385 0.07 
4.289 0.16 4.721 0.09 5.193 0.05 5.242 0.05 
2.760 2.26 3.571 0.48 3.390 0.66 2.067 12.82 
2.551 3.63 3.567 0.49 4.785 0.09 2.171 9.55 
4.834 0.09 5.581 0.03 3.277 0.81 4.183 0.19 
The referenced intensities IH.1-ti.3', 'H-I-ti•5'. 1!1.2-11-3. IH-2.H-5'• IH.3-H-3' and 'H.3-HS '  were 
calculated from their corresponding interproton distances. These intensities were then 
summed up to attain total referenced intensities, i.e. El11.1.u.3', 1IF{.14l-5', IH-2-t1-3'. Y-III-2- 
H-5'• 1IH-3-H-3', EIH-3-H-5'- The summation of 1IH-1-H-3', 1IH ..-H-3' and  EIH-3-H-3'  gave total 
referenced /H-3'. Similarly, the addition of EIH_1 _H_5, EIH-2-H-5' and IH.3-H-5' gave total 
referenced 1I15. 
Since, good correlation was not obtained between calculated and experimental 
ROESY intensities many other structures of CDZ-1 -CD complex were obtained by 
refining WC model. For all these structures ROESY intensities were calculated from 
interproton distances. The best possible correlation was obtained for CDZ--CD 
complex lex having 99.0159 kcal/mol energy (Fig. 112). It was observed that, in this 
complex the orientation of phenyl ring was slightly tilted such that one H-I proton 
vv as outside the cavity and the other H-I proton was present inside. As a consequence 
of which H-2 proton has come closer to H-3' resulting in high intensity of H-3' 
crosspeak. The interproton distances between phenyl ring protons and cavity protons 
4. 
i-J 
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of n-CD for this complex are listed in Table 47. The relative crosspeak intensities 
calculated for MM2 models are given in Table 48. 
Fig. 112. Side and top view of refined MM2 CDZ-(3-CD complex (99.0159 kcal/mol). 
(Colors: orange - n-CD. red - CDZ carbon atoms, light blue - CDZ hydrogen atoms, 
light green - CDZ chlorine atom, dark blue - CDZ nitrogen atom. 
Table: 47 fnterproton distances between CDZ and R-CD protons of refined MM2 
complex (99.0159 kcal/mol) and their corresponding intensities. 
r 	I 
H-1 /H-3 
r 	I 
H-2/H-3' 
r 	I 
H-3/1l-3' 
r 	I 
H-1 /H-5' 
r 	I 
H-2/H-5' 
r 	I 
H-3/H-5' 
3.176 0.97 2.502 4.08 6.350 0.02 4.583 0.11 3.173 0.98 3.237 0.87 
4.234 0.17 4.410 0.14 3.982 0.25 5.328 0.04 2.408 5.13 3.353 0.70 
3.440 0.60 2.475 4.35 4.779 0.08 5.306 0.04 4.229 0.17 4.259 0.17 
6.074 0.02 6.634 0.01 5.350 0.04 6.483 0.01 5.976 0.02 4.890 0.07 
5.288 0.05 5.015 0.06 4.743 0.08 5.918 0.02 4.633 0.10 3.166 0.99 
6.046 0.02 6.621 0.01 5.238 0.05 6.833 0.01 6.241 0.02 4.270 0.16 
6.000 0.02 6.308 0.01 5.631 0.03 7.353 0.01 7.034 0.01 5.237 0.05 
4.956 0.07 5.612 0.03 3.520 0.53 3.503 0.54 
2.170 9.58 6.624 0.01 5.023 0.06 2.264 7.43 
2.555 3.59 6.026 0.02 3.811 0.33 3.127 1.07 
4.793 0.08 5.411 0.04 5.050 0.06 4.219 0.18 
6.077 0.02 4.756 0.09 6.874 0.01 4.411 0.14 
5.977 0.02 ' 	3.454 0.59 6.926 .01 5.682 0.03 
6.942 0.01 3.314 0.75 6.367 0.02 5.397 0.04 
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Table: 48 Experimental and calculated relative ROESY crosspeak intensities. 
IH3' 	IH-5 'Ph-H 
Experimental 3.0 	1 2.63 
(Fig. 106) 
MM2 model 0.80 	1 1.80 
(96.8571 kcal/mol) 
MM2 model 0.50 	1 1.49 
(97.0237 kcal/mol) 
MM2 model 1.29 	1 2.29 
(99.0159 kcal/mol) 
5.2.6 Molecular dynamics (MD) studies 
MD simulations were carried out from wide opening of j3-CD cavity for 
phenyl ring only. 
The phenyl ring started approaching the cavity as soon as simulation started. 
The H-3 proton was inside the cavity after 690 fs while the entire phenyl ring was 
present in the cavity after 1390 fs. After centrally placing itself in the cavity the 
phenyl ring underwent changes in conformation by tilting and rotating itself After _ 
3560 is the H-1 proton was pushed outside. The lowest energy inclusion structure was 
obtained after 4000 Is in which the phenyl ring was inside the cavity. After attaining 
this conformation the phenyl ring came outside the cavity such that after 5170 Is only 
H-3 was inside the cavity. The phenyl ring again penetrated the cavity and after 6000 
fs when the dynamics was stopped, the ring was once again centrally positioned inside 
the cavity. The entire inclusion process of CDZ in the CD cavity is shown with the 
help of crucial snapshots in Fig. 113. 
The time-potential energy plot depicting the inclusion process is shown in Fig. 
114. Lowering of potential energy confirmed that insertion of CDZ into i3-CD cavity 
is energetically favorable. The lowest energy conformation acquired in the MD 
simulation was quantitatively scrutinized (Fig. 115). The interproton distances H-1/H-
3', H-VH-5', H-2/H-3'. H-2/H-5', H-31-1-3' and H-3/H-5'for this complex (Fig. 115, 
frame 400, energy 94.5362 kcallmol) are given in Table 49. From these distances the 
referenced intensities were evaluated as discussed above. The relative intensities Iu-3•, 
Ins. and 1PxtI for this complex were found to be 1.57, 1 and 2.57 respectively. 
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Ifs 	 1390 fs 	 3560 fs 
4500 fs 	 5300 fs 
	 6000 fs 
Fig. 113. Snapshots depicting the inclusion process of CDZ into the 5-CD cavity as 
obtained in MI) trajectory from wide side. 
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Fig. 114. The time evolution of the potential energy calculated from MD run in 
vacuum from wide side entry of CDZ into 13-CD cavity. 
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Fig. 115. Side and top view of 400 frame MD CDZ-~i-CD complex (94.5362 
kcal/mol). (Colors: blue - n-CD. pink - CDZ carbon atoms, light green - CDZ 
hydrogen atoms, magenta - CDZ chlorine atom, dark green - CDZ nitrogen atom) 
Table: 49 Interproton distances between CDZ and n-CD protons of 400 frame MD 
model (94.5362 kcal/mol) and their corresponding intensities. 
r 	I 
H-lIH-3' 
r 	I 
H-2/H-3' 
r 	I 
H-3/H-3' 
r 	I 
H-1/H-5' 
r 	Jr 
H-2/1-1-5' 
I 
H-3/H-5' 
3.737 0.37 3.244 0.89 4.110 0.21 4.966 0.07 4.323 0.15 5.744 0.03 
4.663 0.10 2.549 3.65 5.939 0.02 3.748 0.36 3.523 0.52 4.593 0.11 
5.030 0.06 3.254 0.84 6.228 0.02 3.093 1.14 4.633 0.10 3.047 1.25 
4.584 0.11 5.554 0.03 6.372 0.02 4.729 0.09 5.882 0.02 2.693 2.62 
6.023 0.02 5.588 0.03 4.875 0.07 6.580 0.01 6.853 0.01 3.550 0.50 
5.393 0.04 6.511 0.01 3.802 0.33 6.921 0.01 7.359 0.01 5.013 0.06 
6.501 0.01 7.073 0.01 2.547 3.66 6.400 0.01 5.944 0.02 6.342 0.02 
4.937 	0.07 3.266 	0.82 5.448 	0.04 5.597 	0.03 
2.501 4.09 3.667 0.41 5.851 0.02 5.192 0.05 
2.455 4.57 4.461 0.13 6.788 0.01 4.355 0.15 
4.100 0.21 5.975 0.02 7.047 0.01 2.716 2.49 
5.818 0.03 6.128 0.02 7.088 0.01 2.594 3.28 
6.350 0.02 4.323 0.15 7.054 0.01 4.418 0.13 
7.319 0.01 6.165 0.02 5.904 0.02 5.151 0.05 
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5.3 Conclusion 
The formation of inclusion complex between CDZ and p-CD was evidenced 
by chemical shift changes in the (3-CD cavity protons in the presence of CDZ and 1:1 
stoichiometry of the complex was obtained from NMR titration data as in earlier 
cases. The participation of only phenyl ring in the inclusion process was confirmed by 
cursory examination of ROESY spectrum. MM2 studies performed by only moving 
guest molecule indicated that wide side entry of phenyl ring is more favorable and 
that central position of guest is more preferred. MD simulation studies revealed that 
inclusion of phenyl ring is energetically favorable, All the lowest energy structures 
and refined complex obtained by MM2 studies as well as lowest energy MD model 
were used to calculated ROESY peak intensities and it was found that calculated 
intensities for refined MM2 model (99.0159 kcal/mol) and minimum energy MD 
model have values close to the experiment data except intensity for H-3' of p-CD. 
Close inspection revealed that these two models have very similar structure. The MD 
model was also the lowest energy complex out of all the structures predicted by 
computational studies. In this structure, orientation of phenyl ring was slightly tilted. 
In the ROESY spectrum (Fig. 106) on one side of diagonal TOCSY artifacts were 
observed and it appears that TOCSY type peaks have merged with intermolecular 
peak. Since, intensity values of MD model were more in agreement to experimental 
values it was proposed to be the most probable solution structure of CDZ--CD 
complex l  (Fig. 115). The results of this study suggested that ambiguity associated in 
structure elucidation can be removed by successful combining the results of 
computational studies done in vacuum and experimental data even when the 
resolution of ROESY spectrum is poor. The study shows that complexes which 
appear qualitatively very similar can easily be distinguished by quantitative ROESY 
data analysis. The results of the study further corroborated that combination of 
experimental and computational methods is a useful way of learning the geometry of 
host-guest complexes. 
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Summary 
The work presented in the thesis gives an insight into the molecular 
associations of supramolecules and CD inclusion complexes in particular. The studies 
carried out in this thesis confirmed the formation of inclusion complexes of CD with 
enalapril maleate, xylazine, isoniazid and chiordiazepoxide. The inclusion structures 
of these complexes were investigated by NMR spectroscopy, computational studies 
carried out in vacuum and quantitative ROESY analysis. 
The study of CD host-guest complexes is of great significance for the 
understanding of supramolecular chemistry. It has been demonstrated that a 
combination of experimental, mainly NMR spectroscopic, and computational methods 
is most suitable for establishment of three dimensional structures of CD complexes. A 
comparison of CD cavity proton resonances in the presence and absence of a guest 
molecule is the first indication of formation of an inclusion complex while the 
ROESY spectral data identifies the part of the guest entering the CD cavity. Mixing 
time is an important parameter for recording a ROESY spectrum. A mixing time of 
300-350 ms is considered appropriate for CD inclusion complexes because clear 
contacts can be observed and TOCSY artifacts can be suppressed if experiment is run 
for several hours. A well resolved ROESY spectrum provides clear cut information 
about the depth and mode of entry of guest into the CD cavity i.e. from wide or 
narrow side. Traditionally information derived from NOE/ROE experiments in NMR 
spectroscopy helps in establishment of molecular structures qualitatively or semi-
quantitatively. 
By taking few representative examples, we have shown more accurate 
structural information can be deduced efficiently by the combined use of quantitative 
ROESY and computational studies. It was shown that quantitative ROESY data 
analysis is a very powerful tool for obtaining more accurate structures of CD 
complexes than are usually reported and by its use ambiguity associated with structure 
elucidation of complexes can be removed. The ROESY spectra were recorded in few 
minutes with a mixing time of 500 ms which were poorly resolved and contain large 
number of 1 OCSY artifacts. The only information that can be inferred with certainty 
from qualitative analysis of these spectra was the part of the guest entering the cavity 
because of their poorly resolved nature. But by comparison of the calculated relative 
intensities of the intermolecular cross peaks for the computer models with those 
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observed in the spectra it becomes possible to obtain more accurate structure. 
Furthermore, the results showed that even if all cross peaks are not clearly observed 
due to the presence of false peaks in the region, structure can still be deduced more 
accurately than possible with qualitative use of ROESY data. It was observed that, in 
all the cases the lowest energy structures obtained by computational study matched 
the experimental data qualitatively however the quantitative analysis further refined 
the results. It was also concluded that energy cannot be taken as the only criterion for 
choosing the probable structure of the complex when computational studies are 
performed in vacuum. The methodology devised in this work can be extended to the 
study of other complexes also. 
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and molecular mechanics methods 
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Abstract Structural studies of complexes of enalapril 
maleatc with x-, f3- and ,,-cyclodcxtrins were carried by 
NMR spectroscopy and computational method. The for-
mation of complexes of enalapril with all the three cyclo-
dextrins was established by chemical shift changes 
observed in the cavity protons of cyclodcxtrins in the 
presence of enalapril malcate. The stoichiometry of the 
complexes was determined to be 1:1 by 1 H NMR titrations 
studies using Scott's method. Intermolecular cross peaks 
observed in the 2D ROESY spectra of mixtures of cnalapril 
maleate with three cyclodextrins helped in establishing the 
probable structures of these inclusion complexes which 
were supported by molecular mechanics (MM2) studies. 
Enalapril forms 1:1 inclusion complex with all the studied 
cycitxlextrins through aromatic ring. The mode of approach 
of aromatic ring to the x-cyclodextrin cavity was found to 
he different from those of Ji- and ;,-cyclodextrins. which 
were identical. 
Keywords Cyclodextrin • Enalapril maleate Inclusion 
complex • Molecular mechanics • ROESY 
Introduction 
Enalapril maleatefF.NA) is a drug of choice, for adults and 
children, to withstand congestive heart failure, essential and 
renovascular hypertension, the most prevalent causes of 
mortality today [ I ]. It is an inhibitor of angiotensin con-
verting enzyme which converts angiotensin Ito angiotensin 
S. Khan - K. Fatnia S. M. Alt (k) 
Department of Chemistry, Aligarh Muslim University, 
Aligarh 202002, tiP, India 
e-mail: smashhoodali(?gmail.com  
II which is responsible for narrowing the arteries and con-
sequently leads to hypertension [2]. Its therapeutic appli-
cations have certain limitations due to poor aqueous 
stability. unpleasant taste and certain side effects [3]. The 
formation of maleate salt helps in stabilizing the drug to 
some extent but problem of storing the drug persists [4]. 
Attempts have been made to mask the bitter taste of the drug 
by forming sugar containing or sugar free liquid oral sus-
pensions but this undertaking also lacks durability [5]. 
12 
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Enalapril 
Cyclodextrins have been used extensively as pharma- 
ceutical excipients to increase the solubility of poorly water 
soluble drugs, stability and hioavailahility of drugs and to 
convert liquid drugs into microcrystalline powders, prevent 
drug-drug or drug--additive interactions, reduce gastroin-
testinal or ocular irritation, and reduce or eliminate 
unpleasant taste and smell in many pharmaceutical prepa-
rations [6-8]. Moreover. CD-inclusion complexes have 
proved to be an excellent model for studying the nature of 
noncovalent interactions in aqueous medium [9[. They 
have provided valuable insights concerning hydrophobic 
effect and London dispersion forces [ 10] and are good 
models for understanding the specificity of enzyme-sub-
strate interactions 1 I 1 ]. The possible factors and various 
molecular forces, which may play a role in cyclodextrin 
complexation, have been widely investigated and discussed 
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Abstract 
The complexation of xylazine with 0-cyclodexrrin was studied in aqueous medium. t H NNAR tit rations confirmed the formation of a 
1:l inclusion complex. A ROESY spectrum was recorded with long mixing time which contained TOCSY artifacts. It only 
confirmed the presence of xylazine aromatic ring in the [ -cyclodextrin cavity. No information regarding the mode of penetration, 
from the wide or narrow side, could be obtained. We calculated the peak intensity ratio from the inter-proton distances for the most 
stable conformations obtained by molecular dynamics studies in vacuum. The results show that highly accurate structural informa-
tion can be deduced efficiently by the combined use of quantitative ROESY and molecular dynamics analysis. On the other hand, a 
ROESY spectrum with no spin diffusion can only compliment an averaged ensemble conformation obtained by molecular dynamics 
which is generally considered ambiguous. 
Introduction 
The emergence and establishment of supramolecular chemistry 
as an important domain of science has fueled the development 
of complex chemical systems from components, interacting by 
non-covalent intermolecular forces. This field transcends the 
traditional barriers separating many disciplines of science and is 
the basis for most of the N ital hiological processes [ l ]. The basis 
of supramolecular chemistry is molecular recognition where 
host and guest species interact with each other and exist as a 
single system. These host—guest systems symboliic simplest 
examples of supramolecular systems in which a guest is encap-
sulated into the internal cavity of a larger host molecule. The 
most widely used hosts are cyclodextrins (CDs) which are crys-
talline, homogeneous and non-hygroscopic substances 
composed of a-1--4 linked glucose units. The outside surface 
of CDs is hydrophilic while the interior of the cavity is 
hydrophobic [2.3]. The encapsulation of a guest into the CD 
cavity has a profound effect on the chemical, physical and bio-
logical properties of the guest. 
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